DNA ENCODING MAMMALIAN PHOSPHODIESTERASES

Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca<2+>/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDes). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.

Description: DNA ENCODING MAMMALIAN PHOSPHODIESTERASES This is a continuation-in-part of our co- pending U.S. Patent Application Serial No. 07/688,356, filed April 19, 1991. BACKGROUND OF THE INVENTION The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca 2+ /calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs) . Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products. Cyclic nucleotides are known to mediate a wide variety of cellular responses to biological stimuli. The cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of 3' , 5' cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) , to their corresponding 5'- nucleotide monophosphates and are consequently important in the control of cellular concentration of cyclic nucleotides. The PDEs in turn are regulated by transmembrane signals or second messenger ligands such as calcium ion (Ca 2+ ) or cGMP. The PDEs thus have a central role in regulating the flow of information from extracellular hormones, neurotransmitters, or other signals that use the cyclic nucleotides as messengers. PDEs are a large and complex group of enzymes. They are widely distributed throughout the cells and tissues of most eukaryotic organisms, but are usually present only in trace amounts. At least five different families of PDEs have been described based on characteristics such as substrate specificity, kinetic properties, cellular regulatory control, size, and in some instances, modulation by selective inhibitors. [Beavo, Adv. in Second Mess, and Prot. Phosph. Res. 22:1- 38 (1988)]. The five families include: I Ca 2+ /calmodulin-stimulated II cGMP-stimulated III cGMP-inhibited IV cAMP-specific V cGMP-specific Within each family there are multiple forms of closely related PDEs. See Beavo, "Multiple Phosphodiesterase Isozymes Background, Nomenclature and Implications", pp. 3-15; Wang et al.. "Calmodulin- Stimulated Cyclic Nucleotide Phosphodiesterases", pp. 19- 59; and Manganiello et al. , "Cyclic GMP-Stimulated Cyclic Nucleotide Phosphodiesterases" pp. 62-85; all in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, Beavo, J. and Houslay, M.D., Eds.; John Wiley & Sons, New York (1990) . The Ca 2+ /calmodulin dependent PDEs (CaM-PDEs) are characterized by their responsiveness to intracellular calcium, which leads to a decreased intracellular concentration of cAMP and/or cGMP. A distinctive feature of cGMP-stimulated phosphodiesterases (cGS-PDEs) is their capacity to be stimulated by cGMP in effecting cAMP hydrolysis. In vitro studies have shown increased PDE activity in response to Ca 2+ /calmodulin in nearly every mammalian tissue studied, as well as in Drosophila, Dictyostelium, and trypanosomes. The level of CaM-PDE in tissues and cellular and subcellular compartments varies widely. Most cells contain at least a small amount of CaM-PDE activity, with the highest tissue levels being found in the brain, particularly in the synaptic areas. Greenberg et al. Neuropharmacol.. 17:737-745 (1978) and Kincaid et al.. PNAS (USA.. £4:1118-1122 (1987). A decrease in cAMP in astrocytoma cells in response to muscarinic stimulation may be due to calcium dependent increases in CaM-PDE activity. Tanner et al. , Mol. Pharmacol.. 21:455-460 (1986). Also, CaM-PDE may be an important regulator of cAMP in thyroid tissue. Erneux et al.. Mol. Cell. Endocrinol.. 42.123-134(1985). Early studies suggested that there are distinct tissue-specific isozymes of CaM-PDEs. Several members of the CaM-PDE family have now been described, including a 59 kDa isozyme isolated from bovine heart, and 61 and 63 kDa isozymes isolated from bovine brain. LaPorte et al.. Biochemistry. JL8.:2820-2825 (1979); Hansen et al.. Proc. Natl. Acad. Sci. USA. 79:2788-2792 (1982); and Sharma et al. , J. Biol. Chem.. 261:14160-14166 (1986). Possible counterparts to the bovine 59 and 61 kDa isozymes have also been isolated from rat tissues, Hansen et al.. J. Biol. Chem.. 261:14636-14645 (1986), suggesting that these two isozymes may be expressed in other mammalian species. In addition to molecular weight criteria, other evidence supports both similarities and differences among the CaM-PDE family of isozymes. For example, the 59 kDa heart isozyme and the 61 kDa brain isozyme CaM-PDEs differ in mobility on SDS-PAGE and elution position on DEAE chromatography, and the 59 kDa isozyme has at least a 10-20 fold higher affinity for calmodulin. Oncomodulin, a fetal/onco calcium binding protein present in very high concentrations in the placenta and transformed cells, also binds to the 59 kDa enzyme with a higher affinity than to the 61 kDa enzyme. However, both the 61 kDa brain and the 59 kDa heart isozymes are recognized by a single monoclonal antibody. This antibody binds to the Ca 2+ /CaM-PDE complex with 100-fold higher affinity than to PDE alone. Hansen et al. , 1986, supra. The 59 and 61 kDA isozymes have nearly identical substrate specificities and kinetic constants. Krinks et al. , Adv. Cyc. Nucleotide Prot. Phosphorylation Res.. 1-6:31-47 (1984) have suggested, based on peptide mapping experiments, that the heart 59 kDa protein could be a proteolytic form of the brain 61 kDa isozyme. The 63 kDa bovine brain isozyme differs substantially from the 59 and 61 kDa isozymes. The 63 kDa enzyme is not recognized by the monoclonal antibody which binds to the 59 and 61 kDa enzymes. Hansen et al.. 1986, supra. The 63 kDa protein is not phosphorylated in vitro by cAMP-dependent protein kinase, whereas the 61 kDa protein is phosphorylated. Further, only the 63 kDa protein is phosphorylated in vitro by CaM-kinase II. Sharma et_al., Proc. Natl. Acad. Sci. (USA. , 82:2603-2607 (1985); and Hashimoto et al.. J. Biol. Chem. , 264:10884- 10887 (1989) . The 61 and 63 kDa CaM-PDE isozymes from bovine brain do appear, however, to have similar CaM- binding affinities. Peptide maps generated by limited proteolysis with Staphylococcal V8 protease, Sharma et al. , J. Biol.Chem. r 259:9248 (1984), have suggested that the 61 and 63 kDa proteins have different amino acid sequences. The cGMP-stimulated PDEs (cGS-PDEs) are proposed to have a noncatalytic, cGMP-specific site that may account for the stimulation of cAMP hydrolysis by cGMP. Stoop et al.. J.Biol.Chem.. 264:13718 (1989). At physiological cyclic nucleotide concentrations, this enzyme responds to elevated cGMP concentrations with an enhanced hydrolysis of cAMP. Thus, cGS-PDE allows for increases in cGMP concentration to moderate or inhibit cAMP-mediated responses. The primary sequence presented recently in LeTrong et al.. Biochemistry f 29:10280 (1990) , co-authored by the inventors herein, provides the molecular framework for understanding the regulatory properties and domain substructure of this enzyme and for comparing it with other PDE isozymes that respond to different signals. This publication also notes the cloning of a 2.2kb bovine adrenal cortex cDNA fragment encoding cGS-PDE. See also, Thompson et al. , FASEB J.. J5(6) :A1592 (Abstract No. 7092) reporting on the cloning of a "Type II PDE" from rat pheochromocytoma cells. With the discovery of the large number of different PDEs and their critical role in intracellular signalling, efforts have focused on finding agents that selectively activate or inhibit specific PDE isozymes. Agents which affect cellular PDE activity, and thus alter cellular cAMP, can potentially be used to control a broad range of diseases and physiological conditions. Some drugs which raise cAMP levels by inhibiting PDEs are in use, but generally act as broad nonspecific inhibitors and have deleterious side effects on cAMP activity in nontargeted tissues and cell types. Accordingly, agents are needed which are specific for selected PDE isozymes. Selective inhibitors of specific PDE isozymes may be useful as cardiotonic agents, anti-depressants, anti- hypertensives, anti-thrombotics, and as other agents. Screening studies for agonists/antagonists have been complicated, however, because of difficulties in identifying the particular PDE isozyme present in a particular assay preparation. Moreover, all PDEs catalyze the same basic reaction; all have overlapping substrate specificities; and all occur only in trace amounts. Differentiating among PDEs has been attempted by several different means. The classical enzymological approach of isolating and studying each new isozyme is hampered by current limits of purification techniques and by the inability to accurately assess whether complete resolution of an isozyme has been achieved. A second approach has been to identify isozyme-specific assay conditions which might favor the contribution of one isozyme and minimize that of others. Another approach has been the immunological identification and separation into family groups and/or individual isozymes. There are obvious problems with each of these approaches; for the unambiguous identification and study of a particular isozyme, a large number of distinguishing criteria need to be established, which is often time consuming and in some cases technically quite difficult. As a result, most studies have been done with only partially pure PDE preparations that probably contained more than one isozyme. Moreover, many of the PDEs in most tissues are very susceptible to limited proteolysis and easily form active proteolytic products that may have different kinetic, regulatory, and physiological properties from their parent form. The development of new and specific PDE- modulatory agents would be greatly facilitated by the ability to isolate large quantities of tissue-specific PDEs by recombinant means. Relatively few PDE genes have been cloned to date and of those cloned, most belong to the cAMP-specific family of phosphodiesterases (cAMP- PDEs) . See Davis, "Molecular Genetics of the Cyclic Nucleotide Phosphodiesterases", pp. 227-241 in Cyclic Nucleotide Phosphodiesterases: Structure. Regulation. and Drug Action, Beavo, J. and Houslay, M.D., Eds.; John Wiley & Sons, New York; 1990. See also, e.g., Faure et al. r PNAS (USA) , 5:8076 (1988) - D. discoideum; Sass et al.. PNAS fUSA.. 829303 (1986) - S . cerevisiae. PDE class IV, designated PDE2; Nikawa et al. , Mol. Cell. Biol.. 2:3629 (1987) - S. cerevisiae. designated PDE1; Wilson et al.. Mol. Cell. Biol.. 2:505 (1988) - S. cerevisiae,. designated SRA5; Chen et al. , PNAS .USA) . 23:9313 (1986) - D. melanogaster. designated dnc + ; Ovchinnikow et al.. FEBS. 223:169 (1987) - bovine retina, designated GMP PDE; Davis et al.. PNAS .USA.. 86:3604 (1989) - rat liver, designated rat dnc-1; Colicelli et al.. PNAS fUSA.. 26:3599 (1989) - rat brain, designated DPD; Swinnen et al.. PNAS (USA.. 86:5325 (1989) - rat testis, rat PDE1, PDE2, PDE3 and PDE4; and Livi et al.. Mol. Cell. Biol.. 10:2678 (1990) - human monocyte, designated hPDEl. See also, LeTrong et al. , supra and Thompson et al. , supra. Complementation screening has been used to detect and isolate mammalian cDNA clones encoding certain types of PDEs. Colicelli et al.. PNAS (USA.. 86:3599 (1989) , reported the construction of a rat brain cDNA library in an 2- cerevisiae expression vector and the isolation therefrom of genes having the capacity to function in yeast to suppress the phenotypic effects of RAS2 va119 , a mutant form of the RAS2 gene analogous to an oncogenic mutant of the human HRAS gene. A cDNA so cloned and designated DPD (rat dunce-like phospho- diesterase) has the capacity to complement or "rescue" the loss of growth control associated with an activated RAS2 vaii9 gene harbored in yeast strain TK161-R2V (A.T.C.C. 74050) , as 1 well as the analogous defective growth control phenotype of the yeast mutant 10DAB (A.T.C.C. 74049) which is defective at both yeast PDE gene loci (pde "1 , pde "2 ) . The gene encodes a high-affinity cAMP specific phosphodiesterase, the amino acid sequence of which is highly homologous to the cAMP-specific phosphodiesterase encoded by the dunce locus of Drosophila melanogaster. Through the date of filing of parent application Serial No. 07/688,356, there have been no reports of the cloning and expression of DNA sequences encoding any of the mammalian Ca 2+ /calmodulin stimulated or cGMP-stimulated PDEs (PDE families I and II) and, accordingly, there continues to exist a need in the art for complete nucleotide sequence information for these PDEs. BRIEF SUMMARY OF THE INVENTION The present invention provides novel purified and isolated polynucleotide sequences (e.g. DNA and RNA including sense and antisense strands) which code for expression of mammalian species (e.g., human and bovine) Ca 2+ /calmodulin stimulated cyclic nucleotide phosphodiesterase and cGMP stimulated cyclic nucleotide phosphodiesterase polypeptides. Genomic and cDNA sequences provided by the invention may be associated with homologous or heterologous species expression control DNA sequences such as promoters, operators, regulators, terminators and the like to allow for in vivo and in vitro transcription to messenger RNA and, in turn, translation of mRNAs to provide functional phosphodiesterases and related polypeptides in large quantities. Specifically provided by the invention are mammalian DNA sequences encoding phosphodiesterases and fragments thereof which are present as mammalian DNA inserts in bacterial plasmids and viral vectors which are the subject of deposits made with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 on April 11 and 15, 1991 and on April 14, 1992 in accordance with U.S. Patent and Trademark Office and Budapest Treaty requirements. DNAs deposited in connection with the present invention include: 1. Plasmid pCAM-40 in E. coli (A.T.C.C. accession No. 68576) containing a bovine brain cDNA insert encoding a 61 kDa CaM-PDE isozyme; 2. Plasmid pl2.3A in E. coli (A.T.C.C. 68577) containing a bovine brain cDNA insert encoding a 63 kDa CaM-PDE isozyme; 3. Bacteriophage λ CaM H6a (A.T.C.C. accession No. 75000) containing a human hippocampus cDNA insert fractionally encoding a 61 kDa CaM-PDE isozyme; 4. Plasmid pHσam61-6N-7 in E. coli (A.T.C.C. accession No. 68963) containing a composite human cDNA insert encoding a 61 kDa CaM-PDE isozyme; 5. Plasmid pcamH3EF in E. coli (A.T.C.C. accession No. 68964) containing a human hippocampus cDNA insert encoding a novel PDE homologous to a 61kDa CaM- PDE; 6. Plasmid pcamHella in E. coli (A.T.C.C. accession No. 68965) containing a human heart cDNA insert encoding a novel PDE homologous to a 61kDa CaM-PDE; 7. Plasmid p3CGS-5 in E. coli (A.T.C.C. accession No. 68579) containing a bovine adrenal cDNA insert encoding a cGS-PDE isozyme; 8. Plasmid pBBCGSPDE-5 in E. coli (A.T.C.C. accession No. 68578) containing a bovine brain cDNA insert encoding a cGS-PDE isozyme fragment; 9. Plasmid pBBCGSPDE-7 in E. coli (A.T.C.C. accession No. 68580) containing a bovine brain cDNA encoding a cGS-PDE isozyme; 10. Plasmid pGSPDE6.1 in E. coli (A.T.C.C. accession No. 68583) containing a human heart cDNA encoding a cGS-PDE isozyme fragment; 11. Plasmid pGSPDE7.1 in E. coli (A.T.C.C. accession No. 68585) containing a human hippocampus cDNA insert encoding a cGS-PDE isozyme fragment; and 12. Plasmid pGSPDE9.2 (A.T.C.C. accession No. 68584) containing a human hippocampus cDNA insert encoding a cGS-PDE isozyme fragment. 13. Plasmid pHcgsδn in E. coli (A.T.C.C. accession No. 68962) containing a human cDNA insert encoding a cGS-PDE. Also specifically provided by the present invention is a bovine cDNA sequence containing nucleotides encoding bovine 59 kDa CaM-PDE and characterized by the DNA and amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 17. In related embodiments, the invention concerns DNA constructs which comprise a transcriptional promoter, a DNA sequence which encodes the PDE or a fragment thereof, and a transcriptional terminator, each operably linked for expression of the enzyme or enzyme fragment. The constructs are preferably used to transform or transfect host cells, preferably eukaryotic cells, and more preferably mammalian or yeast cells. For large scale production, the expressed PDE can be isolated from the cells by, for example, immunoaffinity purification. Incorporation of DNA sequences into procaryotic and eucaryotic host cells by standard transformation and transfection processes, potentially involving suitable DNA and RNA viral vectors and circular DNA plasmid vectors, is also within the contemplation of the invention and is expected to provide useful proteins in quantities heretofore unavailable from natural sources. Systems provided by the invention include transformed E. coli cells, including those referred to above, as well as other transformed eukaryotic cells, including yeast and mammalian cells. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., truncation, lipidation, and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Novel protein products of the invention include expression products of the aforementioned nucleic acid sequences and polypeptides having the primary structural conformation (i.e., amino acid sequence) of CaM-PDE and cGS-PDE proteins, as well as peptide fragments thereof and synthetic peptides assembled to be duplicative of amino acid sequences thereof. Proteins, protein fragments, and synthetic peptides of the invention are projected to have numerous uses including therapeutic, diagnostic, and prognostic uses and will provide the basis for preparation of monoclonal and polyclonal antibodies specifically immunoreactive with the proteins of the invention. Also provided by the present invention are antibody substances (including polyclonal and monoclonal antibodies, chimeric antibodies, single chain antibodies and the like) characterized by their ability to bind with high immunospecificity to the proteins of the invention and to their fragments and peptides, recognizing unique epitopes which are not common to other proteins. The monoclonal antibodies of the invention can be used for affinity purification of CaM-PDEs and cGS-PDEs, e.g., Hansen et al.. Meth. Enzymol.. 159:543 (1988). Also provided by the present invention are novel procedures for the detection and/or quantification of normal, abnormal, or mutated forms of CaM-PDEs and cGS-PDEs, as well as nucleic acids (e.g., DNA and mRNA) associated therewith. Illustratively, antibodies of the invention may be employed in known immunological procedures for quantitative detection of these proteins in fluid and tissue samples, and of DNA sequences of the invention that may be suitably labelled and employed for quantitative detection of mRNA encoding these proteins. Among the multiple aspects of the present invention, therefore, is the provision of (a) novel CaM- PDE and cGS-PDE encoding polynucleotide sequences, (b) polynucleotide sequences encoding polypeptides having the activity of a mammalian CaM-PDE or of a mammalian cGS-PDE which hybridize to the novel CaM-PDE and cGS-PDE encoding sequences under hybridization conditions of the stringency equal to or greater than the conditions described herein and employed in the initial isolation of cDNAs of the invention, and (c) polynucleotide sequences encoding the same (or allelic variant or analog polypeptides) through use of, at least in part, degenerate codons. Correspondingly provided are viral DNA and RNA vectors or circular plasmid DNA vectors incorporating polynucleotide sequences and procaryotic and eucaryotic host cells transformed or transfected with such polynucleotide sequences and vectors, as well as novel methods for the recombinant production of these proteins through cultured growth of such hosts and isolation of the expressed proteins from the hosts or their culture media. In yet other embodiments, the invention provides compositions and methods for identifying compounds which can modulate PDE activity. Such methods comprise incubating a compound to be evaluated for PDE modulating activity with eukaryotic cells which express a recombinant PDE polypeptide and determining therefrom the effect of the compound on the phosphodiesterase activity provided by gene expression. The method is effective with either whole cells or cell lysate preparations. In a preferred embodiment, the eukaryotic cell is a yeast cell or mammalian cell which lacks endogenous phosphodiesterase activity. The effect of the compound on phosphodiesterase activity can be determined by means of biochemical assays which monitor the hydrolysis of cAMP and/or cGMP, or by following the effect of the compound on the alteration of a phenotypic trait of the eukaryotic cell associated with the presence or absence of the recombinant PDE polypeptide. Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description thereof which includes numerous illustrative examples of the practice of the invention, reference being made to the drawing wherein: Figure 1 provides the results of amino acid sequence determinations for isolated 59 kDa (bovine heart) and 63 kDa (bovine brain) CaM-PDE proteins in alignment with the complete sequence of the 61 kDa (bovine brain) isozyme. Identities of the 59 and 63 kDa proteins to the 61 kDa isozyme are underlined. Tentative identifications are in lower cases and hyphens denote unidentified residues. The N-terminus of the 59 kDa isozyme, as determined by the subtraction of a methionyl peptide (mDDHVTIRRK) from the composition of an a ino- terminal blocked lysyl peptide, is in parenthesis. Solid boxes are placed above residues within the CaM-binding sites identified in the 61 and 59 kDa isozymes. DETAILED DESCRIPTION OF THE INVENTION The following examples illustrate practice of the invention. Example I relates to the isolation, purification, and sequence determination of 61 kDa CaM- PDE cDNA from bovine brain and to the expression thereof in a mammalian host cell. Example II relates to the isolation, purification, and sequence determination of a 59 kDa CaM-PDE from bovine lung and to the expression thereof in a mammalian host cell. Example III relates to the isolation, purification, and sequence determination of 63 kDa CaM-PDE cDNA from bovine brain and to the expression thereof in a mammalian host cell. Example IV relates to the isolation, purification, and sequence determination of cGS-PDE cDNA from bovine adrenal cortex, as well as the expression of the DNA in mammalian host cells. Example V relates to the isolation, purification, and sequence determination of cGS-PDE cDNA from bovine brain and to the expression thereof in a mammalian host cell. Example VI relates to the use of cGS-PDE bovine adrenal cDNA to obtain human cGS-PDE cDNAs and to the development of a human cDNA encoding a cGS-PDE. Example VII relates to the use of CaM-PDE 61 kDa bovine brain cDNA to obtain a human CaM-PDE 61 kDa cDNA and a novel structurally related cDNA. Example VIII relates to the expression of bovine and human PDE cDNAs for complementation of yeast phenotypic defects and verification of phosphodiesterase activity for the expression product. Example IX relates to tissue expression studies involving Northern analysis and RNase protection studies employing polynucleotides (specifically cDNAs and antisense RNAs) of the invention. In those portions of the text addressing the formation of redundant oligonucleotides, the following Table I single letter code recommendations for ambiguous nucleotide sequence, as reported in J.Biol.Chem.. 2jSl:13- 17 (1986) , are employed: TABLE I Isolation, Purification, and sequence Determination of 61 kDa CaM-PDE cDNA From Bovine Brain In this Example, a cDNA sequence representing that portion of a gene for 61 kDa bovine brain CaM-PDE which encodes the amino terminus of the protein was isolated by PCR from a collection of first strand cDNAs developed from bovine brain mRNA. The PCR-generated fragment was then employed to isolate a full length bovine brain CaM-PDE sequence. Total RNA was prepared from bovine heart using the method of Chomczynski et al.. Anal.Biochem.. 162:156- 159 (1987) and mRNA was selected using a Poly(A) QuikTm mRNA purification kit according to the manufacturer's protocol. First strand cDNA was synthesized by adding 80 units of AMV reverse transcriptase to a reaction mixture (40 μl, final volume) containing 50 mM Tris HCl (pH8.3 § 42°), 10 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM (each) deoxynucleotide triphosphates, 50 mM KC1, 2.5 mM sodium pyrophosphate, 5 μg deoxythymidylic acid oligomers (12-18 bases) and 5 μg bovine heart mRNA denatured for 15 min at 65°. Incorporation of 1 μl [ 32 P]-labeled dCTP (3000 Ci/mmol) was used to quantitate first strand cDNA synthesis. The reaction was incubated at 42° for 60 min. The reaction was phenol/CHC1 3 extracted and EtOH precipitated. The nucleic acid pellet was resuspended in 50 μl of 10 mM Tris-HCl (pH 7.5)/0.1 mM EDTA to a final concentration of 15 ng per μl. Redundant sense and antisense oligomers corresponding to 61 kDa peptide sequences as in Fig. 1 were designed to be minimally redundant, yet long enough to specifically hybridize to the target template. A first 23 base oligomer, designated CaM PCR- 2S, was synthesized on an Applied Biosystems, Inc. DNA synthesizer. The oligomer had the following sequence, SEQ ID NO: 1 5'-AARATGGGNATGAARAARAA-3' which specifies the following amino acid sequence. SEQ ID NO: 2 KMGMMKKK. A second 23 base oligomer, designated CaM PCR- 3AS, was synthesized with the following sequence, SEQ ID NO: 3 5'-ACRTTCATYTCYTCYTCYTGCAT-3' representing the following amino acid sequence, SEQ ID NO: 4 MQEEEMNV. A 612 bp CaM PDE cDNA fragment was synthesized using the PCR amplification technique by adding 15 ng of first strand cDNA to a reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 1.5 mM MgCl 2 , 0.01% gelatin, 0.1% Triton X-100, 0.2 mM (each) deoxynucleotide triphosphates, 1 μM (each) CaM PCR 2S and CaM PCR-3AS oligomers, and 2.5 units of Thermus aquaticus DNA polymerase. The reaction was incubated for 30 cycles as follows: 94° for 1 min; 50° for 2 min; and 72° for 2 min. The reaction products were purified on a 1% agarose gel using 0.04 M Tris-acetate/0.001 M EDTA buffer containing 0.5 μg/ml ethidium bromide. The DNA products were visualized with UV light, cleanly excised from the gel with a razor blade, purified using Geneclean II reagent kit and ligated into Eco RV-cut pBluescript vector DNA. To determine if the PCR amplification products were CaM PDE cDNAs, the subcloned PCR DNA products were sequenced from the ends using T3 and T7 promoter primers and either Sequenase or Taq Polymerase sequencing kits. Approximately 250 bases from each end of this piece of DNA were sequenced and the deduced amino acid sequence from the cDNA corresponded with the Fig. 1 amino acid sequences of the 59 and 61 kDa CaM-PDEs, confirming that the PCR DNA product was a partial CaM PDE cDNA. A bovine brain cDNA library constructed with the lambda ZAP vector (kindly provided by Ronald E. Diehl, Merck, Sharp & Dohme) was screened with the radiolabeled 615 bp CaM-PDE cDNA obtained by PCR amplification. The probe was prepared using the method of Feinberg et al.. Anal.Biochem.. 137:266-267 (1984), and the [ 32 P]-labeled DNA was purified using Elutip-D® columns. Plaques (700,000 plaques on 12-150 mm plates) bound to filter circles were hybridized at 42°C overnight in a solution containing 50% formamide, 20 mM Tris-HCl (pH 7.5), IX Denhardt's solution, 10% dextran sulfate, 0.1% SDS and 10 6 cpm/ml [ 32 P]-labeled probe (10 9 cpm/μg) . The filters were washed three times for 15 min with 2X SSC/0.1% SDS at room temperature, followed by two 15-min washes with 0.1X SSC/0.1% SDS at 45°C. The filters were exposed to x-ray film overnight. Of the fifty-six plaques that hybridized with the [ 32 P]-labeled probes eight randomly selected clones were purified by several rounds of re-plating and screening [Maniatis et al. , Molecular Cloning: A Laboratory Manual 545 pp. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1982)] and the insert cDNA's were subcloned into pBluescript SK(-) by .in vivo excision [Short et al.. Nuc. Acids Res.. 12:7583-7599 (1988)] as recommended by the manufacturer. Plasmid DNA prepared from cultures of each clone were subjected to restriction analysis using EcoRl. Two clones of a suitable length were selected for sequence analysis using Taq Tak® and Sequenase® sequencing kits. The two clones were pCAM-40 (2.3kb) and pCAM-34 (2.7kb). The sequencing information from this procedure confirmed that the insert of pCAM-40 encoded the full length bovine brain 61 kDa CaM-PDE. The sequence of this clone and the amino acid sequence deduced therefrom are set forth in SEQ ID NO: 5 and SEQ ID NO: 6. Transient expression of the 61kDa CaM-PDE cDNA in COS-7 cells (A.T.C.C. CRL 1651) was accomplished as follows. Vector pCDM8 [Seed, Nature, 229.:840-843 (1987)] in ____ coli host cells MC1061-p3 was generously provided by Dr. Brian Seed, Massachusetts General Hospital, Boston, MA. This vector is also available from Invitrogen, Inc. (San Diego, CA) . Plasmid pCAM-40 was digested with Hindlll and Notl. yielding a 2.3kb fragment which was ligated into CDM8 vector DNA which had been digested with Hindlll and Notl. The resulting plasmid was propagated in MC1061-p3 cells. Plasmid DNA was prepared using the alkaline lysis method of Ausubel et al., eds., Current Protocols in Molecular Biology. .1:1.7.1 (John Wiley & Sons, New York, 1989) and purified using Qiagen-Tip 500 columns (Qiagen, Inc. Chatsworth, CA) according to the manufacturer protocol. COS-7 cells were transfected with the p-CAM- 40/CDM8 construct (or mock transfected with the CDM8 vector alone) using the DEAE-dextran method Ausubel et al., supra at .1:9.2 et seg. Specifically, 10 μg of ethanol precipitated DNA was resuspended in 80 μl TBS buffer, and added to 160 μl of 10 mg per ml DEAE-dextran dropwise to a 100 mm plate of 50% confluent COS-7 cells in 4 ml of DMEM supplemented with 10% NuSerum, and mixed by swirling. The cells were incubated for 3-4 hours at 37° in a water-saturated 7% C0 2 atmosphere. The medium was removed and the cells were immediately treated with 10% DMSO in PBS for 1 minute. Following this treatment, the cells were washed with PBS, then DMEM, and finally cultured in DMEM supplemented with 10% fetal bovine serum and antibiotics (50 μg/ml streptomycin sulfate) in a 7%- C0 2 incubator for 36 hours. COS cells were scraped from the plates and homogenized in a buffer containing 40 mM Tris-HCl (pH=7.5), 5 mM EDTA, 15 mM benzamidine, 15 mM beta- mercaptoethanol, 1 μg per ml pepstatin A and 1 μg per ml peupeptin using a Dounce homogenizer (1 ml per 100 mm plate) . Homogenates were assayed for PDE activity according to the procedures of Hanson et al., Proc. Nat'l. Acad. Sci.. U.S.A.. 79:2788-2792 (1982), using [ 3 H]cGMP as the substrate. Reactions were carried out at 30° for 10 minutes in a buffer containing 20 mM Tris-HCl (pH=7.5), 20 mM imidazole (pH=7.5), 3 mM MgCl 2 , 15 mM Mg acetate, 0.2 mg per ml BSA and 1 μM 3 H-cAMP with either 2 mM EGTA or 0.2 mM CaCl 2 and 4 μg per ml CaM. Assays were stopped by incubating the tubes in a 90° water bath for 1 minute. After cooling, 10 μl of 2.5 mg per ml snake venom was added to each assay and incubated at 37° for 5 minutes. The samples were diluted with 250 μl of 20 mM Tris-HCl (pH=7.5) and immediately applied to 0.7 ml A-25 ion exchange columns. The columns were washed three times with 0.5 ml of 20 mM Tris-HCl (pH=7.5) and the eluate was collected in scintillation vials. Samples were counted for 1 minute using a Packard Model 1600TR scintillation counter. Specific cyclic nucleotide hydrolytic activity was expressed as picomoles cAMP or cGMP hydrolyzed per minute per mg protein. Protein concentration was estimated according to the method of Bradford, Anal. Biochem.. 7_2.:248-254 (1976), using BSA as a standard. When compared to mock transfected cells, extracts of cells transfected with pCAM-40 cDNA contained significantly greater CAMP and cGMP hydrolytic activities in the presence of EGTA. Assays of the pCAM-40 cDNA- transfected cells in the presence of calcium and CaM resulted in stimulation of cAMP and cGMP hydrolysis. EXAMPLE II Isolation, Purification, and sequence Determination of a 59 kDa CaM-PDE From Bovine Lung A fully degenerate sense oligonucleotide corresponding to the amino acid sequence SEQ ID NO: 7 MDDHVTI from the bovine heart 59 kDa CaM-pde was synthesized. The nucleotide sequence of this oligonucleotide is SEQ ID NO: 8 5'-ATGAGRAGRCAYGTHACNAT-3'. An antisense oligonucleotide was designed from the Fig. 1 sequence of bovine brain 61 kDa CaM-PDE, corresponding to the amino acid sequence SEQ ID NO: 9 LRCLVKQ and having the sequence, SEQ ID NO: 10 , 5'-CTGCTTCACTAAGCATCTTAG-3'. This primer pair was used to prime a PCR reaction using bovine heart first strand cDNA (as prepared in Example I) as a template. This predicted a PCR product of 75 bp, 54 bp of which were unique 59 kDa sequence and 21 bp of which were shared between the 59 kDa and 61 kDa isozymes. The PCR products were analyzed by sieving agarose gel electrophoresis, and a band migrating at 75 bp was excised from the gel. The DNA was subcloned into pBluescript KS + , and colonies positive by the blue/white selection scheme were screened by PCR using primers directed against vector sequences. Colonies with inserts of the appropriate size were selected, and one of these (pCaM59/75.14) was chosen for sequencing. Plasmid DNA was prepared using a Qiagen P20 push column and used as template for sequencing using the dideoxy method. The sequence of the PCR product is SEQ ID NO: 11 5'-ATGAGAAGGCACGTAACGATCAGGAGGAAACATCTCCAA AGACCCATCTTT-AGACTAAGATGCTTAGTGAAGCAG-3 ' . Analysis of the sequence revealed differences in two codons between the sequence obtained and the predicted sequence. Re-examination of the sense oligonucleotide primer sequence revealed that an inadvertent transposition of two codons had led to a mistake in the design of the oligonucleotide. A second set of oligonucleotide PCR primers was prepared which predicted a 54 bp product with minimum overlap between the 59 and 61 kDa isozymes; in addition, the second sense primer p.. , incorporated a correction of the mistake in the design of the original sense primer. The sense oligonucleotide had the sequence SEQ ID NO: 12 5'-ATGGAYGAYCACGTAACGATC-3' and the antisense oligonucleotide had the sequence SEQ ID NO: 13 5'-AAGTATCTCATTGGAGAACAG-3' This primer pair was used to prime a PCR reaction using bovine heart first-strand cDNA as template and the PCR products subcloned and screened exactly as described above. Two clones (pCaM59/54.9 and pCaM59/54.10) were selected for sequencing based on insert size and sequenced as described above; both clones contained 54 bp inserts of the predicted sequence SEQ ID NO: 14 5'-ATGGATGATCACGTAACGATCAGGAGGAAACATCTCCAAA GACCCATCT-TTAGA-3', predicting the amino acid sequence SEQ ID NO: 15 MDDHVTIRRKHLQRPIFR A cDNA library was constructed from bovine lung mRNA and screened using procedures as described in Example IV, infra , with respect to screening of a bovine adrenal cortex library. Approximately 1.2x10 s plaque- forming units were probed with a 32 P-labelled, 1.6kb EcoRl restriction endonuclease-cleavage product of the pCAM-40 cDNA. This initial screening produced 4 putative 59 kDA CaM-PDE cDNA clones. Preliminary sequence analysis indicated that one clone, designated p59KCAMPDE-2, contained the complete coding sequence of the putative 59 kDa CaM-PDE. A series of nested deletions were constructed from the p59KCAMPDE-2 plasmid [See, Sonnenburg et al. , J. Biol. Chem.. 266 f26. : 17655-17661 (1991) ] , and the resultant templates were sequenced by an adaptation of the method of Sanger using the Taq DyeDeoxy™ Terminator Cycle Sequencing Kit and an Applied Biosystems Model 373A DNA Sequencing System. The DNA and deduced amino acid sequences are set out in SEQ. ID NO: 16 and 17, respectively. A large open reading frame within the cDNA encodes a 515 residue polypeptide with an estimated molecular weight of « 59 kilodaltons that is nearly identical to the 61 kDa CaM-PDE amino acid sequence except for the amino-terminal 18 residues. Moreover, the predicted amino acid sequence of the p59KCAMPDE-2 open reading frame is identical to the available sequence of the 59 kDa CaM-PDE purified from bovine heart, Novack et al.. Biochemistry. 30: 7940-7947 (1991) . These results indicate that the p59KCAMPDE-2 cDNA represents an mRNA species encoding the 59 kDa CaM- PDE. Transient expression of the 59 kDa bovine lung PDE was accomplished as in Example I. Specifically, a 2.66kb, EcoRl/blunt-ended fragment of p59KCAMPDE-2 cDNA was subcloned into pCDM8 which had been digested with Xhol and blunt-ended. The recombinant plasmid, designated p59KCAMPDE-2/CDM8, was used to transiently transfect COS-7 cells and extracts prepared from transfected COS-7 cells were assayed for CaM-PDE activity using 2 μM cAMP. COS-7 cells transfected with the p59KCAMPDE-2 cDNA yielded a cAMP hydrolytic activity that was stimulated 4-5 fold in the presence of calcium and calmodulin. Mock transfected COS-7 cells had no detectable calmodulin-stimulated cAMP hydrolytic activity. EXAMPLE III Isolation, Purification, and Sequence Determination of 63 kDa CaM-PDE cDNA From Bovine Brain Multiple fully and partially redundant oligonucleotides corresponding to the amino acid sequence reported in Fig. 1 were synthesized for use in attempting to obtain a cDNA clone for the 63 kDa CaM-PDE. Annealing temperatures used for the polymerase chain reactions were varied between 2 to 20°C below the theoretical melting temperature for the lowest melting oligonucleotide of each sense-antisense pair. Except for probes 63-12s and 63-13a, which are discussed below, the PCR products of each of the oligonucleotide pairs under a wide range of conditions gave multiple ethidiu bromide bands when agarose gel-electrophoresed. Use of 63-12s and 63-13a resulted in a PCR product that coded for 63 kDa CaM-PDE when sequenced. A fully redundant sense 23-mer oligonucleotide, designated 63-12s, was assembled having the following sequence SEQ ID NO: 18 5'ATHCAYGAYTAYGARCAYACNGG-3' based on an amino acid sequence, SEQ ID NO: 19 IHDYEHTG which is conserved in the 61 kDa bovine CaM-PDEs (see Fig. 1) . A partially redundant antisense 32-mer oligonucleotide, designated 63-13a, had the sequence SEQ ID NO: 20 5'-TCYTTRTCNCCYTGNCGRAARAAYTCYTCCAT-3' and was based on the following conserved sequence in the 63 kDa CaM-PDE, SEQ ID NO: 21 MEEFFRQGDKE Messenger RNA was prepared from bovine brain cerebral cortex and poly A + selected. First strand complementary DNA was produced using AMV or MMLV reverse transcriptase. De-tritylated oligonucleotides were phosphorylated using ImM [γ- 32 P]ATP at 1 X 10 6 cpm/nmol and T4 polynucleotide kinase. After separation of 5' 32 P- labelled oligonucleotides from free ATP using NENsorb 20 columns, each was suspended as a 20 μM (5' phosphate) stock and combined finally at 400 nM each in the PCR. The reaction was run using 50 ng total cDNA and 200 μM dNTP to obtain about 1 μg of PCR product. The reaction had an initial denaturation step at 94°C for 5 min followed by 30 cycles of a 1 min 94°C denaturation, an annealing step at 50°C for 1 min, and a 2 min extension step at 72°C. Under the reaction conditions, a single ethidium bromide-staining band of 450 base pairs was obtained on agarose gel electrophoresis of 100 ng of the PCR product. Five μg of 5' phosphorylated PCR product was ligated to 15 ng EcoRV-cut Bluescript KS(+) plasmid using T4 DNA ligase in 5% PEG-6000 for 12 h at 21°C. Putative positives of XL 1-blue transformations were white colonies using isopropyl thiogalactoside (IPTG) and bromo- chloro- indolyl galactoside (Xgal) for chromogenic selection. Such picks were sequenced using T3 or T7 primers, dideoxynucleotide terminators, and Sequenase. One resultant clone (pll.5B) had the nucleotide sequence and translated amino acid sequence provided in SEQ ID NO: 22 and SEQ ID NO: 23, respectively. The codons for the amino acids YEH found in oligonucleotide 63-12s were replaced by codons for the amino acid sequence NTR in pll.5B. This was probably due to a contaminant in 63-12s. Since the translated open reading frame (ORF) was similar to that reported in Fig. 1 for the 63 kDa CaM PDE, pll.5B was used to screen a bovine brain cDNA library for a full length cDNA clone. A bovine brain cDNA library was constructed in λ ZAP II. First strand cDNA was treated with RNase H, 1. coli DNA polymerase, and E. coli DNA ligase to synthesize second strand cDNA. The cDNA was blunt-ended by T4-DNA polymerase; EcoRl sites in the cDNA were protected with EcoRl methylase and S-adenosyl methionine and EcoRl linkers were ligated on with T4 DNA ligase. After EcoRl restriction endonuclease treatment, free linkers were separated from the cDNA by gel filtration over Sepharose CL-4B. λ ZAP II arms were ligated onto the cDNA and packaged by an _n vitro Gigapack Gold packaging kit obtained from Stratagene. 9.5 X 10 5 recombinants were obtained with 5.8% nonrecombinant plaques as assessed by plating with IPTG and X-gal. The library was amplified once by the plate lysate method to obtain 1.4 X 10 7 pfu/ml. An initial screen of a total bovine brain cDNA library in λ ZAP II was performed. 700,000 pfu were screened using 32 P-labelled oligonucleotide 63-ls at a hybridization and wash temperature of 40°C. Oligonucleotide 63-ls was a fully redundant 23-mer having the sequence SEQ ID NO: 24 5'-AARAARAAYYTNGARTAYACNGC-3' corresponding to the amino acid sequence SEQ ID NO: 25 KKNLEYTA A total of 21 putative positives were picked. Subsequent rescreens were impeded by the very high background found using this screening method. Therefore, aliquots of each primary pick were pooled and 50,000 pfu of the pool were replated and rescreened with pll.5B radiolabelled by random primers and [α- 32 P]dCTP. One positive was obtained, plaque-purified, and rescued as a plasmid pl2.3a. Its DNA sequence is provided in SEQ ID NO: 26. Subsequently, the bovine brain cerebral cortex library was screened further with pll.5B. Two further independent clones, pl2.27.9 and pl2.27.11, were obtained out of a primary screen of 1.4 X 10 6 pfu. They were plaque-purified and rescued for sequencing. Clone pl2.3a codes for a protein sequence with most of the aligned peptides isolated from bovine 63 kDa CaM-PDE as shown in Fig. 1. SEQ ID NO: 26 and SEQ ID NO: 27 set forth the coding region (i.e., the 1844 nucleotides of an approximately 2.5 kilobase insert) of pl2.3a. Base numbers 248-290 code for amino acid sequence SEQ ID NO: 28 QLENGEVNIEELKK, while the comparable (Figure 1) peptide has the sequence SEQ ID NO: 29 QLIPGRVNIISLKK Base numbers 942-990 code for an amino acid sequence SEQ ID NO: 30 KSECAILYNDRSVLEN while the isolated (Figure 1) peptide sequence is SEQ ID NO: 31 KDETAILYNDRTVLEN. None of the nonaligned 63 kDa peptide sequence is found in any reading frame of pl2.3a; also, the molecular weight of the pl2.3a open reading frame, as translated, is 60,951 not 63,000. Therefore, this cDNA may represent an isozyme variant of the 63 kDa protein. The other two independent clones (pl2.27.9 and pl2.27.11) seem to have ORF sequence identical to pl2.3a. The open reading frame of one clone begins at nucleotide number 823 of pl2.3a and is identical to pl2.3a through its termination codon. The other clone starts at nucleotide 198 and is identical to pl2.3a throughout its length. None of the three clones has the anomalous NTR peptide sequence found in pll.5B; all three have YEH as the 61 kDa CaM PDE. Transient expression of the 63kDa CaM-PDE cDNA in COS-7 cells was accomplished as follows. A fragment of the cDNA insert of plasmid p 12.3 including the protein coding region of SEQ.ID NO: 26 and flanked by BamHI restriction sites was prepared by PCR. More specifically, oligonucleotides corresponding to base Nos. 94-117 (with the putative initiation codon) and the antisense of base Nos. 1719-1735 (with sequence immediately 3' of the termination codon) of SEQ.ID NO. 26 were synthesized with two tandem BamHI sites on their 5' ends. The two primers had the following sequences: SEQ.ID NO: 32 5'-GGATCCGGATCCCGCAGACGGAGGCTGAGCATGG-3' SEQ.ID NO: 33 5'-GGATCCGGATCCAGGACCTGGCCAGGCCCGGC-3' The two oligonucleotides were used in a PCR cycling 30 times from a 1 min incubation at 94°C to a 2 min 72°C incubation with a final 10 min extension reaction at 72°C. The 100 μl reaction used 20 μM of each oligonucleotide and 100 pg pl2.3a as the template in order to produce 5 μg 1665 base pair product. The product was extracted once with an equal volume of 1:1 phenol:chloroform, made 0.3 M with regard to sodium acetate, and precipitated with two volumes of ethanol overnight. The precipitate was dried, rehydrated into 50 μl, and the cDNA was digested with 5 units BamHI restriction endonuclease for one hour at 37°C. Afterwards, the solution was extracted once with an equal volume of 1:1 phenol:chloroform. The 1641 base pair cDNA with BamHI 5' and 3 ' ends was purified from the aqueous layer using Qiagen Q-20 columns (Qiagen, Inc., Chatsworth, CA) and the protocol given by the manufacturer. The cut, purified PCR product was ligated into BamHI digested, alkaline phosphatase-treated Bluescript KS(+) plasmid. The ligation product was subcloned into XL1 cells; resulting transformants were screened by sequencing. One transfor ant (designated pll.6.c6) was isolated with the BamHI insert oriented such that the Bluescript KS(+) Hindlll restriction site was 30 bases 5' to the sequence of the insert encoding the initiation codon. This plasmid was digested with Hindlll and Xbal restriction endonucleases to release the 1689 base pair fragment. The fragment was ligated into Hindlll- and Xbal-digested CDM8 vector DNA as in Example I. COS-7 cells were transfected with the pl2.3.a/CDM8 construct or mock transfected with the CDM8 vector alone using the DEAE-dextran method as described in Example 1. A ratio of 10 μg DNA/400 μg DEAE-dextran was used, with a final DEAE-dextran concentration in the media of 100 μg/ml. After 48 h, cells were suspended in 1 ml of homogenization buffer (40 mM Tris HCl, pH=7.5, 15 mM benzamidine HCl, 15 mM 6-mercaptoethanol, 0.7 μg/ml pepstatin A, 0.5 μg/ml leupeptin, and 5 mM Na^EDTA) and disrupted on ice using a Dounce homogenizer. The homogenates were diluted 1/2 to make a final 50% (v/v) glycerol for storage at -20°C and used either to assay for phosphodiesterase activity or to determine protein concentration. CaM-dependent and independent activities were determined as in Example 1. Cells transfected with a pl2.3.a DNA had a 15-fold increase in CaM-stimulated cAMP phosphodiesterase activity and a 12-fold increase in CaM-stimulated cGMP phosphodiesterase activity over basal levels. Mock transfected COS-7 cells showed no PDE activity over basal levels even with CaM stimulation. EXAMPLE IV Isolation, Purification, Sequence Determination, and Expression of cGS- PDE cDNA From Bovine Adrenal Cortex Total RNA was prepared from bovine adrenal outer cortex using the method of Chomczynski et al. , supra. Polyadenylated RNA was purified from total RNA preparations using the Poly(A) QuickTm mRNA purification kit according to the manufacturer's protocol. First strand cDNA was synthesized by adding 80 units of AMV reverse transcriptase to a reaction mixture (40 μl, final volume) containing 50 mM Tris-HCl (pH 8.3 § 42°), 10 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM (each) deoxynucleotide triphosphates, 50 mM KCl, 2.5 mM sodium pyrophosphate, 5 μg deoxythymidylic acid oligomers (12-18 bases) and 5 μg bovine adrenal cortex mRNA denatured for 15 min at 65°C. The reaction was incubated at 42°C for 60 min. The second strand was synthesized using the method of Watson et al.. DNA Cloning: A Practical Approach. 1:79-87 (1985) and the ends of the cDNA were made blunt with T4 DNA polymerase. EcoRl restriction endonuclease sites were methylated [Maniatis et al. , supra1 using a EcoRl methylase (Promega) , and EcoRl linkers (50-fold molar excess) were ligated to the cDNA using T4 DNA ligase. Excess linkers were removed by digesting the cDNA with EcoRI restriction endonuclease, followed by Sepharose CL- 4B chromatography. Ausubel et al.. supra. The cDNA (25- 50 ng per μg vector) was ligated into EcoRI-digested, dephosphorylated ZAP® II (Stratagene) arms [Short et al. , Nuc.Acids Res.. .16:7583-7599 (1988)] and packaged [Maniatis et al. , supra] with Gigapack® Gold extracts according to the manufacturer's protocol. Initially, an unamplified bovine adrenal cortex cDNA library was made and screened with a redundant 23- mer antisense oligonucleotide probes end-labeled with y- [ 32 P]ATP and T4 polynucleotide kinase. The oligomers corresponding to the amino acid sequences SEQ ID NO: 34 EMMMYHMK and SEQ ID NO: 35 YHNWMHAF were made using an Applied Biosystems model 380A DNA synthesizer. Their sequences are as follows: SEQ ID NO: 36 5'-TT CAT RTG RTA CAT CAT CAT YTC-3' SEQ ID NO: 37 5'-AA NGC RTG CAT CCA RTT RTG RTA-3' Duplicate nitrocellulose filter circles bearing plaques from 12 confluent 150 mm plates (approximately 50,000 pfu/plate) were hybridized at 45°C overnight in a solution containing 6X SSC, IX Denhardt's solution, 100 μg/ml yeast tRNA, 0.05% sodium pyrophosphate and 10 6 cpm/ml radiolabeled probe (>10 6 cpm per pmol) . The filters were washed three times in 6X SSC at room temperature, followed by a higher-stringency 6X SSC wash at 10 β C below the •minimum melting temperature of the oligomer probes, and exposed to x-ray film overnight. A single 2.1 kb cDNA clone (designated pcGS- 3:2.1) was isolated and sequenced. The amino acid sequence enclosed by the large ORF of this clone was identical to peptide sequences of the cGS-PDE purified from the supernatant fraction of a bovine heart homogenate. LeTrong et al. , supra. A second, amplified, bovine adrenal cortex cDNA library was screened using the [ 32 P]-labeled CGS-3:2.1 partial cDNA, yielding a 4.2 kb cDNA (designated 3CGS-5) . The library was constructed, amplified as in Maniatis et al. , supra. plated and screened with the bovine cDNA insert from clone CGS-3:2.1. The probe was prepared using the method of Feinberg et al. , supra. and the radiolabeled DNA was purified using Elutip-D® columns. Plaques (600,000 pfu on twelve 150 mm plates) bound to filter circles were hybridized at 42°C overnight in a solution containing 50% formamide, 20 mM Tris-HCl (pH 7.5, IX Denhardt's solution, 10% dextran sulfate, 0.11% SDS and 10 6 cpm/ml [ 32 P]-labeled probe (10 9 cpm/μg) . Th.e filters were washed three times for 15 minutes with 2X SSC/0.1% SDS at room temperature, followed by two 15- minute washes with 0.1X SSC/0.1% SDS at 45°C. The filters were exposed to x-ray film overnight. Ausubel et al., supra. From this initial screening, 52 putative clones were identified. Twenty of these clones were randomly selected, purified by several rounds of re-plating and screening [Maniatis et al., supra] and the insert cDNAs were subcloned into pBluescript SK(-) by in vivo excision [Short et al. f supra] as recommended by the manufacturer. Plasmid DNA prepared from these clones were analyzed by restriction analysis and/or sequencing. From this survey, a 4.2 kb cDNA representing the largest open reading frame was identified. The cDNA inserts from the other putative clones were shorter, and appeared to be identical based on the nucleotide sequence of the insert ends. Putative cGS-PDE cDNAs were sequenced by a modification of the Sanger method [Sanger et al.. Proc.Natl.Acad.Sci. USA. 74.:5463-5467] using Sequenase® or Taq Trak® kits as directed by the manufacturer. Templates were prepared from the cDNAs by constructing a series of nested deletions [Henikoff, Gene. 28:351-359 (1984)] in the vector, pBluescript SK(-) (Stratagene) using exonuclease III and mung bean nuclease according to the manufacturer's protocol. In cases where overlapping templates were not attained by this method, the cDNAs were cleaved at convenient restriction endonuclease sites and subcloned into pBluescript, or specific oligomers were manufactured to prime the template for sequencing. Single-stranded DNA templates were rescued by isolating the DNA from phagemid secreted by helper phage-infected XL1 cells harboring the pBluescript plasmid [Levinson et al. , supra] as recommended by the manufacturer Stratagene) . Homology searches of GENBANK (Release 66.0), EMBL (Release 25.0), and NBRF nucleic acid (Release 36.0) and protein (Release 26.0) databases were conducted using Wordsearch, FASTA and TFASTA programs supplied with the Genetics Computer Group software package Devereux et al.. Nuc.Acids Res.. 12:387-395 (1984) . The nucleotide sequence and deduced amino acid sequence encoded by the large open reading frame of P3CGS-5 cDNA clone insert is provided in SEQ ID NO: 38 and SEQ ID NO: 39. Starting with the first methionine codon, the cDNA encodes a 921 residue polypeptide with a calculated molecular weight of about 103,000. Although no stop codons precede this sequence, an initiator methionine consensus sequence [Kozak, J.Cell Biol.. 108:229-241 (1989)] has been identified. The presence of 36 adenosine residues at the 3' end of the cDNA preceded by a transcription termination consensus sequence .Birnstiel et al.. Cell. 41:349-359 (1985)] suggests that all of the 3' untranslated sequence of the cGS-PDE mRNA is represented by this clone. A putative phosphodiesterase-deficient (PPD) strain of S49 cells [Bourne et al. , J.Cell.Physiol.. 25_:611-620 (1975)] was transiently transfected with the cGS-PDE cDNA using the DEAE-dextran method. The cGS-PDE cDNA was ligated into the unique BamHI cloning site in a mammalian expression vector, designated pZEM 228, following a zinc-inducible metallothionine promoter and prior to an SV40 transcription termination sequence. The DNA was purified from large-scale plasmid preparations using Qiagen pack-500 columns as directed by the manufacturer. PPD-S49 cells were cultured in DMEM containing 10% heat-inactivated horse serum, 50 μg/ml penicillin G and 50 μg/ml streptomycin sulfate at 37°C in a water-saturated 7% C0 2 atmosphere. Prior to transfections, confluent 100 mm dishes of cells were replated at one-fifth of the original density and incubated for 24-36 h. In a typical transfection experiment, PPD-S49 cells (50-80% confluent) were washed with Tris-buffered-saline and approximately 2 x 10 7 cells were transfected with 10 μg of DNA mixed with 400 μg of DEAE-dextran in one ml of TBS. The cells were incubated at 37°C for 1 hr with gentle agitation every 20 min. Next, DMSO was added to a final concentration of 10% and rapidly mixed by pipetting up and down. After 2 min, the cells were diluted with 15 volumes of TBS, collected by centrifugation, and washed, consecutively with TBS and DMEM. The cells were resuspended in complete medium and seeded into fresh 100 mm plates (1-2 x 107 cells/10 ml/plate) . After 24 h, the cells were treated with TBS alone, or containing zinc sulfate (final concentration = 125 μM) and incubated for an additional 24 h. The cells were harvested and washed once with TBS. The final cell pellets were resuspended in two mis of homogenization buffer (40 mM Tris-HCl; pH 7.5, 15 mM benzamidine, 15mM β-mercaptoethanol, 0.7 μg/ml pepstatin A, 0.5 μg/ml leupeptin and 5 mM EDTA) and disrupted on ice using a dounce homogenizer. The homogenates were centrifuged at 10,000 x g for 5 min at 4°C and the supernatants were assayed for phosphodiesterase activity and protein concentration. cGS PDE activity was determined by a previously described method using [ 3 H]cAMP as the substrate as in Martins et al.. J.Biol.Chem.. 257:1973-1979 (1982). Phosphodiesterase assays were performed in triplicate. The Bradford assay [Bradford, Anal. Biochem.. 72:248-254 (1976)] was used to quantitate protein using BSA as the standard. In the absence of zinc treatment, no increase in basal activity or cGMP-stimulated phosphodiesterase activity was detected in PPD S49 cells transfected with the cGS PDE-ZEM 228 construct or the vector alone. However, zinc-treated cells transfected with cGS-PDE cDNA, but not the vector alone, expressed cGMP-enhanced cAMP phosphodiesterase activity indicating that the cDNA encodes a cGS-PDE. The total activity of the homogenates and 50,000 x g supernatants was not significantly different. Transient expression of the cGS-PDE cDNA in COS-7 cells was accomplished as in Example I. A 4.2 kb fragment of p3CGS-5 was isolated using Hindlll and Notl and was inserted into plasmid pCDM8, which had been digested with the same enzymes. The character of products produced in COS-7 cells transformed with the p3CGS-5/pCDM8 construct is discussed in Example V, infra. EXAMPLE V Isolation, Purification, and Partial Sequence Determination of cGS-PDE cDNA from Bovine Brain A. Isolation of Bovine Brain CGSPDE CDNA Clone, PBBCGSPDE-5 A bovine brain cDNA library constructed with the λ ZAP vector (kindly provided by Ronald E. Diehl, Merck, Sharp & Dohme) was screened with a 450 bp EcoRI/Apal restriction endonuclease cleavage fragment of the p3CGS-5 cDNA corresponding to (p3CGS-5) nucleotide position numbers 1-452. The probe was prepared using the method of Feinberg et al.. supra. and the [ 32 P]-labeled DNA was purified using Elutip D® columns. Plaques (a total of 600,000 plaques on 12-150 mm plates) bound to filter circles were hybridized at 42° overnight in a solution containing 50% formamide, 20 mM Tris HCl (pH 7.5), IX Denhardt's solution, 10% dextran sulfate, 0.1% SDS and 10 6 cpm/ml [ 32 P]-labeled probe (10 9 cpm/μg). The filters were washed three times for 15 minutes with 2X SSC/0.1% at room temperature, followed by two 15 minute washes with 0.1X SSC/0.1% SDS at 45%. The filters were exposed to x-ray film overnight. Forty putative clones were picked from this first screen, of which six were randomly selected and purified by several rounds of re-plating and screening [Maniatis et al. , supra] . The insert cDNAs were subcloned into pBluescript SK(-) by in vivo excision as recommended by the manufacturer. Plasmid DNA prepared from cultures of each clone was sequenced from the ends using Sequenase and Taq Trak sequencing kits. The sequence obtained from this experiment confirmed that the bovine brain cDNA clone, pBBCGSPDE-5 was a cGS-PDE cDNA, and that it was different than the adrenal cGS-PDE cDNA at the five-prime end. Partial sequence analysis of the pBBCGSPDE-5 insert at its 5' end (encoding the amino terminal region of the protein) revealed the sense strand set out in SEQ ID NO: 40, while sequencing of the 3' end of the insert revealed the antisense sequence of SEQ ID NO: 41. B. Isolation of Bovine Brain CGS-PDE CDNA Clone. PBBCGSPDE-7 Each of the forty putative clones selected from the first round of purification described above was spotted individually onto a lawn of host XL1 cells and incubated overnight at 37°. The plaques were screened with a 370 bp Pstl/Smal restriction endonuclease cleavage fragment of the p3CGS-5 cDNA (corresponding p3CGS-5 nucleotide position numbers 2661-3034) . The probe was prepared using the method of Feinberg et al. , supra. and the [ 32 P]-labeled DNA was purified using Elutip-D® columns. Plaques bound to filter circles were hybridized at 42° overnight in a solution containing 50% formamide, 20 mM Tris-HCl (pH 7.5), IX Denhardt's solution, 10% dextran sulfate, 0.1% SDS and 10 6 cpm/ml [ 32 P]-labeled probe (10 9 cpm/μg) . The filters were washed three times for 15 minutes with 2X SSC/0.1% SDS at room temperature, followed by two 15-minute washes with 0.1X SSC/0.1% SDS at 45°. The filters were exposed to x-ray film overnight. After several rounds of plating and rescreening, six putative clones were purified and sequenced from the ends. The sequence of the five-prime end of the cDNA clone pBBCGSPDE-7 was identical to clone pBBCGSPDE-5, but not the adrenal gland-derived clone, p3CGS-5. The sequence of the three-prime end of the pBBCGSPDE-7 cDNA clone was identical to the p3CGS-5 insert sequence. Sequence analysis of the pBBCGSPDE-7 insert revealed the DNA sequence set out in SEQ ID NO: 42 and the amino acid sequence of SEQ. ID NO: 43. The large open reading frame encodes a 942- residue polypeptide that is nearly identical to the adrenal gland cGS-PDE isozyme (921 residues) . The difference in the primary structure of these two isozymes lies in the amino-terminal residues 1-46 of the brain cGS-PDE, and residues 1-25 of the adrenal cGS-PDE. The remaining carboxy-terminal residues of the brain and adrenal cGS-PDE are identical. For transient expression in COS-7 cells, a 3.8kb fragment of pBBCGSPDE-7 was isolated using Hindlll and Notl and inserted into plasmid pCDMδ which had been cut with Hindlll and Notl restriction endonucleases. The recombinant pBBCGSPDE-7/CDM8 construct was used to transiently transfect COS-7 cells. The properties of the pBBCGSPDE-7/CDM8 construct and the p3CGS-5/CDM8 construct prepared in Example IV products were subsequently compared. Membrane and supernatant fractions were prepared from extracts of transfected COS-7 cells and assayed for cGS-PDE activity. Both the pBBCGSPDE-7/CDM8 and p3CGS5/CDM8 plasmid constructs produced cGS-PDE activities in COS-7 cell extracts, and most of the activity was detected in the supernatant fractions. However, a 10-fold greater percentage of total cGS-PDE activity was detected in membranes from COS-7 cell extracts transfected with the pBBCGSPDE-7/CDM8 construct than in membranes prepared from p3CGS-5/CDM8-transfected COS-7 cells. These results indicate that, relative to the adrenal cGS-PDE, the isozyme encoded by the pBBCGSPDE-7 cDNA preferentially associates with cellular membranes. EXAMPLE VI Use of cGS-PDE Bovine Adrenal CDNA to Obtain TTiimw cGS-PDE cDNAs Several human cDNA clones, homologous to a cDNA clone encoding the bovine cyclic GMP-stimulated phosphodiesterase, were isolated by hybridization using a nucleic acid probe derived from the bovine cDNA. A combination of sequence analysis and hybridization studies indicates that these human cDNA clones encompass an open reading frame corresponding to a human phosphodiesterase. cDNA libraries were probed with DNA from plasmid p3CGS-5 which contains a 4.2-kb cDNA insert encoding the bovine cGS-PDE. This plasmid was digested with the restriction enzymes Smal and EcoRI. The approximately 3.0 kb fragment derived from the cDNA insert was isolated and purified by agarose gel electrophoresis. This fragment contains the entire open reading frame of the PDE. The fragment was labeled with radioactive nucleotides by random priming. The cDNA libraries were plated on a 150 mm petri dishes at a density of approximately 50,000 plaques per plate. Duplicate nitrocellulose filter replicas were prepared. The radioactive nucleic acid probe was used for hybridization to the filters overnight at 42°C in 50% formamide, 5x SSPE (0.9 M NaCl, 0.05 M NaH 2 PO 4 -H 2 0, 0.04 M NaOH, and 0.005 M Na 2 EDTA 2 H 2 0) , 0.5% SDS, 100 μg/ml salmon testes DNA, and 5x Denhardt's solution. The filters were washed initially at room temperature and subsequently at 65°C in 2x SSC containing 0.1% SDS. Positive plaques were purified and their inserts were subcloned into an appropriate sequencing vector for DNA sequence analysis by standard techniques. First, a λgtlO cDNA library prepared from human hippocampus mRNA (clontech, random and dT primed) was screened. Of the approximately 500,000 plaques examined, 33 hybridized to the probe. One of these phages was digested with EcoRI to remove the cDNA insert. This insert-containing EcoRI fragment was cloned into Bluescript KS that had been digested with EcoRI and then treated with calf intestine alkaline phosphatase. One product of this reaction was the plasmid pGSPDE9.2, which showed two major differences when compared to the bovine cGS-PDE cDNA. The 5'0.4 kb of the pGSPDE9.2 insert diverged from the bovine cDNA. Approximately 0.7kb from the 5' end of the human cDNA there is a 0.7kb region that diverges from the bovine cDNA. This region may be an intron. Twenty-five of the remaining hippocampus plaques that had hybridized to the bovine probe were examined by PCR, hybridization and/or sequencing. None were found to extend through the regions that differed between the bovine and human cDNAs. Phages λ GSPDE7.1 and λ GSPDE7.4, two other phages from the hippocampus library, were digested with EcoRI and Hindlll. Each yielded a 1.8-kb fragment that contains most of the cDNA insert and approximately 0.2-kb of phage lambda DNA. The λ DNA is present in the fragment because in each case one of the EcoRI sites that typically bracket a cDNA insert had been destroyed, possibly when the library was constructed. The EcoRI/Hindlll fragments were cloned into Bluescript KS digested with EcoRI and Hindlll. This procedure gave rise to the plasmids pGSPDE7.1 and pGSPDE7.4. The cDNA inserts encode DNA homologous to the 3' portion of the bovine phosphodiesterase cDNA. Both of the cDNA inserts in these clones begin at an EcoRI site and the sequences are homologous adjacent this site. Portions of pGSPDE7.1 and pGSPDE7.4 cDNA inserts were sequenced and are identical except for a short region of their 3' ends. The cDNA insert in pGSPDE7.1 ends with a sequence of approximately 70 adenine bases, while the cDNA insert in pGSPDE7.4 ends with three additional nucleotides not present in pGSPDE7.1 followed by a sequence of approximately 20 adenine bases. Next, a cDNA library prepared in λ ZapII (Stratagene) from human heart mRNA yielded one hybridizing plaque from the approximately 500,000 screened. The Bluescript SK(-) plasmid pGSPDE6.1 containing the hybridizing insert was excised in vivo from the λ ZapII clone. Sequence analysis showed that the insert is homologous to the bovine phosphodiesterase cDNA. The homologous region spans the position of the EcoRI found in the sequence formed by joining the sequence of the insert from pGSPDE9.2 to the sequence of the insert in pGSPDE7.1 or pGSPDE7.4. Thus, it is thought that the two clones from the hippocampus form a complete open reading frame. A third λ gtlO library derived from human placenta mRNA yielded five hybridizing plaques from approximately 800,000 screened. These placental cDNA clones were short and their sequences were identical to portions of the hippocampus cDNA pGSPDE9.2. Screening 5xl0 5 plaques from U118 glioblastoma cDNA library, 5xl0 5 from a spleen cDNA library and 5xl0 5 from an adrenal library (Cushings Disease) gave no hybridization plaques. Given the homology between the bulk of human and bovine cGS-PDE sequence, it was decided to obtain multiple independent cDNA clones containing the 5' end of the human cGS-PDE to determine if the 0.4kb 5' sequence was an artifact. An approximately 0.95kb EcoRI-Hindll fragment from the 5' end of the bovine cGS cDNA plasmid p3cgs5 was random primed and used as a probe to screen a number of human cDNA libraries. Hippocampus library screening was carried out under the same screening conditions as described above. All remaining screenings were carried out as described with respect to human heart cDNA library screenings in Example VII, infra. No positives were obtained screening 5xl0 5 plaques from a human T cell library (Hut78, dT-primed) , 10 6 plaques from the hippocampus cDNA library (random and dT-primed) , 5xl0 5 plaques from a human liver cDNA library (dT-primed, 5' stretch, Clontech) , 5xl0 5 plaques from a human SW1088 glioblastoma cDNA library (dT-primed) , 5xl0 5 plaques from the same heart cDNA library (random and dT-primed) , and 1.5xl0 6 plaques from a human lung cDNA library (random primed) . Two positives were obtained from screening 5xl0 5 plaques from a human fetal brain cDNA library (random and dT-primed, Stratagene) . These were designated as HFB9.1 and HFB9.2. Bluescript SK(-) plasmids pHFB9.2 and pHFB9.1 were excised in vivo from the λZapII clones. DNA sequence analysis revealed that HFB9.1 starts about 80 nucleotides further 3' than does HFB9.2 and reads into an intron approximately 1.9kb of the way into HFB9.2. HFB9.2 covers the entire open reading frame of the cGS- PDE, but reads into what may be an intron 59 nucleotides after the stop codon. Both of them lack the 5'0.4kb and the presumed intron found in pGSPDE9.2. The entire open reading frame of HFB9.2 was isolated and assembled into yeast expression vector pBNY6N. The resulting plasmid, designated pHcgsδn, includes the coding region of the cDNA as an EcoRI/Xhol insert. DNA and deduced amino acid sequences for the insert are provided in SEQ.ID No: 44 and 45, respectively. EXAMPLE VII Use of CaM-PDE 61 kDa Bovine Brain cDNA to Obtain Human CaM-PDE 61 KDa cDNA Human cDNA clones, λ CaM H6a and λ CaM H3a, which are homologous to the cDNA encoding the bovine 61 kDa CaM-PDE, were obtained by hybridization using a nucleic acid probe derived from the cDNA encoding the bovine species enzyme. A combination of sequence analysis and hybridization studies indicate that λ Cam H6a contains most of an open reading frame encoding a human CaM-PDE. The hybridization probe used to isolate the human DNA was derived from first strand cDNA of bovine lung tissue by PCR treatment. More specifically, the 23- mer oligonucleotide designated PCR-2S in Example I (see, SEQ ID NO: 1) was combined in a PCR reaction with bovine lung cDNA and a redundant antisense 23-mer oligonucleotide (PCR-5AS) based on the pCAM insert sequence with SEQ ID NO: 46 5'TCRTTNGTNGTNCCYTTCATRTT-3' representing the amino acid sequence SEQ ID NO: 47 NMKGTTND, according to the general procedures of Examples I and III, to generate a 1098 bp cDNA fragment representing a large portion of the coding region of the pCAM-40 insert. The PCR products were purified on a 1% agarose gel using 0.4 M Tris-acetate/0.001 M EDTA buffer containing 0.5 μg/ml ethidium bromide. The DNA products were visualized with UV light, cleanly excised from the gel with a razor blade, purified using Geneclean II reagent kit and ligated into EcoRV-cut pBluescript vector DNA. To determine if the PCR amplification products were CAM-PDE cDNAs, the subcloned PCR DNA products were sequenced from the ends using T3 and T7 promoter primers and either Sequenase or Taq Polymerase sequencing kits. Approximately 250 bases from each end of this DNA were then compared to the amino acid sequence of bovine CAM- PDE, confirming that the PCR DNA product was a partial CAM PDE cDNA. This clone was designated pCAM-1000 and contained a 1.1-kb insert of nucleic acid that corresponds to nucleotides 409 to 1505 of the insert of pCAM-40. pCaMlOOO was digested with the restriction enzymes HinDIII and BamHI. The 1.1-kb fragment was purified by agarose gel electrophoresis and then digested with the restriction enzyme Accl. The two fragments were separated and purified by agarose gel electrophoresis. These separated fragments were labeled with radioactive nucleotides by random priming. Human cDNA libraries were plated on 150 mm petri dishes at a density of approximately 50,000 plaques per dish and duplicate nitrocellulose filter replicas were prepared. Each probe was hybridized to a separate set of the duplicate filters. The filters were hybridized overnight at 65°C in 3x SSC, 0.1% sarkosyl, 50 μg/ml salmon testes DNA, lOx Denhardt's solution, 20 mM sodium phosphate (pH 6.8) . They were washed at 65°C in 2x SSC containing 0.1% SDS. A λ gtlO library prepared from human hippocampus mRNA yielded three hybridizing plaques of the approximately 500,000 screened. Of these three hybridizing plaques, two hybridized to both probes and the third hybridized to the longer of the two probes. The λ Cam H6a clone contains an approximately 2kb insert that is homologous to the cDNA encoding the bovine clone of pCAM-40. The λ cam H6a cDNA was subcloned into the plasmid Bluescript KS for sequence analysis. Although the cDNA library had been constructed with EcoRI linkers, one of the EcoRI sites that should have flanked the cDNA insert did not cut with EcoRI. Thus, the cDNA was subcloned as two fragments: an approximately 0.7kb EcoRI/Hindlll fragment (pcamH6C) and an approximately 1.6kb Hindlll fragment that contained approximately 1.3kb of cDNA and 0.25kb of flanking λgtlO vector DNA (pcamH6B) . DNA sequence analysis revealed that it encoded most of a human CaM-PDE homologous to the bovine 61k CaM-PDE, except that the human cDNA appeared to be missing two base pairs in the middle of the coding region. These missing nucleotides correspond to positions 626 and 627 of the human cDNA sequence if it is aligned with the pCAM-40 bovine 61kDa CaM-PDE (SEQ. ID NO: 5 for maximum homology. Another of the cDNA clones from the hippocampus cDNA library that had been screened with the bovine 61kDa CaM-PDE probes was λcamH2a. It contained an approximately l.Okb insert. As was the case for λcamH6a cDNA, only one of the two EcoRI sites that should be prvesent at the ends of the insert would cut. The original subcloning and DNA sequence analysis for this cDNA utilized PCR fragments generated with oligos in the flanking λgtlO vector arms. This cDNA overlaps much of the 5' end of the insert in λcamH6a and contained the additional two nucleotides predicted by the bovine sequence and required to maintain the PDE open reading frame. The λcamH2a insert also appeared to contain two introns; one 5' of the initiator methionine and one downstream of the Hindlll site. The EcoRI/Hindlll fragment from λcamH2a (corresponding to the region covered by pcamH6C) was subcloned into the plasmid Bluescript SK " and designated pcamH2A-16. This was then used as the source of the two additional bp in the construction of yeast expression plasmids described below. Two different plasmids were constructed for human CaM-PDE expression in yeast. One plasmid, pHcamδl- 6N-7, contains the entire open reading frame. The second plasmid, pHcam61metl40, starts at an internal methionine (beginning at nucleotide position 505) and extends to the end of the open reading frame. These expression plasmids were constructed by modifying the 3' portion of the open reading frame and then adding the two differently modified 5' ends to the 3' end. The sequence of the cDNA insert of pHcam61-6N-7 is set out in SEQ. ID NO: 48 and the deduced amino acid sequence of the CaM-PDE encoded thereby is set out in SEQ. ID NO: 49. During construction of the cDNA insert, the nucleotide at position 826 was altered from T to C, but the encoded amino acid was conserved. Plasmid pHcam61metl40, as noted above, has a cDNA insert lacking the first 140 codons of the coding region of the pHcam61-6N-7 but is otherwise identical thereto. A third cDNA, λcamH3a, contained an approximately 2.7kb insert. This cDNA insert was subcloned for sequence analysis. Although the cDNA library had been constructed with EcoRI. the inserted cDNA in λcamH3a could not be excised with EcoRI. Presumably one of the EcoRI sites was destroyed during the construction of the library. The cDNA insert was excised from the λ clone by digestion with Hindlll and EcoRI. This digestion yields two relevant fragments, a 0.6kb Hindlll fragment which contains a portion of DNA from the left arm of λgtlO attached to the cDNA insert and an approximately 2.4kb Hindlll/EcoRI fragment containing the remainder of the cDNA insert. These two fragments were assembled in the plasmid Bluescript KS to yield an approximately 3kb fragment. The orientation of the small Hindlll fragment was the same as the original λ clone. This subclone is known as pcamH3EF. Although this cDNA hybridizes to the bovine probe from the bovine CaM-PDE 61kDa cDNA, sequence analysis revealed that it appeared to be the product of a different CaM-PDE gene. Plasmid pcamH3EF contains what may be the entire open reading frame and would encode a protein approximately 75% homologous to the protein encoded by the insert of pHcam61-6N-7 over much of its lengths. DNA and deduced amino acid sequences are set out in SEQ. ID NOS: 50 and 51, respectively. The DNA sequence of the region between nucleotide 80 and 100 of pcamH3EF is uncertain. This area is 5' to the initiator methionine codon and thus does not effect the open reading frame. An approximately 2.4kb fragment of pcamH3EF was gel purified following digestion with the restriction enzymes Hindlll and EcoRI. This fragment was used to screen additional human cDNA libraries in a similar manner to the screen described above. Screening approximately 5x10 5 plaques from a human heart cDNA library (Stratagene) yielded two plaques that hybridized to the pcamH3EF probe. The Bluescript SK " plasmid pcamHella was excised in vivo from one of these positive λZapII clones. DNA and deduced amino acid sequences for the cDNA insert are set out in SEQ. ID NO: 52 and 53, respectively. Sequence analysis of pcamHella showed that the insert began at nucleotide position 610 of pcamH3EF and was nearly identical through nucleotide position 2066, at which point the DNA sequence diverged from that of pcamH3EF. The cDNA insert of pcamHella continued for approximately 0.6kb. The consequence of this divergence is to alter the carboxy terminus of the protein that would be encoded by the open reading frame within the cDNA. The pcamH3EF cDNA could encode a protein of 634 amino acids (MW72,207). Assuming the 5' end of the pcamHella cDNA is the same as that of the 5' end of pcamH3EF (5' to nucleotide position 610) , pcamHella could encode a 709 amino acid protein (MW80,759). These divergent 3' ends may be the consequence of alternative splicing, lack of splicing, or unrelated DNA sequences being juxtaposed during the cloning process. EXAMPLE VIII Expression of Bovine and Human PDE cDNAs for Complementation of Yeast Phenotypic Defects The present example relates to the expression of bovine and PDE clones in yeast demonstrating the capacity of functional PDE expression products to suppress the heat shock phenotype associated with mutation of yeast phosphodiesterase genes and also relates to the biochemical assay of expression products. The host cells used in these procedures were 2« cerevisiae yeast strains 10DAB (ATCC accession No. 74049) and YKS45, both of which were pde 1— pde2— resulting in a phenotype characterized by heat shock sensitivity, i.e., the inability of cells to survive exposure to elevated temperatures on the order of 55-56°C. In these complementation procedures, the inserted gene product was noted to conspicuously modify the heat shock phenotype. This capacity, in turn, demonstrates the feasibility of systems designed to assay chemical compounds for their ability to modify (and especially the ability to inhibit) the in vivo enzymatic activity of mammalian Ca 2+ /calmodulin stimulated and cGMP stimulated cyclic nucleotide phosphodiesterases. A. Yeast Phenotype complementation by Expression of a cDNA Encoding CaM-PDE A 2.2 kb cDNA fragment, adapted for insertion into yeast expression plasmids pADNS (ATCC accession No. 68588) and pADANS (ATCC accession No. 68587) was derived from plasmid pCAM-40 (Example I) by polymerase chain reaction. Briefly, the following PCR amplification was employed to alter the pCAM-40 DNA insert to align it appropriately with the ADH1 promoter in the vectors. One oligonucleotide primer (Oligo A) used in the PCR reaction SEQ ID NO: 54 5'-TACGAAGCTTTGATGGGGTCTACTGCTAC-3' anneals to the pCaM-40 cDNA clone at base pair positions 100-116 and includes a Hindlll site before the initial methionine codon. A second oligonucleotide primer (Oligo B) SEQ ID NO: 55 5'-TACGAAGCTTTGATGGTTGGCTTGGCATATC-3' was designed to anneal at positions 520-538 and also includes a Hindlll site two bases before a methionine codon. The third oligonucleotide SEQ ID NO: 56 5'-ATTACCCCTCATAAAG-3' annealed to a position in the plasmid that was 3' of the insert. For one reaction, Oligo A and Oligo C were used as primers with pCAM-40 as the template. The nucleic acid product of this reaction included the entire open reading frame. A second reaction used Oligo B and Oligo C as primers on the template pCAM-40 and yielded a nucleic acid product that lacked the portion of the cDNA sequence encoding the calmodulin binding domain. These amplified products were digested with Hindlll and Notl and ligated to Hindlll/Notl-digested yeast expression vectors pADNS and pADANS. Plasmid clones containing inserts were selected and transformed into _S . cerevisiae strain 10DAB by lithium acetate transformation. Transformed yeast were streaked in patches on agar plates containing synthetic medium lacking the amino acid leucine (SC-leucine agar) and grown for 3 days at 30°C. Replicas of this agar plate were made with three types of agar plates: one replica on SC-leucine agar, one replica on room temperature YPD agar, and three replicas on YPD agar plates that had been warmed to 56°C. The three warmed plates were maintained at 56°C for 10, 20, or 30 minutes. These replicas were than allowed to cool to room temperature and then all of the plates were placed at 30°C. Yeast transformed with plasmids constructed to express the CaM-PDE were resistant to the thermal pulse. More specifically, both the construct designed to express the complete open reading frame and that designed to express the truncated protein (including the catalytic region but not the calmodulin binding domain) , in either pADNS or pADANS, complemented the heat shock sensitivity phenotype of the 10DAB host cells, i.e., rendered them resistant to the 56°C temperature pulse. In a like manner, plasmids pHcam61-6N-7 and pHcam61metl40 (Example VII) were transformed into yeast host 10DAB. Heat shock phenotypes were suppressed in both transformants. B. Biochemical Assay of Expression Products The bovine CaM-PDE expression product was also evaluated by preparing cell-free extracts from the 10DAB yeast cells and measuring the extracts' biochemical phosphodiesterase activity. For this purpose, 200 ml cultures of transformed yeast were grown in liquid SC- leucine to a density of about 6 million cells per ml. The cells were collected by centrifugation and the cell pellets were frozen. Extracts were prepared by thawing the frozen cells on ice, mixing the cells with 1 ml of PBS and an equal volume of glass beads, vortexing them to disrupt the yeast cells, and centrifuging the disrupted cells at approximately 12,000 x g for 5 min to remove insoluble debris. The supernatant was assayed for phosphodiesterase activity. Extracts of yeast cells, up to 50 μl, were assayed for phosphodiesterase activity in 50mM Tris (pH 8.0), 1.0 mM EGTA, 0.01 mg/mL BSA (bovine serum albumin), [ 3 H]-cyclic nucleotide (4-10,000 cpm/pmol), and 5 mM MgCl 2 in a final volume of 250 μl at 30°C in 10 x 75 mm glass test tubes. The incubations were terminated by adding 250 μl of 0.5 M sodium carbonate pH 9.3, 1M NaCl, and 0.1% SDS. The products of the phosphodiesterase reaction were separated from the cyclic nucleotide by chromatography on 8 x 33 mm columns of BioRad Affi-Gel 601 boronic acid gel. The columns were equilibrated with 0 * .25M sodium bicarbonate (pH 9.3) and 0.5 M NaCl. The reactions were applied to the columns. The assay tubes were rinsed with 0.25M sodium bicarbonate (pH 9.3) and 0.5 M NaCl and this rinse was applied to the columns. The boronate columns were washed twice with 3.75 ml of 0.25 M sodium bicarbonate (pH 9.3) and 0.5 M NaCl followed by 0.5 ml of 50 mM sodium acetate (pH 4.5). The product was eluted with 2.5 ml of 50 mM sodium acetate (pH 4.5) containing 0.1 M sorbitol and collected in scintillation vials. The eluate was mixed with 4.5 ml Ecolite Scintillation Cocktail and the radioactivity measured by liquid scintillation spectrometry. Both the construct designed to express the complete bovine open reading frame and that designed to express a truncated protein, in either pADNS or pADANS, expressed active protein as determined by biochemical phosphodiesterase assay of cell extracts. Extracts of 10DAB harboring pcam61metl40 yielded measurable phorphodiesterase activity (see, infra, second method of part D) while the extract of 10DAB cells harboring pcamH61-6N-7 lacked detectable activity. c. Yeast Phenotype Complementation by Expression of a cDNA Encoding a cGS-PDE The plasmid p3CGS-5, which contains a 4.2-kb DNA fragment encoding the bovine cGS-PDE, was adapted for cloning into pADNS and pADANS by replacing the first 147 bases of the cDNA with a restriction site suitable for use in insertion into plasmids. The oligonucleotide BS1, having the sequence SEQ ID NO: 57 5'TACGAAGCTTTGATGCGCCGACAGCCTGC, encodes a Hindlll site and anneals to positions 148-165 of the cDNA insert. An oligonucleotide designated BS3 SEQ ID NO: 58 GGTCTCCTGTTGCAGATATTG, anneals to positions 835-855 just 3' of a unique Nsil site. The resulting PCR-generated fragment following digestion with Hindlll and Nsil was then ligated to Hindlll- and Nsil-digested p3CGS-5 thereby replacing the original 5' end of the bovine cDNA. A plasmid derived from this ligation was digested with Hindlll and Notl to release the modified cDNA insert. The insert was cloned into pADNS and pADANS at their Hindlll and Notl sites. These plasmids were then transformed into the yeast strain 10DAB by the lithium acetate method and the transformed cells were grown and subjected to elevated temperatures as in Section A, above. Yeast transformed with plasmids constructed to express the bovine cGS-PDE were resistant to the thermal pulse. In a like manner, plasmid pHcgsδn (Example VI) was transformed into yeast host strain YKS45 by lithium acetate transformation. Heat shock analysis was performed as above except that the plates were initially grown two days at 30°C and the warmed plates were maintained at 56°C for 10, 20, 30 and 45 minutes. Yeast transformed with the plasmid designed to express the full length human cGS-PDE was resistant to thermal pulse. D. Biochemical Assay of Expression Product The expression of the bovine cGS-PDE was also evaluated by preparing cell-free extracts from the yeast and measuring the extracts' biochemical phosphodiesterase activity. For this purpose, 50 ml cultures of transformed 10DAB yeast cells were grown in liquid SC- leucine to a density of about 10 million cells per ml. Sherman et al. , Methods in Yeast Genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1986) . The cells were collected by centrifugation, the cell pellets were washed once with water, and the final cell pellets were frozen. To prepare an extract, the frozen cells were thawed on ice, mixed with 1 ml of PBS and an equal volume of glass beads, vortexed to disrupt the yeast cells, and centrifuged to remove debris. The supernatant was then assayed for phosphodiesterase activity as in Section B, above. Constructs in either pADNS or pADANS expressed active protein as determined by biochemical phosphodiesterase assay of cell extracts. YKS45 transformed with plasmid pHcgsβn were grown in SC-leu medium to 1-2X10 7 cells/ml. The cells were harvested by centrifugation and the cell pellets were frozen. A frozen cell pellet, typically containing 10 10 cells, was mixed with lysis buffer (25mM Tris HCl pH 8, 5mM EDTA, 5mM EGTA, lmM o-phenathroline, 0.5mM AEBSF, O.Olmg/mL pepstatin, O.Olmg/mL leupeptin, O.Olmg/mL aprotinin, 0.1% 2-mercaptoethanol) to bring the total volume to 2.5 ml. The mixture was thawed on ice and then added to an equal volume of glass beads. The cells were disrupted by cycles of vortexing and chilling on ice, then additional lysis buffer was mixed with the disrupted cells to bring the total lysis buffer added to 5 ml. The suspension was centrifuged for 5 min. at 12,000xg. The supernatant was removed and either assayed immediately or frozen rapidly in a dry ice ethanol bath and stored at - 70°C. Phosphodiesterase activity was assayed by mixing an aliquot of cell extract in (40mM Tris-Cl pH 8.0, l.mM EGTA, O.lmg/mL BSA) containing 5mM MgCl 2 and radioactive substrate, incubating at 30°C for up to 30 min. and terminating the reaction with stop buffer (0.1M ethanola ine pH 9.0, 0.5M ammonium sulfate, lOmM EDTA, 0.05% SDS final concentration) . The product was separated from the cyclic nucleotide substrate by chromatography on BioRad Affi-Gel 601. The sample was applied to a column containing approximately 0.25 ml of Affi-Gel 601 equilibrated in column buffer (0.1M ethanolamine pH 9.0 containing 0.5M ammonium sulfate) . The column was washed five times with 0.5ml of column buffer. The product was eluted with four 0.5 ml aliquots of 0.25M acetic acid and mixed with 5 ml Ecolume (ICN Biochemicals) . The radioactive product was measured by scintillation counting. Extracts from yeast expressing the human cGS-PDE hydrolyzed both cyclic AMP and cyclic GMP, as expected for this isozyme. EXAMPLE IX Tissue Expression Studies Involving CaM-PDE and cGS-PDE Polynucleotides A. Northern Blot Analysis DNAs isolated in Examples I, III, and IV above were employed to develop probes for screening total or poly A-selected RNAs isolated from a variety of tissues and the results are summarized below. 1. Northern analysis was performed on mRNA prepared from a variety of bovine adrenal cortex, adrenal medulla, heart, aorta, cerebral cortex, basal ganglia, hippocampus, cerebellum, medulla/spinal cord, liver, kidney cortex, kidney medulla, kidney papillae, trachea, lung, spleen and T-lymphocyte tissues using an approximately 3kb radiolabeled cDNA fragment isolated from plasmid p3CGS-5 upon digestion with EcoRI and Smal. A single 4.5kb mRNA species was detected in most tissues. The size of the cGS-PDE mRNA appeared to be slightly larger (approximately 4.6kb) in RNA isolated from cerebral cortex, basal ganglia and hippocampus. The cGS PDE mRNA was most abundant in adrenal cortex. It was also abundant in adrenal medulla and heart. It appeared to be differentially expressed in anatomically distinct regions of the brain and kidney. Among RNAs isolated from five different brain regions, cGS PDE mRNA was most abundant in hippocampus, cerebral cortex, and basal ganglia. Very little cGS PDE transcript was detected in cerebellum or medulla and spinal cord RNAs. Although the cGS PDE mRNA was detected in all regions of the kidney, it appeared to be most abundant in the outer red medulla and papillae. The cGS PDE mRNA was also detected in liver, trachea, lung, spleen, and T-lymphocyte RNA. Very little cGS PDE mRNA was detected in RNA isolated from aorta. 2. Radiolabeled DNA probes were prepared from random hexamer primed fragments extended on heat denatured 1.6kb EcoRI restriction endonuclease fragments of the cDNA insert of plasmid pCAM-40. In Northern analysis, the DNA probes hybridized with 3.8 and 4.4kb mRNAs in brain and most of the other tissues analyzed including cerebral cortex, basal ganglia, hippocampus, cerebellum, medulla and spinal cord, heart, aorta, kidney medulla, kidney papillae, and lung. Hybridization of probe with the 3.8kb mRNA from liver, kidney cortex and trachea was only detected after longer autoradiographic exposure. 3. Northern blot analysis of mRNA from several tissues of the central nervous system was carried out using a subcloned, labeled pl2.3a DNA fragment (containing most of the conserved PDE catalytic domain) as a probe. The most intense hybridization signal was seen in mRNA from the basal ganglia and strong signals were also seen in mRNA from other tissues including kidney papilla and adrenal medulla. B. RNAse Protection 1. Three antisense riboprobes were constructed. Probe III corresponds to the catalytic domain-encoding region of p3cGS-5 (273 bp corresponding to bases 2393 through 2666 of SEQ. ID NO: 38) ; probe II to the cGMP-binding domain encoding (468 bp corresponding to bases 959 through 1426; and probe I to the 5' end and portions of amino terminal-encoding region (457 bases corresponding to bases 1 through 457) . Total RNAs extracted from all of the examined tissues completely protected probes II and III. Nearly complete protection (457 bases) of riboprobe I with RNAs isolated from adrenal cortex, adrenal medulla, and liver was also observed. However, RNA isolated from cerebral cortex, basal ganglia, and hippocampus only protected an approximately 268-base fragment of riboprobe I. A relatively small amount of partially protected probe I identical in size with the major fragments observed in the brain RNA samples was also detected in RNAs isolated from all of the examined tissues except liver. Interestingly, heart RNA yielded both completely protected (457 base) riboprobe and, like brain RNA, a 268-base fragment. Unlike the protection pattern observed using RNAs isolated from any of the other tissues, however, the partially protected riboprobe I fragment appeared to be more abundant. The results suggest that two different cGS-PDE RNA species are expressed. 2. Radiolabeled antisense riboprobes corresponding to a portion of either the CaM-binding domain on the catalytic domain of CaM-PDE were constructed from restriction endonuclease cleavage fragments (Accl/Sstl and Tthllll/HincII) of pCAM-40cDNA. Total RNAs isolated from five different brain regions (cerebral cortex, basal ganglia, hippocampus, cerebellum, and medulla/spinal cord) completely protected the antisense riboprobes encoding both the CaM-binding and catalytic domains. Total RNAs from heart, aorta, lung, trachea and kidney completely protected the riboprobe corresponding to the catalytic domain but only protected about 150 bases of the CaM-binding domain riboprobe, suggesting that an isoform structurally related to the 61kD CaM-PDE is expressed in these tissues. 3. Antisense riboprobes were generated based on plasmid pl2.3a and corresponding to bases -1 through 363 and 883-1278 of SEQ. ID NO: 26. The former probe included 113 bases of the 5' noncoding sequence as well as the start methionine codon through the putative CaM- binding domain, while the latter encoded the catalytic domain. Among all tissues assayed, RNA from basal ganglia most strongly protected each probe. Strong signals of a size corresponding to the probe representing the amino terminus were observed in protection by cerebral cortex, cerebellum, basal ganglia, hippocampus and adrenal medulla RNA. No protection was afforded to this probe by kidney papilla or testis RNA even though the tissue showed signals on the Northern analysis and RNAse protection of the conserved domain probe, suggesting that a structurally related isozyme is expressed in this tissue. While the present invention has been described in terms of specific methods and compositions, it is understood that variations and modifications will occur to those skilled in the art upon consideration of the invention. Consequently only such limitations as appear in the appended claims should be placed thereon. Accordingly, it is intended in the appended claims to cover all such equivalent variations which come within the scope of the invention as claimed. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Beavo, Joseph A. Bentley, Kelley Charbonneau, Harry Sonnenburg, William K. (ii) TITLE OF INVENTION: DNA Encoding Mammalian Phosphodiesterases (iii) NUMBER OF SEQUENCES: 58 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Bicknell (B) STREET: Two First National Plaza, 20 South Clark Street (C) CITY: Chicago (D) STATE: Illinois (E) COUNTRY: USA (F) ZIP: 60603 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/688,356 (B) FILING DATE: 04-APR-1991 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Noland, Greta E. (B) REGISTRATION NUMBER: 35,302 (C) REFERENCE/DOCKET NUMBER: 27866/30822 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (312) 346-5750 (B) TELEFAX: (312) 984-9740 (C) TELEX: 25-3856 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: AARATGGGNA TGAARAARAA 20 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO;2: Lys Met Gly Met Met Lys Lys Lys 1 5 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ACRTTCATYT CYTCYTCYTG CAT 23 (2) INFORMATION FOR SEQ ID NO: : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 Met Gin Glu Glu Glu Met Asn Val 1 5 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: . (A) LENGTH: 2291 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 100..1689 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GGCTCAGAAA CTGTAGGAAT TCTGATGTGC TTCGGTGCAT GGAACAGTAA CAGATGAGCT 60 GCTTTGGGGA GAGCTGGAAC GCTCAGTCGG AGTATCATC ATG GGG TCT ACT GCT 114 Met Gly Ser Thr Ala 1 5 ACA GAA ACT GAA GAA CTG GAA AAC ACT ACT TTT AAG TAT CTC ATT GGA 162 Thr Glu Thr Glu Glu Leu Glu Asn Thr Thr Phe Lys Tyr Leu lie Gly 10 15 20 GAA CAG ACT GAA AAA ATG TGG CAA CGC CTG AAA GGA ATA CTA AGA TGC 210 Glu Gin Thr Glu Lys Met Trp Gin Arg Leu Lys Gly lie Leu Arg Cys 25 30 35 TTA GTG AAG CAG CTG GAA AAA GGT GAT GTT AAC GTC ATC GAC TTA AAG 258 Leu Val Lys Gin Leu Glu Lys Gly Asp Val Asn Val lie Asp Leu Lys 40 45 50 AAG AAT ATT GAA TAT GCA GCA TCT GTG TTG GAA GCA GTT TAT ATT GAT 306 Lys Asn lie Glu Tyr Ala Ala Ser Val Leu Glu Ala Val Tyr lie Asp 55 60 65 GAA ACA AGG AGA CTG CTG GAC ACC GAT GAT GAG CTC AGT GAC ATT CAG 354 Glu Thr Arg Arg Leu Leu Asp Thr Asp Asp Glu Leu Ser Asp lie Gin 70 75 80 85 TCG GAT TCC GTC CCA TCA GAA GTC CGG GAC TGG TTG GCT TCT ACC TTT 402 Ser Asp Ser Val Pro Ser Glu Val Arg Asp Trp Leu Ala Ser Thr Phe 90 95 100 ACA CGG AAA ATG GGG ATG ATG AAA AAG AAA TCT GAG GAA AAA CCA AGA 450 Thr Arg Lys Met Gly Met Met Lys Lys Lys Ser Glu Glu Lys Pro Arg 105 110 115 TTT CGG AGC ATT GTG CAT GTT GTT CAA GCT GGA ATT TTT GTG GAA AGA 498 Phe Arg Ser lie Val His Val Val Gin Ala Gly lie Phe Val Glu Arg 120 125 130 ATG TAC AGA AAG TCC TAT CAC ATG GTT GGC TTG GCA TAT CCA GAG GCT 546 Met Tyr Arg Lys Ser Tyr His Met Val Gly Leu Ala Tyr Pro Glu Ala 135 140 145 GTC ATA GTA ACA TTA AAG GAT GTT GAT AAA TGG TCT TTT GAT GTA TTT 594 Val lie Val Thr Leu Lys Asp Val Asp Lys Trp Ser Phe Asp Val Phe 150 155 160 165 GCC TTG AAT GAA GCA AGT GGA GAA CAC AGT CTG AAG TTT ATG ATT TAT 642 Ala Leu Asn Glu Ala Ser Gly Glu His Ser Leu Lys Phe Met lie Tyr 170 175 180 GAA CTA TTC ACC AGA TAT GAT CTT ATC AAC CGT TTC AAG ATT CCT GTT 690 Glu Leu Phe Thr Arg Tyr Asp Leu lie Asn Arg Phe Lys lie Pro Val 185 190 195 TCT TGC CTA ATT GCC TTT GCA GAA GCT CTA GAA GTT GGT TAC AGC AAG 738 Ser Cys Leu lie Ala Phe Ala Glu Ala Leu Glu Val Gly Tyr Ser Lys 200 205 210 TAC AAA AAT CCA TAC CAC AAT TTG ATT CAT GCA GCT GAT GTC ACT CAA 786 Tyr Lys Asn Pro Tyr His Asn Leu lie His Ala Ala Asp Val Thr Gin 215 220 225 ACT GTG CAT TAC ATA ATG CTT CAT ACA GGT ATC ATG CAC TGG CTC ACT 834 Thr Val His Tyr lie Met Leu His Thr Gly lie Met His Trp Leu Thr 230 235 240 245 GAA CTG GAA ATT TTA GCA ATG GTC TTT GCC GCT GCC ATT CAT GAC TAT 882 Glu Leu Glu lie Leu Ala Met Val Phe Ala Ala Ala lie His Asp Tyr 250 255 260 GAG CAT ACA GGG ACT ACA AAC AAT TTT CAC ATT CAG ACA AGG TCA GAT 930 Glu His Thr Gly Thr Thr Asn Asn Phe His lie Gin Thr Arg Ser Asp 265 270 275 GTT GCC ATT TTG TAT AAT GAT CGC TCT GTC CTT GAA AAT CAT CAT GTG 978 Val Ala lie Leu Tyr Asn Asp Arg Ser Val Leu Glu Asn His His Val 280 285 290 AGT GCA GCT TAT CGC CTT ATG CAA GAA GAA GAA ATG AAT GTC CTG ATA 1026 Ser Ala Ala Tyr Arg Leu Met Gin Glu Glu Glu Met Asn Val Leu lie 295 300 305 AAT TTA TCC AAA GAT GAC TGG AGG GAT CTT CGG AAC CTA GTG ATT GAA 1074 Asn Leu Ser Lys Asp Asp Trp Arg Asp Leu Arg Asn Leu Val lie Glu 310 315 320 325 ATG GTG TTG TCT ACA GAC ATG TCG GGT CAC TTC CAG CAA ATT AAA AAT 1122 Met Val Leu Ser Thr Asp Met Ser Gly His Phe Gin Gin lie Lys Asn 330 335 340 ATA AGA AAT AGT TTG CAG CAA CCT GAA GGG CTT GAC AAA GCC AAA ACC 1170 lie Arg Asn Ser Leu Gin Gin Pro Glu Gly Leu Asp Lys Ala Lys Thr 345 350 355 ATG TCC CTG ATT CTC CAT GCA GCA GAC ATC AGT CAC CCA GCC AAA TCC 1218 Met Ser Leu lie Leu His Ala Ala Asp lie Ser His Pro Ala Lys Ser 360 365 370 TGG AAG CTG CAC CAC CGA TGG ACC ATG GCC CTA ATG GAG GAG TTT TTC 1266 Trp Lys Leu His His Arg Trp Thr Met Ala Leu Met Glu Glu Phe Phe 375 380 385 CTA CAG GGA GAT AAA GAA GCT GAA TTA GGG CTT CCA TTT TCC CCG CTT 1314 Leu Gin Gly Asp Lys Glu Ala Glu Leu Gly Leu Pro Phe Ser Pro Leu 390 395 400 405 TGC GAT CGG AAG TCA ACG ATG GTG GCC CAG TCC CAA ATA GGT TTC ATT 1362 Cys Asp Arg Lys Ser Thr Met Val Ala Gin Ser Gin lie Gly Phe lie 410 415 420 GAT TTC ATA GTA GAA CCA ACA TTT TCT CTT CTG ACA GAC TCA ACA GAG 1410 Asp Phe lie Val Glu Pro Thr Phe Ser Leu Leu Thr Asp Ser Thr Glu 425 430 435 AAA ATT ATT ATT CCT CTT ATA GAG GAA GAC TCG AAA ACC AAA ACT CCT 1458 Lys lie lie lie Pro Leu lie Glu Glu Asp Ser Lys Thr Lys Thr Pro 440 445 450 TCC TAT GGA GCA AGC AGA CGA TCA AAT ATG AAA GGC ACC ACC AAT GAT 1506 Ser Tyr Gly Ala Ser Arg Arg Ser Asn Met Lys Gly Thr Thr Asn Asp 455 460 465 GGA ACC TAC TCC CCC GAC TAC TCC CTT GCC AGC GTG GAC CTG AAG AGC 1554 Gly Thr Tyr Ser Pro Asp Tyr Ser Leu Ala Ser Val Asp Leu Lys Ser 470 475 480 485 TTC AAA AAC AGC CTG GTG GAC ATC ATC CAG CAG AAC AAA GAG AGG TGG 1602 Phe Lys Asn Ser Leu Val Asp lie lie Gin Gin Asn Lys Glu Arg Trp 490 495 500 AAA GAG TTA GCT GCT CAA GGT GAA CCT GAT CCC CAT AAG AAC TCA GAT 1650 Lys Glu Leu Ala Ala Gin Gly Glu Pro Asp Pro His Lys Asn Ser Asp 505 510 515 CTA GTA AAT GCT GAA GAA AAA CAT GCT GAA ACA CAT TCA TAGGTCTGAA 1699 Leu Val Asn Ala Glu Glu Lys His Ala Glu Thr His Ser 520 525 530 ACACCTGAAA GACGTCTTTC ATTCTAAGGA TGGGAGGAAA CAAATTCACA AGAAATCATG 1759 AAGACATATA AAAGCTACAT ATGCATAAAA AACTCTGAAT TCAGGTCCCC ATGGCTGTCA 1819 CAAATGAATG AACAGAACTC CCAACCCCGC CTTTTTTTAA TATAATGAAA GTGCCTTAGC 1879 ATGGTTGCAG CTGTCACCAC TACAGTGTTT TACAGACGGT TTCTACTGAG CATCACAATA 1939 AAGAGAATCT TGCATTACAA AAAAAAGAAA AAAATGTGGC TCGCTTTTAA GATGAAGCAT 1999 TTCCCAGTAT TTCTGAGTCA GTTGTAAGAT TCTTTAATCG ATACTAATAG TTTCACTAAT 2059 AGCCACTGTC AGTGTCACGC ACTGTGATGA AATCTTATAC TTAGTCCTTC AACAGTTCCA 2119 GAGTTGTGAC TGTGCTTAAT AGTTTGCATA TGAATTCTGG ATAGAAATCA AATCACAAAC 2179 TGCATAGAAA TTTTAAAAAC CAGCTCCATA TTAAATTTTT TTAAGATATT GTCTTGTATT 2239 GAAACTCCAA TACTTTGGCC ACCTGATGCA AAGAGCTGAC TCATTTGAAA CC 2291 (2) INFORMATION FOR SEQ ID NO:6 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 530 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 Met Gly Ser Thr Ala Thr Glu Thr Glu Glu Leu Glu Asn Thr Thr Phe 1 5 10 15 Lys Tyr Leu lie Gly Glu Gin Thr Glu Lys Met Trp Gin Arg Leu Lys 20 25 30 Gly lie Leu Arg Cys Leu Val Lys Gin Leu Glu Lys Gly Asp Val Asn 35 40 45 Val lie Asp Leu Lys Lys Asn lie Glu Tyr Ala Ala Ser Val Leu Glu 50 55 60 Ala Val Tyr lie Asp Glu Thr Arg Arg Leu Leu Asp Thr Asp Asp Glu 65 70 75 80 Leu Ser..Asp lie Gin Ser Asp Ser Val Pro Ser Glu Val Arg Asp Trp 85 90 95 Leu Ala Ser Thr Phe Thr Arg Lys Met Gly Met Met Lys Lys Lys Ser 100 105 110 Glu Glu Lys Pro Arg Phe Arg Ser lie Val His Val Val Gin Ala Gly 115 120 125 lie Phe Val Glu Arg Met Tyr Arg Lys Ser Tyr His Met Val Gly Leu 130 135 140 Ala Tyr Pro Glu Ala Val lie Val Thr Leu Lys Asp Val Asp Lys Trp 145 150 155 160 Ser Phe Asp Val Phe Ala Leu Asn Glu Ala Ser Gly Glu His Ser Leu 165 170 175 Lys Phe Met lie Tyr Glu Leu Phe Thr Arg Tyr Asp Leu lie Asn Arg 180 185 190 Phe Lys lie Pro Val Ser Cys Leu lie Ala Phe Ala Glu Ala Leu Glu 195 200 205 Val Gly Tyr Ser Lys Tyr Lys Asn Pro Tyr His Asn Leu lie His Ala 210 215 220 Ala Asp Val Thr Gin Thr Val His Tyr lie Met Leu His Thr Gly He 225 230 235 240 Met His Trp Leu Thr Glu Leu Glu He Leu Ala Met Val Phe Ala Ala 245 250 255 Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn Asn Phe His He 260 265 270 Gin Thr Arg Ser Asp Val Ala He Leu Tyr Asn Asp Arg Ser Val Leu 275 280 285 Glu Asn His His Val Ser Ala Ala Tyr Arg Leu Met Gin Glu Glu Glu 290 295 300 Met Asn Val Leu He Asn Leu Ser Lys Asp Asp Trp Arg Asp Leu Arg 305 310 315 320 Asn Leu Val He Glu Met Val Leu Ser Thr Asp Met Ser Gly His Phe 325 330 335 Gin Gin He Lys Asn He Arg Asn Ser Leu Gin Gin Pro Glu Gly Leu 340 345 350 Asp Lys Ala Lys Thr Met Ser Leu He Leu His Ala Ala Asp He Ser 355 360 365 His Pro Ala Lys Ser Trp Lys Leu His His Arg Trp Thr Met Ala Leu 370 375 380 Met Glu Glu Phe Phe Leu Gin Gly Asp Lys Glu Ala Glu Leu Gly Leu 385 390 395 400 Pro Phe Ser Pro Leu Cys Asp Arg Lys Ser Thr Met Val Ala Gin Ser 405 410 415 Gin He Gly Phe He Asp Phe He Val Glu Pro Thr Phe Ser Leu Leu 420 425 430 Thr Asp Ser Thr Glu Lys He He He Pro Leu He Glu Glu Asp Ser 435 440 445 Lys Thr Lys Thr Pro Ser Tyr Gly Ala Ser Arg Arg Ser Asn Met Lys 450 455 460 Gly Thr Thr Asn Asp Gly Thr Tyr Ser Pro Asp Tyr Ser Leu Ala Ser 465 470 475 480 Val Asp Leu Lys Ser Phe Lys Asn Ser Leu Val Asp He He Gin Gin 485 490 495 Asn Lys Glu Arg Trp Lys Glu Leu Ala Ala Gin Gly Glu Pro Asp Pro 500 505 510 His Lys Asn Ser Asp Leu Val Asn Ala Glu Glu Lys His Ala Glu Thr 515 520 525 His Ser 530 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Asp Asp His Val Thr He 1 5 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: ATGAGRAGRC AYGTHACNAT 20 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Leu Arg Cys Leu Val Lys Gin 1 5 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CTGCTTCACT AAGCATCTTA G 21 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 75 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: ATGAGAAGGC ACGTAACGAT CAGGAGGAAA CATCTCCAAA GACCCATCTT TAGACTAAGA 60 TGCTTAGTGA AGCAG 75 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATGGAYGAYC ACGTAACGAT C 21 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: AAGTATCTCA TTGGAGAACA G 21 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ATGGATGATC ACGTAACGAT CAGGAGGAAA CATCTCCAAA GACCCATCTT TAGA 54 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Asp Asp His Val Thr He Arg Arg Lys His Leu Gin Arg Pro He 1 5 10 15 Phe Arg (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2656 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 136..1677 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: TTGCTGTCGA GAGAAAGAGG AAACTACTTT TGCCTTCTGG GCTCCTTGCA GGACAATAGA 60 TCAGGATAAG CTTCCACATT CTCTCCCTGG ATTTCTGGAG TGGTTTCCAG GAACAAGCTA 120 AACTTTCACC TTTAA ATG GAT GAC CAT GTC ACA ATC AGG AGG AAA CAT CTC 171 Met Asp Asp His Val Thr He Arg Arg Lys His Leu 1 5 10 CAA AGA ^ CCC ATC TTT AGA CTA AGA TGC TTA GTG AAG CAG CTG GAA AAA 219 Gin Arg Pro He Phe Arg Leu Arg Cys Leu Val Lys Gin Leu Glu Lys 15 20 25 GGT GAT GTT AAC GTC ATC GAC TTA AAG AAG AAT ATT GAA TAT GCA GCA 267 Gly Asp Val Asn Val He Asp Leu Lys Lys Asn He Glu Tyr Ala Ala 30 35 40 TCT GTG TTG GAA GCA GTT TAT ATT GAT GAA ACA AGG AGA CTG CTG GAC 315 Ser Val Leu Glu Ala Val Tyr He Asp Glu Thr Arg Arg Leu Leu Asp 45 50 55 60 ACC GAT GAT GAG CTC AGT GAC ATT CAG TCG GAT TCC GTC CCA TCA GAA 363 Thr Asp Asp Glu Leu Ser Asp He Gin Ser Asp Ser Val Pro Ser Glu 65 70 75 GTC CGG GAC TGG TTG GCT TCT ACC TTT ACA CGG AAA ATG GGG ATG ATG 411 Val Arg Asp Trp Leu Ala Ser Thr Phe Thr Arg Lys Met Gly Met Met 80 85 90 AAA AAG AAA TCT GAG GAA AAA CCA AGA TTT CGG AGC ATT GTG CAT GTT 459 Lys Lys Lys Ser Glu Glu Lys Pro Arg Phe Arg Ser He Val His Val 95 100 105 GTT CAA GCT GGA ATT TTT GTG GAA AGA ATG TAC AGA AAG TCC TAT CAC 507 Val Gin Ala Gly He Phe Val Glu Arg Met Tyr Arg Lys Ser Tyr His 110 115 120 ATG GTT GGC TTG GCA TAT CCA GAG GCT GTC ATA GTA ACA TTA AAG GAT 555 Met Val Gly Leu Ala Tyr Pro Glu Ala Val He Val Thr Leu Lys Asp 125 130 135 140 GTT GAT AAA TGG TCT TTT GAT GTA TTT GCC TTG AAT GAA GCA AGT GGA 603 Val Asp Lys Trp Ser Phe Asp Val Phe Ala Leu Asn Glu Ala Ser Gly 145 150 155 GAA CAC AGT CTG AAG TTT ATG ATT TAT GAA CTA TTC ACC AGA TAT GAT 651 Glu His Ser Leu Lys Phe Met He Tyr Glu Leu Phe Thr Arg Tyr Asp 160 165 170 CTT ATC AAC CGT TTC AAG ATT CCT GTT TCT TGC CTA ATT GCC TTT GCA 699 Leu He Asn Arg Phe Lys He Pro Val Ser Cys Leu He Ala Phe Ala 175 180 185 GAA GCT CTA GAA GTT GGT TAC AGC AAG TAC AAA AAT CCA TAC CAC AAT 747 Glu Ala Leu Glu Val Gly Tyr Ser Lys Tyr Lys Asn Pro Tyr His Asn 190 195 200 TTG ATT CAT GCA GCT GAT GTC ACT CAA ACT GTG CAT TAC ATA ATG CTT 795 Leu He His Ala Ala Asp Val Thr Gin Thr Val His Tyr He Met Leu 205 210 215 220 CAT ACA GGT ATC ATG CAC TGG CTC ACT GAA CTG GAA ATT TTA GCA ATG 843 His Thr Gly He Met His Trp Leu Thr Glu Leu Glu He Leu Ala Met 225 230 235 GTC TTT GCC GCT GCC ATT CAT GAC TAT GAG CAT ACA GGG ACT ACA AAC 891 Val Phe Ala Ala Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn 240 245 250 AAT TTT CAC ATT CAG ACA AGG TCA GAT GTT GCC ATT TTG TAT AAT GAT 939 Asn Phe His He Gin Thr Arg Ser Asp Val Ala He Leu Tyr Asn Asp 255 260 265 CGC TCT GTC CTT GAA AAT CAT CAT GTG AGT GCA GCT TAT CGC CTT ATG 987 Arg Ser Val Leu Glu Asn His His Val Ser Ala Ala Tyr Arg Leu Met 270 275 280 CAA GAA ^ GAA GAA ATG AAT GTC CTG ATA AAT TTA TCC AAA GAT GAC TGG 1035 Gin Glu Glu Glu Met Asn Val Leu He Asn Leu Ser Lys Asp Asp Trp 285 290 295 300 AGG GAT CTT CGG AAC CTA GTG ATT GAA ATG GTG TTG TCT ACA GAC ATG 1083 Arg Asp Leu Arg Asn Leu Val He Glu Met Val Leu Ser Thr Asp Met 305 310 315 TCG GGT CAC TTC CAG CAA ATT AAA AAT ATA AGA AAT AGT TTG CAG CAA 1131 Ser Gly His Phe Gin Gin He Lys Asn He Arg Asn Ser Leu Gin Gin 320 325 330 CCT GAA GGG CTT GAC AAA GCC AAA ACC ATG TCC CTG ATT CTC CAT GCA 1179 Pro Glu Gly Leu Asp Lys Ala Lys Thr Met Ser Leu He Leu His Ala 335 340 345 GCA GAC ATC AGT CAC CCA GCC AAA TCC TGG AAG CTG CAC CAC CGA TGG 1227 Ala Asp He Ser His Pro Ala Lys Ser Trp Lys Leu His His Arg Trp 350 355 360 ACC ATG GCC CTA ATG GAG GAG TTT TTC CTA CAG GGA GAT AAA GAA GCT 1275 Thr Met Ala Leu Met Glu Glu Phe Phe Leu Gin Gly Asp Lys Glu Ala 365 370 375 380 GAA TTA GGG CTT CCA TTT TCC CCG CTT TGC GAT CGG AAG TCA ACG ATG 1323 Glu Leu Gly Leu Pro Phe Ser Pro Leu Cys Asp Arg Lys Ser Thr Met 385 390 395 GTG GCC CAG TCC CAA ATA GGT TTC ATT GAT TTC ATA GTA GAA CCA ACA 1371 Val Ala Gin Ser Gin He Gly Phe He Asp Phe He Val Glu Pro Thr 400 405 410 TTT TCT CTT CTG ACA GAC TCA ACA GAG AAA ATT ATT ATT CCT CTT ATA 1419 Phe Ser Leu Leu Thr Asp Ser Thr Glu Lys He He He Pro Leu He 415 420 425 GAG GAA GAC TCG AAA ACC AAA ACT CCT TCC TAT GGA GCA AGC AGA CGA 1467 Glu Glu Asp Ser Lys Thr Lys Thr Pro Ser Tyr Gly Ala Ser Arg Arg 430 435 440 TCA AAT ATG AAA GGC ACC ACC AAT GAT GGA ACC TAC TCC CCC GAC TAC 1515 Ser Asn Met Lys Gly Thr Thr Asn Asp Gly Thr Tyr Ser Pro Asp Tyr 445 450 455 460 TCC CTT GCC AGC GTG GAC CTG AAG AGC TTC AAA AAC AGC CTG GTG GAC 1563 Ser Leu Ala Ser Val Asp Leu Lys Ser Phe Lys Asn Ser Leu Val Asp 465 470 475 ATC ATC CAG CAG AAC AAA GAG AGG TGG AAA GAG TTA GCT GCT CAA GGT 1611 He He Gin Gin Asn Lys Glu Arg Trp Lys Glu Leu Ala Ala Gin Gly 480 485 490 GAA CCT GAT CCC CAT AAG AAC TCA GAT CTA GTA AAT GCT GAA GAA AAA 1659 Glu Pro Asp Pro His Lys Asn Ser Asp Leu Val Asn Ala Glu Glu Lys 495 500 505 CAT GCT GAA ACA CAT TCA TAGGTCTGAA ACACCTGAAA GACGTCTTTC 1707 His Ala Glu Thr His Ser 510 ATTCTAAGGA TGGGAGAGTG CTGTAACTAC AAAACTTTCA AGCTTCTAAG TAAAAGGAAA 1767 GCAAAAACAA AATTACAGAA AAATATTTTT GCAGCTCTGA GGCTATTTAG ATTGTCCTTG 1827 TTGTTTTAAA TACATGGGAA CCAAGTGAGA AGAGGGGCTG CTCAGAAGTT GTAGTCGAAG 1887 TCCTAAGACA ACAATGAAGC ATCAGAGCCC TGACTCTGTG ACCTGATGAA CTCTTCGTTG 1947 TAACTCTCAA GCTGGGAAAC CACAGCGAAT CCTGTTCCTG AAAGCAGTGA ACCAGCCTGC 2007 ATCCACCACT GTTATTGCAA AGCACGAAAG CATCACCCAC GTGGGGGTCA TCACAATGCA 2067 AGTCACGCAA GACCTATGAC CAAGATGACA AGAACCTCCA GCCCTTGTTG GAGACAGACA 2127 CTAGAACTGA GAGTGGGATT TGCCTTCTGG GGTGTTAATC CCATCAGGAT GTAACAAAAT 2187 ATATTACAGG TCAAGGGATA AGGGACAAGA AGTGTGTGTC TGTGTGTGTG TGTGTGTATG 2247 TGCGCGCACT CAAAAATGTC TGTGAAAATG GAAGCCCACA CTCTTCTGCA CAGAGAGCAT 2307 TATTTGATGT GATTTATAAT TTTACTACAA ACAAACGAAC TGCAGCCATT GGAGACTGCT 2367 TCCTTGTCAT GTTTTGCCTG AGCATGTGCA GAGCCTTGCC TTTGTTCCAA ATTGAAGAAC 2427 TACCTTTATT TGTTATTAGC TGCCAAGAAA GGTCAAGCCC AAGTAGGTGT TGTCATTTTC 2487 ACCGTACAAA CTCTTCAATG ATTGTTAGAC TAAAGGAATT TGTTTTTGTG AAAGGTAGAA 2547 ATTAGATGGA AAAGATCAAG AGTAGTCATC AATTAAAGAA GAAAGTGAAG GTGGATATGT 2607 CCATCCTAAT GAGTTTTCTG TTGCACCTGC TTCTTCCCTG CGACAGCAA 2656 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 514 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: . SEQ ID NO:17: Met Asp Asp His Val Thr He Arg Arg Lys His Leu Gin Arg Pro He 1 5 10 15 Phe Arg Leu Arg Cys Leu Val Lys Gin Leu Glu Lys Gly Asp Val Asn 20 25 30 Val He Asp Leu Lys Lys Asn He Glu Tyr Ala Ala Ser Val Leu Glu 35 40 45 Ala Val Tyr He Asp Glu Thr Arg Arg Leu Leu Asp Thr Asp Asp Glu 50 55 60 Leu Ser Asp He Gin Ser Asp Ser Val Pro Ser Glu Val Arg Asp Trp 65 70 75 80 Leu Ala Ser Thr Phe Thr Arg Lys Met Gly Met Met Lys Lys Lys Ser 85 90 95 Glu Glu Lys Pro Arg Phe Arg Ser He Val His Val Val Gin Ala Gly 100 105 110 He Phe Val Glu Arg Met Tyr Arg Lys Ser Tyr His Met Val Gly Leu 115 120 125 Ala Tyr Pro Glu Ala Val He Val Thr Leu Lys Asp Val Asp Lys Trp 130 135 140 Ser Phe Asp Val Phe Ala Leu Asn Glu Ala Ser Gly Glu His Ser Leu 145 150 155 160 Lys Phe Met He Tyr Glu Leu Phe Thr Arg Tyr Asp Leu He Asn Arg 165 170 175 Phe Lys He Pro Val Ser Cys Leu He Ala Phe Ala Glu Ala Leu Glu 180 185 190 Val Gly Tyr Ser Lys Tyr Lys Asn Pro Tyr His Asn Leu He His Ala 195 200 205 Ala Asp Val Thr Gin Thr Val His Tyr He Met Leu His Thr Gly He 210 215 220 Met His Trp Leu Thr Glu Leu Glu He Leu Ala Met Val Phe Ala Ala 225 230 235 240 Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn Asn Phe His He 245 250 255 Gln Thr Arg Ser Asp Val Ala He Leu Tyr Asn Asp Arg Ser Val Leu 260 265 270 Glu Asn His His Val Ser Ala Ala Tyr Arg Leu Met Gin Glu Glu Glu 275 280 285 Met Asn Val Leu He Asn Leu Ser Lys Asp Asp Trp Arg Asp Leu Arg 290 295 300 Asn Leu Val He Glu Met Val Leu Ser Thr Asp Met Ser Gly His Phe 305 310 315 320 Gin Gin He Lys Asn He Arg Asn Ser Leu Gin Gin Pro Glu Gly Leu 325 330 335 Asp Lys Ala Lys Thr Met Ser Leu He Leu His Ala Ala Asp He Ser 340 345 350 His Pro Ala Lys Ser Trp Lys Leu His His Arg Trp Thr Met Ala Leu 355 360 365 Met Glu Glu Phe Phe Leu Gin Gly Asp Lys Glu Ala Glu Leu Gly Leu 370 375 380 Pro Phe Ser Pro Leu Cys Asp Arg Lys Ser Thr Met Val Ala Gin Ser 385 390 395 400 Gin He Gly Phe He Asp Phe He Val Glu Pro Thr Phe Ser Leu Leu 405 410 415 Thr Asp Ser Thr Glu Lys He He He Pro Leu He Glu Glu Asp Ser 420 425 430 Lys Thr Lys Thr Pro Ser Tyr Gly Ala Ser Arg Arg Ser Asn Met Lys 435 440 445 Gly Thr Thr Asn Asp Gly Thr Tyr Ser Pro Asp Tyr Ser Leu Ala Ser 450 455 460 Val Asp Leu Lys Ser Phe Lys Asn Ser Leu Val Asp He He Gin Gin 465 470 475 480 Asn Lys Glu Arg Trp Lys Glu Leu Ala Ala Gin Gly Glu Pro Asp Pro 485 490 495 His Lys Asn Ser Asp Leu Val Asn Ala Glu Glu Lys His Ala Glu Thr 500 505 510 His Ser (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: ATHCAYGAYT AYGARCAYAC NGG 23 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: He His Asp Tyr Glu His Thr Gly 1 5 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: TCYTTRTCNC CYTGNCGRAA RAAYTCYTCC AT 32 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Met Glu Glu Phe Phe Arg Gin Gly Asp Lys Glu 1 5 10 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: ,. (A) LENGTH: 412 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..412 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: ATT CAT GAT TAT AAC ACA CGG GGC ACT ACC AAC AGC TTC CAC ATC CAG 48 He His Asp Tyr Asn Thr Arg Gly Thr Thr Asn Ser Phe His He Gin 1 5 10 15 ACC AAA TCG GAA TGC GCC ATC CTG TAC AAC GAC CGC TCA GTG CTG GAG 96 Thr Lys Ser Glu Cys Ala He Leu Tyr Asn Asp Arg Ser Val Leu Glu 20 25 30 AAT CAC CAC ATC AGC TCG GTT TTC CGA ATG ATG CAG GAC GAC GAC ATG 144 Asn His His He Ser Ser Val Phe Arg Met Met Gin Asp Asp Asp Met 35 40 45 AAC ATC TTC ATC AAC CTC ACC AAG GAT GAG TTT GTA GAG CTG CGG GCT 192 Asn He Phe He Asn Leu Thr Lys Asp Glu Phe Val Glu Leu Arg Ala 50 55 60 CTG GTC ATT GAG ATG GTG TTG GCC ACA GAC ATG TCC TGC CAT TTC CAG 240 Leu Val He Glu Met Val Leu Ala Thr Asp Met Ser Cys His Phe Gin 65 70 75 80 CAA GTG AAG TCC ATG AAG ACA GCC TTG CAG CAG CTG GAG AGG ATT GAC 288 Gin Val Lys Ser Met Lys Thr Ala Leu Gin Gin Leu Glu Arg He Asp 85 90 95 AAG TCC AAG GCC CTC TCT CTG CTG CTT CAT GCT GCT GAC ATC AGC CAC 336 Lys Ser Lys Ala Leu Ser Leu Leu Leu His Ala Ala Asp He Ser His 100 105 110 CCC ACC AAG CAG TGG TCG GTT CAC AGC CGC TGG ACC AAG GCC CTC ATG 384 Pro Thr Lys Gin Trp Ser Val His Ser Arg Trp Thr Lys Ala Leu Met 115 120 125 GAG GAG TTC TTC CGA CAA GGG GAC AAA G 412 Glu Glu Phe Phe Arg Gin Gly Asp Lys 130 135 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: He His Asp Tyr Asn Thr Arg Gly Thr Thr Asn Ser Phe His He Gin 1 5 10 15 Thr Lys Ser Glu Cys Ala He Leu Tyr Asn Asp Arg Ser Val Leu Glu 20 25 30 Asn His His He Ser Ser Val Phe Arg Met Met Gin Asp Asp Asp Met 35 40 45 Asn He Phe He Asn Leu Thr Lys Asp Glu Phe Val Glu Leu Arg Ala 50 55 60 Leu Val He Glu Met Val Leu Ala Thr Asp Met Ser Cys His Phe Gin 65 70 75 80 Gin Val Lys Ser Met Lys Thr Ala Leu Gin Gin Leu Glu Arg He Asp 85 90 95 Lys Ser Lys Ala Leu Ser Leu Leu Leu His Ala Ala Asp He Ser His 100 105 110 Pro Thr Lys Gin Trp Ser Val His Ser Arg Trp Thr Lys Ala Leu Met 115 120 125 Glu Glu Phe Phe Arg Gin Gly Asp Lys 130 135 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: AARAARAAYY TNGARTAYAC NGC 23 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Lys Lys Asn Leu Glu Tyr Thr Ala 1 5 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1844 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 114..1715 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: GGCTGGGCAG CGGGAAAGGA GGAGCCGCAG GAACTGCAGC TCTGCCAGCT TGGGCCGAGC 60 TTTAGAGACC CCCGGCCTGG CTGGTCCCTG CCAGCCGCAG ACGGAGGCTG AGC ATG 116 Met 1 GAG CTG TCC CCC CGC AGC CCT CCC GAG ATG CTA GAG TCG GAC TGC CCT 164 Glu Leu Ser Pro Arg Ser Pro Pro Glu Met Leu Glu Ser Asp Cys Pro 5 10 15 TCA CCC CTG GAG CTG AAG TCA GCC CCC AGC AAG AAG ATG TGG ATT AAG 212 Ser Pro Leu Glu Leu Lys Ser Ala Pro Ser Lys Lys Met Trp He Lys 20 25 30 CTC CGG TCT CTG CTG CGC TAC ATG GTG AAG CAG TTG GAG AAC GGG GAG 260 Leu Arg Ser Leu Leu Arg Tyr Met Val Lys Gin Leu Glu Asn Gly Glu 35 40 45 GTA AAC ATT GAG GAG CTG AAG AAA AAC CTG GAG TAC ACA GCT TCT CTG 308 Val Asn He Glu Glu Leu Lys Lys Asn Leu Glu Tyr Thr Ala Ser Leu 50 55 60 65 CTG GAG GCC GTC TAT ATA GAT GAG ACT CGG CAA ATC CTG GAC ACG GAG 356 Leu Glu Ala Val Tyr He Asp Glu Thr Arg Gin He Leu Asp Thr Glu 70 75 80 GAT GAG CTG CAG GAG CTG CGG TCT GAT GCG GTG CCT TCA GAG GTG CGG 404 Asp Glu Leu Gin Glu Leu Arg Ser Asp Ala Val Pro Ser Glu Val Arg 85 90 95 GAC TGG CTG GCC TCC ACC TTC ACC CAG CAG ACC CGG GCC AAA GGC CCG 452 Asp Trp Leu Ala Ser Thr Phe Thr Gin Gin Thr Arg Ala Lys Gly Pro 100 105 110 AGC GAA GAG AAG CCC AAG TTC CGG AGC ATC GTG CAC GCG GTG CAG GCT 500 Ser Glu Glu Lys Pro Lys Phe Arg Ser He Val His Ala Val Gin Ala 115 120 125 GGC ATC TTT GTG GAG CGG ATG TTC CGG AGA ACG TAC ACC TCT GTG GGC 548 Gly He Phe Val Glu Arg Met Phe Arg Arg Thr Tyr Thr Ser Val Gly 130 135 140 145 CCC ACC TAC TCC ACT GCC GTC CTC AAC TGT CTC AAG AAC GTG GAC CTT 596 Pro Thr Tyr Ser Thr Ala Val Leu Asn Cys Leu Lys Asn Val Asp Leu 150 155 160 TGG TGC TTT GAT GTC TTT TCC TTG AAC CGG GCA GCA GAT GAC CAC GCC 644 Trp Cys Phe Asp Val Phe Ser Leu Asn Arg Ala Ala Asp Asp His Ala 165 170 175 CTG AGG ACC ATC GTT TTT GAG CTG CTG ACT CGG CAC AAC CTC ATC AGC 692 Leu Arg Thr He Val Phe Glu Leu Leu Thr Arg His Asn Leu He Ser 180 185 190 CGC TTT AAG ATT CCC ACT GTG TTT TTG ATG ACT TTC CTG GAT GCC TTG 740 Arg Phe Lys He Pro Thr Val Phe Leu Met Thr Phe Leu Asp Ala Leu 195 200 205 GAG ACA ^ GGC TAC GGA AAG TAC AAG AAC CCT TAC CAC AAC CAG ATC CAC 788 Glu Thr Gly Tyr Gly Lys Tyr Lys Asn Pro Tyr His Asn Gin He His 210 215 220 225 GCA GCT GAC GTC ACC CAG ACG GTC CAC TGC TTC TTG CTC CGC ACA GGG 836 Ala Ala Asp Val Thr Gin Thr Val His Cys Phe Leu Leu Arg Thr Gly 230 235 240 ATG GTG CAC TGC CTG TCG GAG ATT GAG GTC CTG GCC ATC ATC TTT GCT 884 Met Val His Cys Leu Ser Glu He Glu Val Leu Ala He He Phe Ala 245 250 255 a GCA GCG ATC CAC GAC TAT GAG CAC ACT GGC ACT ACC AAC AGC TTC CAC 932 Ala Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn Ser Phe His 260 265 270 ATC CAG ACC AAA TCG GAA TGC GCC ATC CTG TAC AAC GAC CGC TCA GTG 980 He Gin Thr Lys Ser Glu Cys Ala He Leu Tyr Asn Asp Arg Ser Val 275 280 285 CTG GAG AAT CAC CAC ATC AGC TCG GTT TTC CGA ATG ATG CAG GAC GAC 1028 Leu Glu Asn His His He Ser Ser Val Phe Arg Met Met Gin Asp Asp 290 295 300 305 GAG ATG AAC ATC TTC ATC AAC CTC ACC AAG GAT GAG TTT GTA GAG CTG 1076 Glu Met Asn He Phe He Asn Leu Thr Lys Asp Glu Phe Val Glu Leu 310 315 320 CGG GCT CTG GTC ATT GAG ATG GTG TTG GCC ACA GAC ATG TCC TGC CAT 1124 Arg Ala Leu Val He Glu Met Val Leu Ala Thr Asp Met Ser Cys His 325 330 335 TTC CAG CAA GTG AAG TCC ATG AAG ACA GCC TTG CAG CAG CTG GAG AGG 1172 Phe Gin Gin Val Lys Ser Met Lys Thr Ala Leu Gin Gin Leu Glu Arg 340 345 350 ATT GAC AAG TCC AAG GCC CTC TCT CTG CTG CTT CAT GCT GCT GAC ATC 1220 He Asp Lys Ser Lys Ala Leu Ser Leu Leu Leu His Ala Ala Asp He 355 360 365 AGC CAC CCC ACC AAG CAG TGG TCG GTT CAC AGC CGC TGG ACC AAG GCC 1268 Ser His Pro Thr Lys Gin Trp Ser Val His Ser Arg Trp Thr Lys Ala 370 375 380 385 CTC ATG GAG GAA TTC TTC CGC CAG GGT GAC AAG GAG GCT GAG CTG GGC 1316 Leu Met Glu Glu Phe Phe Arg Gin Gly Asp Lys Glu Ala Glu Leu Gly 390 395 400 CTG CCC TTT TCT CCG CTC TGT GAC CGC ACT TCC ACC CTC GTG GCG CAG 1364 Leu Pro Phe Ser Pro Leu Cys Asp Arg Thr Ser Thr Leu Val Ala Gin 405 410 415 TCC CAG ATT GGT TTC ATC GAC TTC ATT GTG GAG CCC ACG TTC TCT GTG 1412 Ser Gin He Gly Phe He Asp Phe He Val Glu Pro Thr Phe Ser Val 420 425 430 CTC ACC GAT GTG GCT GAG AAG AGT GTC CAG CCC ACC GGG GAC GAC GAC 1460 Leu Thr Asp Val Ala Glu Lys Ser Val Gin Pro Thr Gly Asp Asp Asp 435 440 445 TCG AAG TCT AAA AAC CAG CCC AGC TTC CAG TGG CGC CAG CCT TCT CTG 1508 Ser Lys Ser Lys Asn Gin Pro Ser Phe Gin Trp Arg Gin Pro Ser Leu 450 455 460 465 GAT GTA GAA GTG GGA GAC CCC AAC CCT GAC GTG GTC AGC TTC CGC TCC 1556 Asp Val Glu Val Gly Asp Pro Asn Pro Asp Val Val Ser Phe Arg Ser 470 475 480 ACC TGG ACC AAA TAC ATT CAG GAG AAC AAG CAG AAA TGG AAG GAA CGG 1604 Thr Trp Thr Lys Tyr He Gin Glu Asn Lys Gin Lys Trp Lys Glu Arg 485 490 495 GCG GCG AGC GGC ATC ACC AAC CAG ATG TCC ATT GAC GAA CTG TCC CCT 1652 Ala Ala Ser Gly He Thr Asn Gin Met Ser He Asp Glu Leu Ser Pro 500 505 510 TGT GAG GAA GAG GCC CCA GCC TCC CCT GCC GAA GAC GAG CAC AAC CAG 1700 Cys Glu Glu Glu Ala Pro Ala Ser Pro Ala Glu Asp Glu His Asn Gin 515 520 525 AAC GGG AAT CTG GAC TAGCGGGGCC TGGCCAGGTC CTCACTGAGT CCTGAGTGTT 1755 Asn Gly Asn Leu Asp 530 CGATGTCATC AGCACCATCC ATCGGGACTG GCTCCCCCAT CTGCTCCGAG GGCGAATGGA 1815 TGTCAAGGAA CAGAAAACCC ACCCGAAGA 1844 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 534 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Met Glu Leu Ser Pro Arg Ser Pro Pro Glu Met Leu Glu Ser Asp Cys 1 5 10 15 Pro Ser Pro Leu Glu Leu Lys Ser Ala Pro Ser Lys Lys Met Trp He 20 25 30 Lys Leu Arg Ser Leu Leu Arg Tyr Met Val Lys Gin Leu Glu Asn Gly 35 40 45 Glu Val Asn He Glu Glu Leu Lys Lys Asn Leu Glu Tyr Thr Ala Ser 50 55 60 Leu Leu Glu Ala Val Tyr He Asp Glu Thr Arg Gin He Leu Asp Thr 65 70 75 80 Glu Asp Glu Leu Gin Glu Leu Arg Ser Asp Ala Val Pro Ser Glu Val 85 90 95 Arg Asp Trp Leu Ala Ser Thr Phe Thr Gin Gin Thr Arg Ala Lys Gly 100 105 110 Pro Ser Glu Glu Lys Pro Lys Phe Arg Ser He Val His Ala Val Gin 115 120 125 Ala Gly He Phe Val Glu Arg Met Phe Arg Arg Thr Tyr Thr Ser Val 130 135 140 Gly Pro Thr Tyr Ser Thr Ala Val Leu Asn Cys Leu Lys Asn Val Asp 145 150 155 160 Leu Trp Cys Phe Asp Val Phe Ser Leu Asn Arg Ala Ala Asp Asp His 165 170 175 Ala Leu Arg Thr He Val Phe Glu Leu Leu Thr Arg His Asn Leu He 180 185 190 Ser Arg Phe Lys He Pro Thr Val Phe Leu Met Thr Phe Leu Asp Ala 195 200 205 Leu Glu Thr Gly Tyr Gly Lys Tyr Lys Asn Pro Tyr His Asn Gin He 210 215 220 His Ala Ala Asp Val Thr Gin Thr Val His Cys Phe Leu Leu Arg Thr 225 230 235 240 Gly Met Val His Cys Leu Ser Glu He Glu Val Leu Ala He He Phe 245 250 255 Ala Ala Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn Ser Phe 260 265 270 His He Gin Thr Lys Ser Glu Cys Ala He Leu Tyr Asn Asp Arg Ser 275 280 285 Val Leu Glu Asn His His He Ser Ser Val Phe Arg Met Met Gin Asp 290 295 300 Asp Glu Met Asn He Phe He Asn Leu Thr Lys Asp Glu Phe Val Glu 305 310 315 320 Leu Arg Ala Leu Val He Glu Met Val Leu Ala Thr Asp Met Ser Cys 325 330 335 His Phe Gin Gin Val Lys Ser Met Lys Thr Ala Leu Gin Gin Leu Glu 340 345 350 Arg He Asp Lys Ser Lys Ala Leu Ser Leu Leu Leu His Ala Ala Asp 355 360 365 He Ser His Pro Thr Lys Gin Trp Ser Val His Ser Arg Trp Thr Lys 370 375 380 Ala Leu Met Glu Glu Phe Phe Arg Gin Gly Asp Lys Glu Ala Glu Leu 385 390 395 400 Gly Leu Pro Phe Ser Pro Leu Cys Asp Arg Thr Ser Thr Leu Val Ala 405 410 415 Gin Ser Gin He Gly Phe He Asp Phe He Val Glu Pro Thr Phe Ser 420 425 430 Val Leu Thr Asp Val Ala Glu Lys Ser Val Gin Pro Thr Gly Asp Asp 435 440 445 Asp Ser Lys Ser Lys Asn Gin Pro Ser Phe Gin Trp Arg Gin Pro Ser 450 455 460 Leu Asp Val Glu Val Gly Asp Pro Asn Pro Asp Val Val Ser Phe Arg 465 470 475 480 Ser Thr Trp Thr Lys Tyr He Gin Glu Asn Lys Gin Lys Trp Lys Glu 485 490 495 Arg Ala Ala Ser Gly He Thr Asn Gin Met Ser He Asp Glu Leu Ser 500 505 510 Pro Cys Glu Glu Glu Ala Pro Ala Ser Pro Ala Glu Asp Glu His Asn 515 520 525 Gin Asn Gly Asn Leu Asp 530 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE; peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Gin Leu Glu Asn Gly Glu Val Asn He Glu Glu Leu Lys Lys 1 5 10 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Gin Leu He Pro Gly Arg Val Asn He He Ser Leu Lys Lys 1 5 10 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Lys Ser Glu Cys Ala He Leu Tyr Asn Asp Arg Ser Val Leu Glu Asn 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Lys Asp Glu Thr Ala He Leu Tyr Asn Asp Arg Thr Val Leu Glu Asn 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: GGATCCGGAT CCCGCAGACG GAGGCTGAGC ATGG 34 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: GGATCCGGAT CCAGGACCTG GCCAGGCCCG GC 32 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Glu Met Met Met Tyr His Met Lys 1 5 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: Tyr His Asn Trp Met His Ala Phe 1 5 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: TTCATRTGRT ACATCATCAT YTC 23 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: AANGCRTGCA TCCARTTRTG RTA 23 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 148..2910 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: AGGCGCAGCG GCCGGGCCGG CGGGCGGGCG GGCGGCTGCG AGCATGGTCC TGGTGCTGCA 60 CCACATCCTC ATCGCTGTTG TCCAATTCTT CAGGCGGGGC CAGCAGGTCT TCCTCAAGCC 120 GGACGAGCCG CCGCCGCCGC CGCAGCC ATG CGC CGA CAG CCT GCA GCC AGC 171 Met Arg Arg Gin Pro Ala Ala Ser 1 5 CGG GAC CTC TTT GCA CAG GAG CCA GTG CCC CCA GGG AGT GGA GAC GGC 219 Arg Asp Leu Phe Ala Gin Glu Pro Val Pro Pro Gly Ser Gly Asp Gly 10 15 20 GCA TTG CAG GAT GCT TTG CTG AGC CTG GGC TCC GTC ATC GAC GTT GCA 267 Ala Leu Gin Asp Ala Leu Leu Ser Leu Gly Ser Val He Asp Val Ala 25 30 35 40 GGC TTG CAA CAG GCT GTC AAG GAG GCC CTG TCG GCT GTG CTT CCC AAA 315 Gly Leu .Gin Gin Ala Val Lys Glu Ala Leu Ser Ala Val Leu Pro Lys 45 50 55 GTG GAG ACG GTC TAC ACC TAC CTG CTG GAT GGG GAA TCC CGG CTG GTG 363 Val Glu Thr Val Tyr Thr Tyr Leu Leu Asp Gly Glu Ser Arg Leu Val 60 65 70 TGT GAG GAG CCC CCC CAC GAG CTG CCC CAG GAG GGG AAA GTG CGA GAG 411 Cys Glu Glu Pro Pro His Glu Leu Pro Gin Glu Gly Lys Val Arg Glu 75 80 85 GCT GTG ATC TCC CGG AAG CGG CTG GGC TGC AAT GGA CTG GGC CCC TCA 459 Ala Val He Ser Arg Lys Arg Leu Gly Cys Asn Gly Leu Gly Pro Ser 90 95 100 GAC CTG CCT GGG AAG CCC TTG GCA AGG CTG GTG GCT CCA CTG GCT CCT 507 Asp Leu Pro Gly Lys Pro Leu Ala Arg Leu Val Ala Pro Leu Ala Pro 105 110 115 120 GAC ACC CAA GTG CTG GTC ATA CCG CTG GTG GAC AAG GAG GCC GGG GCT 555 Asp Thr Gin Val Leu Val He Pro Leu Val Asp Lys Glu Ala Gly Ala 125 130 135 GTG GCA GCT GTC ATC TTG GTG CAC TGT GGT CAG CTG AGT GAC AAT GAG 603 Val Ala Ala Val He Leu Val His Cys Gly Gin Leu Ser Asp Asn Glu 140 145 150 GAG TGG AGC CTG CAA GCT GTG GAG AAG CAT ACC CTG GTG GCC CTG AAA 651 Glu Trp Ser Leu Gin Ala Val Glu Lys His Thr Leu Val Ala Leu Lys 155 160 165 AGG GTG CAG GCC TTG CAG CAG CGC GAG TCC AGC GTG GCC CCG GAA GCG 699 Arg Val Gin Ala Leu Gin Gin Arg Glu Ser Ser Val Ala Pro Glu Ala 170 175 180 ACC CAG AAT CCT CCG GAG GAG GCA GCG GGA GAC CAG AAG GGT GGG GTC 747 Thr Gin Asn Pro Pro Glu Glu Ala Ala Gly Asp Gin Lys Gly Gly Val 185 190 195 200 GCA TAC ACA AAC CAA GAC CGA AAG ATC CTG CAG CTT TGC GGG GAG CTC 795 Ala Tyr Thr Asn Gin Asp Arg Lys He Leu Gin Leu Cys Gly Glu Leu 205 210 215 TAC GAC CTG GAT GCA TCT TCC CTG CAG CTC AAA GTC CTC CAA TAT CTG 843 Tyr Asp Leu Asp Ala Ser Ser Leu Gin Leu Lys Val Leu Gin Tyr Leu 220 225 230 CAA CAG GAG ACC CAG GCA TCC CGC TGC TGC CTG CTG CTG GTA TCC GAG 891 Gin Gin Glu Thr Gin Ala Ser Arg Cys Cys Leu Leu Leu Val Ser Glu 235 240 245 GAC AAT CTT CAG CTC TCC TGC AAG GTC ATT GGA GAT AAA GTA CTG GAG 939 Asp Asn Leu Gin Leu Ser Cys Lys Val He Gly Asp Lys Val Leu Glu 250 255 260 GAA GAG ATC AGC TTT CCG TTG ACC ACA GGA CGC CTG GGC CAA GTG GTG 987 Glu Glu He Ser Phe Pro Leu Thr Thr Gly Arg Leu Gly Gin Val Val 265 270 275 280 GAA GAC AAG AAG TCT ATC CAG CTG AAA GAT CTC ACC TCC GAG GAT ATG 1035 Glu Asp Lys Lys Ser He Gin Leu Lys Asp Leu Thr Ser Glu Asp Met 285 290 295 CAA CAG CTG CAA AGC ATG TTG GGC TGT GAG GTG CAG GCC ATG CTC TGT 1083 Gin Gin Leu Gin Ser Met Leu Gly Cys Glu Val Gin Ala Met Leu Cys 300 305 310 GTC CCT GTC ATC AGC CGG GCC ACT GAC CAG GTC GTG GCC CTG GCC TGT 1131 Val Pro Val He Ser Arg Ala Thr Asp Gin Val Val Ala Leu Ala Cys 315 320 325 GCC TTC AAC AAG CTC GGA GGA GAC TTG TTC ACA GAC CAG GAC GAG CAC 1179 Ala Phe Asn Lys Leu Gly Gly Asp Leu Phe Thr Asp Gin Asp Glu His 330 335 340 GTG ATC CAG CAC TGC TTC CAC TAC ACC AGC ACA GTG CTC ACC AGC ACC 1227 Val He Gin His Cys Phe His Tyr Thr Ser Thr Val Leu Thr Ser Thr 345 350 355 360 CTG GCC TTC CAG AAG GAG CAG AAG CTC AAG TGT GAG TGC CAG GCT CTT 1275 Leu Ala Phe Gin Lys Glu Gin Lys Leu Lys Cys Glu Cys Gin Ala Leu 365 370 375 CTC CAA GTG GCG AAG AAC CTC TTC ACT CAT CTG GAT GAC GTC TCC GTG 1323 Leu Gin Val Ala Lys Asn Leu Phe Thr His Leu Asp Asp Val Ser Val 380 385 390 CTG CTC CAG GAG ATC ATC ACA GAG GCC AGG AAC CTC AGC AAT GCT GAG 1371 Leu Leu Gin Glu He He Thr Glu Ala Arg Asn Leu Ser Asn Ala Glu 395 400 405 ATC TGC TCT GTG TTC CTG CTG GAT CAG AAC GAG CTG GTG GCC AAG GTG 1419 He Cys Ser Val Phe Leu Leu Asp Gin Asn Glu Leu Val Ala Lys Val 410 415 420 TTC GAT GGG GGT GTG GTG GAA GAT GAG AGC TAT GAG ATC CGC ATT CCC 1467 Phe Asp Gly Gly Val Val Glu Asp Glu Ser Tyr Glu He Arg He Pro 425 430 435 440 GCT GAC CAG GGC ATC GCG GGT CAT GTG GCG ACC ACC GGC CAG ATC CTA 1515 Ala Asp Gin Gly He Ala Gly His Val Ala Thr Thr Gly Gin He Leu 445 450 455 AAC ATC CCA GAT GCT TAC GCA CAT CCG CTT TTC TAC CGA GGC GTG GAC 1563 Asn He Pro Asp Ala Tyr Ala His Pro Leu Phe Tyr Arg Gly Val Asp 460 465 470 GAC AGC ACC GGC TTC CGG ACG CGC AAC ATC CTC TGC TTC CCC ATC AAG 1611 Asp Ser Thr Gly Phe Arg Thr Arg Asn He Leu Cys Phe Pro He Lys 475 480 485 AAC GAG AAC CAG GAG GTC ATC GGT GTG GCC GAG CTG GTG AAC AAG ATC 1659 Asn Glu Asn Gin Glu Val He Gly Val Ala Glu Leu Val Asn Lys He 490 495 500 AAT GGA CCA TGG TTC AGC AAG TTT GAT GAA GAC CTG GCT ACA GCC TTC 1707 Asn Gly Pro Trp Phe Ser Lys Phe Asp Glu Asp Leu Ala Thr Ala Phe 505 510 515 520 TCC ATC TAC TGT GGC ATC AGC ATT GCC CAT TCC CTC CTA TAC AAG AAA 1755 Ser He Tyr Cys Gly He Ser He Ala His Ser Leu Leu Tyr Lys Lys 525 530 535 GTG AAT GAG GCG CAG TAT CGC AGC CAC CTT GCC AAT GAG ATG ATG ATG 1803 Val Asn Glu Ala Gin Tyr Arg Ser His Leu Ala Asn Glu Met Met Met 540 545 550 TAC CAC ATG AAG GTC TCT GAT GAC GAG TAC ACC AAA CTT CTC CAT GAC 1851 Tyr His Met Lys Val Ser Asp Asp Glu Tyr Thr Lys Leu Leu His Asp 555 560 565 GGG ATC CAG CCT GTG GCT GCC ATC GAC TCC AAC TTT GCC AGT TTC ACA 1899 Gly He Gin Pro Val Ala Ala He Asp Ser Asn Phe Ala Ser Phe Thr 570 575 580 TAC ACT CCT CGC TCT CTG CCC GAG GAT GAC ACT TCC ATG GCC ATC CTG 1947 Tyr Thr Pro Arg Ser Leu Pro Glu Asp Asp Thr Ser Met Ala He Leu 585 590 595 600 AGC ATG CTG CAG GAC ATG AAT TTC ATC AAT AAC TAC AAA ATT GAC TGC 1995 Ser Met Leu Gin Asp Met Asn Phe He Asn Asn Tyr Lys He Asp Cys 605 610 615 CCG ACA CTG GCC CGG TTC TGT TTG ATG GTG AAG AAG GGC TAC CGG GAT 2043 Pro Thr Leu Ala Arg Phe Cys Leu Met Val Lys Lys Gly Tyr Arg Asp 620 625 630 CCC CCC TAC CAC AAC TGG ATG CAC GCC TTT TCT GTC TCC CAC TTC TGC 2091 Pro Pro Tyr His Asn Trp Met His Ala Phe Ser Val Ser His Phe Cys 635 640 645 TAC CTG CTC TAC AAG AAC CTG GAG CTC ACC AAC TAC CTC GAG GAC ATG 2139 Tyr Leu Leu Tyr Lye Asn Leu Glu Leu Thr Asn Tyr Leu Glu Asp Met 650 655 660 GAG ATC TTT GCC TTG TTT ATT TCC TGC ATG TGT CAC GAC CTG GAC CAC 2187 Glu He Phe Ala Leu Phe He Ser Cys Met Cys His Asp Leu Asp His 665 670 675 680 AGA GGC ACA AAC AAC TCC TTC CAG GTG GCC TCG AAA TCT GTG CTG GCC 2235 Arg Gly Thr Asn Asn Ser Phe Gin Val Ala Ser Lys Ser Val Leu Ala 685 690 695 GCG CTC TAC AGC TCG GAA GGC TCT GTC ATG GAG AGG CAC CAC TTC GCT 2283 Ala Leu Tyr Ser Ser Glu Gly Ser Val Met Glu Arg His His Phe Ala 700 705 710 CAG GCC ATT GCC ATC CTC AAC ACC CAC GGC TGC AAC ATC TTT GAC CAC 2331 Gin Ala He Ala He Leu Asn Thr His Gly Cys Asn He Phe Asp His 715 720 725 TTC TCC CGG AAG GAT TAT CAG CGC ATG TTG GAC CTG ATG CGG GAC ATC 2379 Phe Ser Arg Lys Asp Tyr Gin Arg Met Leu Asp Leu Met Arg Asp He 730 735 740 ATC TTG GCC ACA GAT CTG GCC CAC CAC CTC CGC ATC TTC AAG GAC CTC 2427 He Leu Ala Thr Asp Leu Ala His His Leu Arg He Phe Lys Asp Leu 745 750 755 760 CAA AAG ATG GCC GAA GTG GGC TAT GAT CGA ACC AAC AAG CAG CAC CAC 2475 Gin Lys Met Ala Glu Val Gly Tyr Asp Arg Thr Asn Lys Gin His His 765 770 775 AGC CTC CTT CTC TGC CTC CTT ATG ACC TCC TGT GAC CTC TCT GAC CAG 2523 Ser Leu Leu Leu Cys Leu Leu Met Thr Ser Cys Asp Leu Ser Asp Gin 780 785 790 ACC AAG GGC TGG AAG ACC ACG AGG AAG ATC GCG GAG CTG ATC TAC AAA 2571 Thr Lys Gly Trp Lys Thr Thr Arg Lys He Ala Glu Leu He Tyr Lys 795 800 805 GAG TTC TTC TCC CAG GGA GAC TTG GAG AAG GCC ATG GGC AAC AGG CCG 2619 Glu Phe Phe Ser Gin Gly Asp Leu Glu Lys Ala Met Gly Asn Arg Pro 810 815 820 ATG GAG ATG ATG GAC CGT GAG AAG GCC TAC ATC CCC GAG CTG CAG ATC 2667 Met Glu Met Met Asp Arg Glu Lys Ala Tyr He Pro Glu Leu Gin He 825 830 835 840 AGC TTC ATG GAG CAC ATC GCA ATG CCC ATC TAC AAG CTG CTG CAA GAC 2715 Ser Phe Met Glu His He Ala Met Pro He Tyr Lys Leu Leu Gin Asp 845 850 855 CTG TTC ^ CCC AAG GCG GCC GAG TTG TAC GAA CGC GTG GCC TCT AAT CGT 2763 Leu Phe Pro Lys Ala Ala Glu Leu Tyr Glu Arg Val Ala Ser Asn Arg 860 865 870 GAG CAC TGG ACC AAG GTG TCA CAC AAG TTC ACC ATC CGA GGC CTC CCG 2811 Glu His Trp Thr Lys Val Ser His Lys Phe Thr He Arg Gly Leu Pro 875 880 885 AGC AAC AAC TCG TTG GAC TTC CTG GAC GAG GAG TAT GAG GTG CCT GAC 2859 Ser Asn Asn Ser Leu Asp Phe Leu Asp Glu Glu Tyr Glu Val Pro Asp 890 895 900 CTG GAT GGC GCT AGG GCT CCC ATC AAT GGC TGT TGC AGC CTT GAT GCT 2907 Leu Asp Gly Ala Arg Ala Pro He Asn Gly Cys Cys Ser Leu Asp Ala 905 910 915 920 GAG TGAGTCCCTC CTGGGACCCC TCCCTGTCCA GGCCTCCTCC CACAAGCCTC 2960 Glu CACGGGCCTG GCCGCACGCC CTGGGACCAG AGCCAAGGGT CCTGGATTCT AGGCCAGGAC 3020 TTCCCATGTG ACCCGGGCGA GGTCTGACCT TCCCGGGCCT CAGCTTTCTT GTCTGTATAA 3080 TGGAAGACTT CAGCCTCACT GAGACTTTGT CACTTGTCCT CTGAGAGCAC AGGGGTAACC 3140 AATGAGCAGT GGACCCTGCT CTGCACCTCT GACCGCATCT TGGCAAGTCC CCACCCTCCA 3200 GGCCACTCCT TCTCTGAGGC AGCCGGATGG TTTCTTCTGG GCCCCATTCC TGCCCTACCA 3260 GACCTGTGCC CTTTCCTGTG GGGGCACCCT CACTGGCTCC CAGGATCCTC AGGCAAGAAC 3320 ATGAGACATC TGAGTGGGCA AAGGGTGGGT CTTAGAGACA GTTATCAGCC TGGCTGGAGG 3380 ACTAGAAGTA GCCATGGGAC CACCTGTGGC CCAGAGGACT GCCTTTGTAC TTATGGTGGG 3440 GACTGGGACC TGGGGATATA AGGGTCCCAG GAGGACACTG CCAGGGGGCC AGTGCAGTGC 3500 TCTGGGGAGA GGGGGCTCAG GAAGAGAGGA GGATAAGAAC AGTGAGAAGG AAGGATCCCT 3560 GGGTTGGGAG GCAGGCCCAG CATGGGTCAG CCATGCTTCC TCCTGGCTGT GTGACCCTGG 3620 GCAAGTCCCT TCCCCTCTCT GCGAAACAGT AGGGTGAGAC AATCCATTCT CTAAGACCCC 3680 TTTTAGATCC AAGTCCCCAT AGTTCTGTGG AGTCCCAGTA GAGGCCACCG AGGGTCCCTG 3740 GCCCCCTTGG GCACAGAGCT GACACTGAGT CCCTCAGTGG CCCCCTGAGT ATACCCCCTT 3800 AGCCGGAGCC CCTTCCCCAT TCCTACAGCC AGAGGGGGAC CTGGCCTCAG CCTGGCAGGG 3860 CCTCTCTCCT CTTCAAGGCC ATATCCACCT GTGCCCCGGG GCTTGGGAGA CCCCCTAGGG 3920 CCGGAGCTCT GGGGTCATCC TGGCCACTGG CTTCTCCTTT CTCTGTTTTG TTCTGTATGT 3980 GTTGTGGGGT GGGGGGAGGG GGGCCACCTG CCTTACCTAT TCTGAGTTGC CTTTAGAGAG 4040 ATGCGTTTTT TCTAGGACTC TGTGCAACTG TTGTATATGG TTCCGTGGGC TGACCGCTTT 4100 GTACATGAGA ATAAATCTAT TTCTTTCTAC C 4131 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 921 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: Met Arg Arg Gin Pro Ala Ala Ser Arg Asp Leu Phe Ala Gin Glu Pro 1 5 10 15 Val Pro Pro Gly Ser Gly Asp Gly Ala Leu Gin Asp Ala Leu Leu Ser 20 25 30 Leu Gly Ser Val He Asp Val Ala Gly Leu Gin Gin Ala Val Lys Glu 35 40 45 Ala Leu Ser Ala Val Leu Pro Lys Val Glu Thr Val Tyr Thr Tyr Leu 50 55 60 Leu Asp Gly Glu Ser Arg Leu Val Cys Glu Glu Pro Pro His Glu Leu 65 70 75 80 Pro Gin Glu Gly Lys Val Arg Glu Ala Val He Ser Arg Lys Arg Leu 85 90 95 Gly Cys Asn Gly Leu Gly Pro Ser Asp Leu Pro Gly Lys Pro Leu Ala 100 105 110 Arg Leu Val Ala Pro Leu Ala Pro Asp Thr Gin Val Leu Val He Pro 115 120 125 Leu Val Asp Lys Glu Ala Gly Ala Val Ala Ala Val He Leu Val His 130 135 140 Cys Gly Gin Leu Ser Asp Asn Glu Glu Trp Ser Leu Gin Ala Val Glu 145 150 155 160 Lys His Thr Leu Val Ala Leu Lys Arg Val Gin Ala Leu Gin Gin Arg 165 170 175 Glu Ser Ser Val Ala Pro Glu Ala Thr Gin Asn Pro Pro Glu Glu Ala 180 185 190 Ala Gly Asp Gin Lys Gly Gly Val Ala Tyr Thr Asn Gin Asp Arg Lys 195 200 205 He Leu Gin Leu Cys Gly Glu Leu Tyr Asp Leu Asp Ala Ser Ser Leu 210 215 220 Gin Leu Lys Val Leu Gin Tyr Leu Gin Gin Glu Thr Gin Ala Ser Arg 225 230 235 240 Cys Cys Leu Leu Leu Val Ser Glu Asp Asn Leu Gin Leu Ser Cys Lys 245 250 255 Val He Gly Asp Lys Val Leu Glu Glu Glu He Ser Phe Pro Leu Thr 260 265 270 Thr Gly Arg Leu Gly Gin Val Val Glu Asp Lys Lys Ser He Gin Leu 275 280 285 Lys Asp Leu Thr Ser Glu Asp Met Gin Gin Leu Gin Ser Met Leu Gly 290 295 300 Cys Glu Val Gin Ala Met Leu Cys Val Pro Val He Ser Arg Ala Thr 305 310 315 320 Asp Gin Val Val Ala Leu Ala Cys Ala Phe Asn Lys Leu Gly Gly Asp 325 330 335 Leu Phe hr Asp Gin Asp Glu His Val He Gin His Cys Phe His Tyr 340 345 350 Thr Ser Thr Val Leu Thr Ser Thr Leu Ala Phe Gin Lys Glu Gin Lys 355 360 365 Leu Lys Cys Glu Cys Gin Ala Leu Leu Gin Val Ala Lys Asn Leu Phe 370 375 380 Thr His Leu Asp Asp Val Ser Val Leu Leu Gin Glu He He Thr Glu 385 390 395 400 Ala Arg Asn Leu Ser Asn Ala Glu He Cys Ser Val Phe Leu Leu Asp 405 410 415 Gln Asn Glu Leu Val Ala Lys Val Phe Asp Gly Gly Val Val Glu Asp 420 425 430 Glu Ser Tyr Glu He Arg He Pro Ala Asp Gin Gly He Ala Gly His 435 440 445 Val Ala Thr Thr Gly Gin He Leu Asn He Pro Asp Ala Tyr Ala His 450 455 460 Pro Leu Phe Tyr Arg Gly Val Asp Asp Ser Thr Gly Phe Arg Thr Arg 465 470 475 480 Asn He Leu Cys Phe Pro He Lys Asn Glu Asn Gin Glu Val He Gly 485 490 495 Val Ala Glu Leu Val Asn Lys He Asn Gly Pro Trp Phe Ser Lys Phe 500 505 510 Asp Glu Asp Leu Ala Thr Ala Phe Ser He Tyr Cys Gly He Ser He 515 520 525 Ala His Ser Leu Leu Tyr Lys Lys Val Asn Glu Ala Gin Tyr Arg Ser 530 535 540 His Leu Ala Asn Glu Met Met Met Tyr His Met Lys Val Ser Asp Asp 545 550 555 560 Glu Tyr Thr Lys Leu Leu His Asp Gly He Gin Pro Val Ala Ala He 565 570 575 Asp Ser Asn Phe Ala Ser Phe Thr Tyr Thr Pro Arg Ser Leu Pro Glu 580 585 590 Asp Asp Thr Ser Met Ala He Leu Ser Met Leu Gin Asp Met Asn Phe 595 600 605 He Asn Asn Tyr Lys He Asp Cys Pro Thr Leu Ala Arg Phe Cys Leu 610 615 620 Met Val Lys Lys Gly Tyr Arg Asp Pro Pro Tyr His Asn Trp Met His 625 630 635 640 Ala Phe Ser Val Ser His Phe Cys Tyr Leu Leu Tyr Lys Asn Leu Glu 645 650 655 Leu Thr Asn Tyr Leu Glu Asp Met Glu He Phe Ala Leu Phe He Ser 660 665 670 Cys Met Cys His Asp Leu Asp His Arg Gly Thr Asn Asn Ser Phe Gin 675 680 685 Val Ala. Ser Lys Ser Val Leu Ala Ala Leu Tyr Ser Ser Glu Gly Ser 690 695 700 Val Met Glu Arg His His Phe Ala Gin Ala He Ala He Leu Asn Thr 705 710 715 720 His Gly Cys Asn He Phe Asp His Phe Ser Arg Lys Asp Tyr Gin Arg 725 730 735 Met Leu Asp Leu Met Arg Asp He He Leu Ala Thr Asp Leu Ala His 740 745 750 His Leu Arg He Phe Lys Asp Leu Gin Lys Met Ala Glu Val Gly Tyr 755 760 765 Asp Arg Thr Asn Lys Gin His His Ser Leu Leu Leu Cys Leu Leu Met 770 775 780 Thr Ser Cys Asp Leu Ser Asp Gin Thr Lys Gly Trp Lys Thr Thr Arg 785 790 795 800 Lys He Ala Glu Leu He Tyr Lys Glu Phe Phe Ser Gin Gly Asp Leu 805 810 815 Glu Lys Ala Met Gly Asn Arg Pro Met Glu Met Met Asp Arg Glu Lys 820 825 830 Ala Tyr He Pro Glu Leu Gin He Ser Phe Met Glu His He Ala Met 835 840 845 Pro He Tyr Lys Leu Leu Gin Asp Leu Phe Pro Lys Ala Ala Glu Leu 850 855 860 Tyr Glu Arg Val Ala Ser Asn Arg Glu His Trp Thr Lys Val Ser His 865 870 875 880 Lys Phe Thr He Arg Gly Leu Pro Ser Asn Asn Ser Leu Asp Phe Leu 885 890 895 Asp Glu Glu Tyr Glu Val Pro Asp Leu Asp Gly Ala Arg Ala Pro He 900 905 910 Asn Gly Cys Cys Ser Leu Asp Ala Glu 915 920 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: ATATCGAATT CGGTTTAGTC TGGTTGGGGA GGCAGACGAT GAGGAGCGAT GGGGCAGGCA 60 TGCGGCCACT CCATCCTCTG CAGGAGCCAG CAGTACCCGG CTGCGCGACC GGCTGAGCCG 120 CGGGGCCAGC AGGTCTTCCT CAAGCCGGAC GAGCCGCCGC CGCCGCCGCA GCCATGCGCC 180 GACAGCCTGC AGGATGCTTT GCTGAGCCTG GGCTCCGTCA TTGAGCTTGC AGGCTTGCGA 240 CAGGCTGTC 249 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 250 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: GAATTCGGGT AGAGCAGGTA GCAGAAGTGG GAGACAGAAA AGGCGTGCAT CCAGTTGTGG 60 TAGGGGGGAT CCCGGTAGCC CTTCTTCACC ATCAAACAGA ACCGGGCCAG TGTCGGGCAG 120 TCAATTTTGT AGTTATTGAT GAAATTCATG TTCTGCAGCA TGCTCAGGAT GGCCATGGAG 180 TGTCATCCTT GGGCAGAGAG CGAGGAGTGT ATGTGAACTG GCAAGTTGGA GTCGATGGCA 240 GCCACAGGCT 250 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3789 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATUR : (A) NAME/KEY: CDS (B) LOCATION: 181..3006 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: GCGGGAACTG CCAGGGCAGC AGGGCTGGAT TGGGGTGTTG AGTCCAGGCT GAGTCGGGGA 60 CAGGCCACTG TTCTTGGTCC CCGTGCCTGC TGGGCCAGGC GCCCTGCCTG GAGCCCCGGG 120 CAGGGTGGAC AGGGTGAGGT GCCACTTTAG TCTGGTTGGG GAGGCAGACG ATGAGGAGCG 180 ATG GGG CAG GCA TGC GGC CAC TCC ATC CTC TGC AGG AGC CAG CAG TAC 228 Met Gly Gin Ala Cys Gly His Ser He Leu Cys Arg Ser Gin Gin Tyr 1 5 10 15 CCG GCT GCG CGA CCG GCT GAG CCG CGG GGC CAG CAG GTC TTC CTC AAG 276 Pro Ala Ala Arg Pro Ala Glu Pro Arg Gly Gin Gin Val Phe Leu Lys 20 25 30 CCG GAC GAG CCG CCG CCG CCG CCG CAG CCA TGC GCC GAC AGC CTG CAG 324 Pro Asp Glu Pro Pro Pro Pro Pro Gin Pro Cys Ala Asp Ser Leu Gin 35 40 45 GAT GCT TTG CTG AGC CTG GGC TCC GTC ATT GAC GTT GCA GGC TTG CAA 372 Asp Ala Leu Leu Ser Leu Gly Ser Val He Asp Val Ala Gly Leu Gin 50 55 60 CAG GCT GTC AAG GAG GCC CTG TCG GCT GTG CTT CCC AAA GTG GAG ACG 420 Gin Ala Val Lys Glu Ala Leu Ser Ala Val Leu Pro Lys Val Glu Thr 65 70 75 80 GTC TAC ACC TAC CTG CTG GAT GGG GAA TCC CGG CTG GTG TGT GAG GAG 468 Val Tyr Thr Tyr Leu Leu Asp Gly Glu Ser Arg Leu Val Cys Glu Glu 85 90 95 CCC CCC CAC GAG CTG CCC CAG GAG GGG AAA GTG CGA GAG GCT GTG ATC 516 Pro Pro His Glu Leu Pro Gin Glu Gly Lys Val Arg Glu Ala Val He 100 105 110 TCC CGG AAG CGG CTG GGC TGC AAT GGA CTG GGC CCC TCA GAC CTG CCT 564 Ser Arg Lys Arg Leu Gly Cys Asn Gly Leu Gly Pro Ser Asp Leu Pro 115 120 125 GGG AAG CCC TTG GCA AGG CTG GTG GCT CCA CTG GCT CCT GAC ACC CAA 612 Gly Lys Pro Leu Ala Arg Leu Val Ala Pro Leu Ala Pro Asp Thr Gin 130 135 140 GTG CTG GTC ATA CCG CTG GTG GAC AAG GAG GCC GGG GCT GTG GCA GCT 660 Val Leu Val He Pro Leu Val Asp Lys Glu Ala Gly Ala Val Ala Ala 145 150 155 160 GTC ATC TTG GTG CAC TGT GGT CAG CTG AGT GAC AAT GAG GAG TGG AGC 708 Val He Leu Val His Cys Gly Gin Leu Ser Asp Asn Glu Glu Trp Ser 165 170 175 CTG CAA GCT GTG GAG AAG CAT ACC CTG GTG GCC CTG AAA AGG GTG CAG 756 Leu Gin Ala Val Glu Lys His Thr Leu Val Ala Leu Lys Arg Val Gin 180 185 190 GCC TTG CAG CAG CGC GAG TCC AGC GTG GCC CCG GAA GCG ACC CAG AAT 804 Ala Leu Gin Gin Arg Glu Ser Ser Val Ala Pro Glu Ala Thr Gin Asn 195 200 205 CCT CCG GAG GAG GCA GCG GGA GAC CAG AAG GGT GGG GTC GCA TAC ACA 852 Pro Pro Glu Glu Ala Ala Gly Asp Gin Lys Gly Gly Val Ala Tyr Thr 210 215 220 GAC CAA GAC CGA AAG ATC CTG CAG CTT TGC GGG GAG CTC TAC GAC CTG 900 Asp Gin Asp Arg Lys He Leu Gin Leu Cys Gly Glu Leu Tyr Asp Leu 225 230 235 240 GAT GCA TCT TCC CTG CAG CTC AAA GTC CTC CAA TAT CTG CAA CAG GAG 948 Asp Ala Ser Ser Leu Gin Leu Lys Val Leu Gin Tyr Leu Gin Gin Glu 245 250 255 ACC CAG GCA TCC CGC TGC TGC CTG CTG CTG GTA TCC GAG GAC AAT CTT 996 Thr Gin Ala Ser Arg Cys Cys Leu Leu Leu Val Ser Glu Asp Asn Leu 260 265 270 CAG CTC TCC TGC AAG GTC ATT GGA GAT AAA GTA CTG GAG GAA GAG ATC 1044 Gin Leu Ser Cys Lys Val He Gly Asp Lys Val Leu Glu Glu Glu He 275 280 285 AGC TTT CCG TTG ACC ACA GGA CGC CTG GGC CAA GTG GTG GAA GAC AAG 1092 Ser Phe Pro Leu Thr Thr Gly Arg Leu Gly Gin Val Val Glu Asp Lys 290 295 300 AAG TCT ATC CAG CTG AAA GAT CTC ACC TCC GAG GAT ATG CAA CAG CTG 1140 Lys Ser He Gin Leu Lys Asp Leu Thr Ser Glu Asp Met Gin Gin Leu 305 310 315 320 CAA AGC ATG TTG GGC TGT GAG GTG CAG GCC ATG CTC TGT GTC CCT GTC 1188 Gin Ser Met Leu Gly Cys Glu Val Gin Ala Met Leu Cys Val Pro Val 325 330 335 ATC AGC CGG GCC ACT GAC CAG GTC GTG GCC CTG GCC TGT GCC TTC AAC 1236 He Ser Arg Ala Thr Asp Gin Val Val Ala Leu Ala Cys Ala Phe Asn 340 345 350 AAG CTC GGA GGA GAC TTG TTC ACA GAC CAG GAC GAG CAC GTG ATC CAG 1284 Lys Leu Gly Gly Asp Leu Phe Thr Asp Gin Asp Glu His Val He Gin 355 360 365 CAC TGC TTC CAC TAC ACC AGC ACA GTG CTC ACC AGC ACC CTG GCC TTC 1332 His Cys Phe His Tyr Thr Ser Thr Val Leu Thr Ser Thr Leu Ala Phe 370 375 380 CAG AAG GAG CAG AAG CTC AAG TGT GAG TGC CAG GCT CTT CTC CAA GTG 1380 Gin Lys Glu Gin Lys Leu Lys Cys Glu Cys Gin Ala Leu Leu Gin Val 385 390 395 400 GCG AAG AAC CTC TTC ACT CAT CTG GAT GAC GTC TCC GTG CTG CTC CAG 1428 Ala Lys Asn Leu Phe Thr His Leu Asp Asp Val Ser Val Leu Leu Gin 405 410 415 GAG ATC ATC ACA GAG GCC AGG AAC CTC AGC AAT GCT GAG ATC TGC TCT 1476 Glu He He Thr Glu Ala Arg Asn Leu Ser Asn Ala Glu He Cys Ser 420 425 430 GTG TTC CTG CTG GAT CAG AAC GAG CTG GTG GCC AAG GTG TTC GAT GGG 1524 Val Phe Leu Leu Asp Gin Asn Glu Leu Val Ala Lys Val Phe Asp Gly 435 440 445 GGT GTG GTG GAA GAT GAG AGC TAT GAG ATC CGC ATT CCC GCT GAC CAG 1572 Gly Val Val Glu Asp Glu Ser Tyr Glu He Arg He Pro Ala Asp Gin 450 455 460 GGC ATC GCG GGT CAT GTG GCG ACC ACC GGC CAG ATC CTA AAC ATC CCA 1620 Gly He Ala Gly His Val Ala Thr Thr Gly Gin He Leu Asn He Pro 465 470 475 480 GAT GCT TAC GCA CAT CCG CTT TTC TAC CGA GGC GTG GAC GAC AGC ACC 1668 Asp Ala Tyr Ala His Pro Leu Phe Tyr Arg Gly Val Asp Asp Ser Thr 485 490 495 GGC TTC CGG ACG CGC AAC ATC CTC TGC TTC CCC ATC AAG AAC GAG AAC 1716 Gly Phe Arg Thr Arg Asn He Leu Cys Phe Pro He Lys Asn Glu Asn 500 505 510 CAG GAG GTC ATC GGT GTG GCC GAG CTG GTG AAC AAG ATC AAT GGA CCA 1764 Gin Glu Val He Gly Val Ala Glu Leu Val Asn Lys He Asn Gly Pro 515 520 525 TGG TTC AGC AAG TTT GAT GAA GAC CTG GCT ACA GCC TTC TCC ATC TAC 1812 Trp Phe Ser Lys Phe Asp Glu Asp Leu Ala Thr Ala Phe Ser He Tyr 530 535 540 TGT GGC ATC AGC ATT GCC CAT TCC CTC CTA TAC AAG AAA GTG AAT GAG 1860 Cys Gly He Ser He Ala His Ser Leu Leu Tyr Lys Lys Val Asn Glu 545 550 555 560 GCG CAG TAT CGC AGC CAC CTT GCC AAT GAG ATG ATG ATG TAC CAC ATG 1908 Ala Gin Tyr Arg Ser His Leu Ala Asn Glu Met Met Met Tyr His Met 565 570 575 AAG GTC TCT GAT GAC GAG TAC ACC AAA CTT CTC CAT GAC GGG ATC CAG 1956 Lys Val Ser Asp Asp Glu Tyr Thr Lys Leu Leu His Asp Gly He Gin 580 585 590 CCT GTG GCT GCC ATC GAC TCC AAC TTT GCC AGT TTC ACA TAC ACT CCT 2004 Pro Val Ala Ala He Asp Ser Asn Phe Ala Ser Phe Thr Tyr Thr Pro 595 600 605 CGC TCT "cTG CCC GAG GAT GAC ACT TCC ATG GCC ATC CTG AGC ATG CTG 2052 Arg Ser Leu Pro Glu Asp Asp Thr Ser Met Ala He Leu Ser Met Leu 610 615 620 CAG GAC ATG AAT TTC ATC AAT AAC TAC AAA ATT GAC TGC CCG ACA CTG 2100 Gin Asp Met Asn Phe He Asn Asn Tyr Lys He Asp Cys Pro Thr Leu 625 630 635 640 GCC CGG TTC TGT TTG ATG GTG AAG AAG GGC TAC CGG GAT CCC CCC TAC 2148 Ala Arg Phe Cys Leu Met Val Lys Lys Gly Tyr Arg Asp Pro Pro Tyr 645 650 655 CAC AAC TGG ATG CAC GCC TTT TCT GTC TCC CAC TTC TGC TAC CTG CTC 2196 His Asn Trp Met His Ala Phe Ser Val Ser His Phe Cys Tyr Leu Leu 660 665 670 TAC AAG AAC CTG GAG CTC ACC AAC TAC CTC GAG GAC ATG GAG ATC TTT 2244 Tyr Lys Asn Leu Glu Leu Thr Asn Tyr Leu Glu Asp Met Glu He Phe 675 680 685 GCC TTG TTT ATT TCC TGC ATG TGT CAC GAC CTG GAC CAC AGA GGC ACA 2292 Ala Leu Phe He Ser Cys Met Cys His Asp Leu Asp His Arg Gly Thr 690 695 700 AAC AAC TCC TTC CAG GTG GCC TCG AAA TCT GTG CTG GCC GCG CTC TAC 2340 Asn Asn Ser Phe Gin Val Ala Ser Lys Ser Val Leu Ala Ala Leu Tyr 705 710 715 720 AGC TCG GAA GGC TCT GTC ATG GAG AGG CAC CAC TTC GCT CAG GCC ATT 2388 Ser Ser Glu Gly Ser Val Met Glu Arg His His Phe Ala Gin Ala He 725 730 735 GCC ATC CTC AAC ACC CAC GGC TGC AAC ATC TTT GAC CAC TTC TCC CGG 2436 Ala He Leu Asn Thr His Gly Cys Asn He Phe Asp His Phe Ser Arg 740 745 750 AAG GAT TAT CAG CGC ATG TTG GAC CTG ATG CGG GAC ATC ATC TTG GCC 2484 Lys Asp Tyr Gin Arg Met Leu Asp Leu Met Arg Asp He He Leu Ala 755 760 765 ACA GAT CTG GCC CAC CAC CTC CGC ATC TTC AAG GAC CTC CAA AAG ATG 2532 Thr Asp Leu Ala His His Leu Arg He Phe Lys Asp Leu Gin Lys Met 770 775 780 GCC GAA GTG GGC TAT GAT CGA ACC AAC AAG CAG CAC CAC AGC CTC CTT 2580 Ala Glu Val Gly Tyr Asp Arg Thr Asn Lys Gin His His Ser Leu Leu 785 790 795 800 CTC TGC CTC CTT ATG ACC TCC TGT GAC CTC TCT GAC CAG ACC AAG GGC 2628 Leu Cys Leu Leu Met Thr Ser Cys Asp Leu Ser Asp Gin Thr Lys Gly 805 810 815 TGG AAG ACC ACG AGG AAG ATC GCG GAG CTG ATC TAC AAA GAG TTC TTC 2676 Trp Lys Thr Thr Arg Lys He Ala Glu Leu He Tyr Lys Glu Phe Phe 820 825 830 TCC CAG GGA GAC TTG GAG AAG GCC ATG GGC AAC AGG CCG ATG GAG ATG 2724 Ser Gin Gly Asp Leu Glu Lys Ala Met Gly Asn Arg Pro Met Glu Met 835 840 845 ATG GAC CGT GAG AAG GCC TAC ATC CCC GAG CTG CAG ATC AGC TTC ATG 2772 Met Asp Arg Glu Lys Ala Tyr He Pro Glu Leu Gin He Ser Phe Met 850 855 860 GAG CAC ATC GCA ATG CCC ATC TAC AAG CTG CTG CAA GAC CTG TTC CCC 2820 Glu His He Ala Met Pro He Tyr Lys Leu Leu Gin Asp Leu Phe Pro 865 870 875 880 _ AAG GCG GCC GAG TTG TAC GAA CGC GTG GCC TCT AAT CGT GAG CAC TGG 2868 Lys Ala Ala Glu Leu Tyr Glu Arg Val Ala Ser Asn Arg Glu His Trp 885 890 895 ACC AAG GTG TCA CAC AAG TTC ACC ATC CGA GGC CTC CCG AGC AAC AAC 2916 Thr Lys Val Ser His Lys Phe Thr He Arg Gly Leu Pro Ser Asn Asn 900 905 910 TCG TTG GAC TTC CTG GAC GAG GAG TAT GAG GTG CCT GAC CTG GAT GGC 2964 Ser Leu Asp Phe Leu Asp Glu Glu Tyr Glu Val Pro Asp Leu Asp Gly 915 920 925 GCT AGG GCT CCC ATC AAT GGC TGT TGC AGC CTT GAT GCT GAG 3006 Ala Arg Ala Pro He Asn Gly Cys Cys Ser Leu Asp Ala Glu 930 935 940 TGAGTCCCTC CTGGGACCCC TCCCTGTCCA GGCCTCCTCC CACAAGCCTC CACGGGCCTG 3066 GCCGCACGCC CTGGGACCAG AGCCAAGGGT CCTGGATTCT AGGCCAGGAC TTCCCATGTG 3126 ACCCGGGCGA GGTCTGACCT TCCCGGGCCT CAGCTTTCTT GTCTGTATAA TGGAAGACTT 3186 CAGCCTCACT GAGACTTTGT CACTTGTCCT CTGAGAGCAC AGGGGTAACC AATGAGCAGT 3246 GGACCCTGCT CTGCACCTCT GACCGCATCT TGGCAAGTCC CCACCCTCCA GGCCACTCCT 3306 TCTCTGAGGC AGCCGGATGG TTTCTTCTGG GCCCCATTCC TGCCCTACCA GACCTGTGCC 3366 CTTTCCTGTG GGGGCACCCT CACTGGCTCC CAGGATCCTC AGGCAAGAAC ATGAGACATC 3426 TGAGTGGGCA AAGGGTGGGT CTTAGAGACA GTTATCAGCC TGGCTGGAGG ACTAGAAGTA 3486 GCCATGGGAC CACCTGTGGC CCAGAGGACT GCCTTTGTAC TTATGGTGGG GACTGGGACC 3546 TGGGGATATA AGGGTCCCAG GAGGACACTG CCAGGGGGCC AGTGCAGTGC TCTGGGGAGA 3606 GGGGGCTCAG GAAGAGAGGA GGATAAGAAC AGTGAGAAGG AAGGATCCCT GGGTTGGGAG 3666 GCAGGCCCAG CATGGGTCAG CCATGCTTCC TCCTGGCTGT GTGACCCTGG GCAAGTCCCT 3726 TCCCCTCTCT GCGAAACAGT AGGGTGAGAC AATCCATTCT CTAAGACCCC TTTTAGATCC 3786 AAG 3789 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 942 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: Met Gly Gin Ala Cys Gly His Ser He Leu Cys Arg Ser Gin Gin Tyr 1 5 10 15 Pro Ala Ala Arg Pro Ala Glu Pro Arg Gly Gin Gin Val Phe Leu Lys 20 25 30 Pro Asp Glu Pro Pro Pro Pro Pro Gin Pro Cys Ala Asp Ser Leu Gin 35 40 45 Asp Ala Leu Leu Ser Leu Gly Ser Val He Asp Val Ala Gly Leu Gin 50 55 60 Gin Ala Val Lys Glu Ala Leu Ser Ala Val Leu Pro Lys Val Glu Thr 65 70 75 80 Val Tyr Thr Tyr Leu Leu Asp Gly Glu Ser Arg Leu Val Cys Glu Glu 85 90 95 Pro Pro His Glu Leu Pro Gin Glu Gly Lys Val Arg Glu Ala Val He 100 105 110 Ser Arg Lys Arg Leu Gly Cys Asn Gly Leu Gly Pro Ser Asp Leu Pro 115 120 125 Gly Lys Pro Leu Ala Arg Leu Val Ala Pro Leu Ala Pro Asp Thr Gin 130 135 140 Val Leu Val He Pro Leu Val Asp Lys Glu Ala Gly Ala Val Ala Ala 145 150 155 160 Val He Leu Val His Cys Gly Gin Leu Ser Asp Asn Glu Glu Trp Ser 165 170 175 Leu Gin Ala Val Glu Lys His Thr Leu Val Ala Leu Lys Arg Val Gin 180 185 190 Ala Leu Gin Gin Arg Glu Ser Ser Val Ala Pro Glu Ala Thr Gin Asn 195 200 205 Pro Pro Glu Glu Ala Ala Gly Asp Gin Lys Gly Gly Val Ala Tyr Thr 210 215 220 Asp Gin Asp Arg Lys He Leu Gin Leu Cys Gly Glu Leu Tyr Asp Leu 225 230 235 240 Asp Ala Ser Ser Leu Gin Leu Lys Val Leu Gin Tyr Leu Gin Gin Glu 245 250 255 Thr Gin Ala Ser Arg Cys Cys Leu Leu Leu Val Ser Glu Asp Asn Leu 260 265 270 Gin Leu Ser Cys Lys Val He Gly Asp Lys Val Leu Glu Glu Glu He 275 280 285 Ser Phe Pro Leu Thr Thr Gly Arg Leu Gly Gin Val Val Glu Asp Lys 290 295 300 Lys Ser He Gin Leu Lys Asp Leu Thr Ser Glu Asp Met Gin Gin Leu 305 310 315 320 Gin Ser Met Leu Gly Cys Glu Val Gin Ala Met Leu Cys Val Pro Val 325 330 335 He Ser Arg Ala Thr Asp Gin Val Val Ala Leu Ala Cys Ala Phe Asn 340 345 350 Lys Leu Gly Gly Asp Leu Phe Thr Asp Gin Asp Glu His Val He Gin 355 360 365 His Cys Phe His Tyr Thr Ser Thr Val Leu Thr Ser Thr Leu Ala Phe 370 375 380 Gin Lys Glu Gin Lys Leu Lys Cys Glu Cys Gin Ala Leu Leu Gin Val 385 390 395 400 Ala Lys Asn Leu Phe Thr His Leu Asp Asp Val Ser Val Leu Leu Gin 405 410 415 Glu IleJle Thr Glu Ala Arg Asn Leu Ser Asn Ala Glu He Cys Ser 420 425 430 Val Phe Leu Leu Asp Gin Asn Glu Leu Val Ala Lys Val Phe Asp Gly 435 440 445 Gly Val Val Glu Asp Glu Ser Tyr Glu He Arg He Pro Ala Asp Gin 450 455 460 Gly He Ala Gly His Val Ala Thr Thr Gly Gin He Leu Asn He Pro 465 470 475 480 Asp Ala Tyr Ala His Pro Leu Phe Tyr Arg Gly Val Asp Asp Ser Thr 485 490 495 Gly Phe Arg Thr Arg Asn He Leu Cys Phe Pro He Lys Asn Glu Asn 500 505 510 Gin Glu Val He Gly Val Ala Glu Leu Val Asn Lys He Asn Gly Pro 515 520 525 Trp Phe Ser Lys Phe Asp Glu Asp Leu Ala Thr Ala Phe Ser He Tyr 530 535 540 Cys Gly He Ser He Ala His Ser Leu Leu Tyr Lys Lys Val Asn Glu 545 550 555 560 Ala Gin Tyr Arg Ser His Leu Ala Asn Glu Met Met Met Tyr His Met 565 570 575 Lys Val Ser Asp Asp Glu Tyr Thr Lys Leu Leu His Asp Gly He Gin 580 585 590 Pro Val Ala Ala He Asp Ser Asn Phe Ala Ser Phe Thr Tyr Thr Pro 595 600 605 Arg Ser Leu Pro Glu Asp Asp Thr Ser Met Ala He Leu Ser Met Leu 610 615 620 Gin Asp Met Asn Phe He Asn Asn Tyr Lys He Asp Cys Pro Thr Leu 625 630 635 640 Ala Arg Phe Cys Leu Met Val Lys Lys Gly Tyr Arg Asp Pro Pro Tyr 645 650 655 His Asn Trp Met His Ala Phe Ser Val Ser His Phe Cys Tyr Leu Leu 660 665 670 Tyr Lys Asn Leu Glu Leu Thr Asn Tyr Leu Glu Asp Met Glu He Phe 675 680 685 Ala Leu Phe He Ser Cys Met Cys His Asp Leu Asp His Arg Gly Thr 690 695 700 Asn Asn Ser Phe Gin Val Ala Ser Lys Ser Val Leu Ala Ala Leu Tyr 705 710 715 720 Ser Ser Glu Gly Ser Val Met Glu Arg His His Phe Ala Gin Ala He 725 730 735 Ala He Leu Asn Thr His Gly Cys Asn He Phe Asp His Phe Ser Arg 740 745 750 Lys Asp Tyr Gin Arg Met Leu Asp Leu Met Arg Asp He He Leu Ala 755 760 765 Thr Asp.Leu Ala His His Leu Arg He Phe Lys Asp Leu Gin Lys Met 770 775 780 Ala Glu Val Gly Tyr Asp Arg Thr Asn Lys Gin His His Ser Leu Leu 785 790 795 800 Leu Cys Leu Leu Met Thr Ser Cys Asp Leu Ser Asp Gin Thr Lys Gly 805 810 815 Trp Lys Thr Thr Arg Lys He Ala Glu Leu He Tyr Lys Glu Phe Phe 820 825 830 Ser Gin Gly Asp Leu Glu Lys Ala Met Gly Asn Arg Pro Met Glu Met 835 840 845 Met Asp Arg Glu Lys Ala Tyr He Pro Glu Leu Gin He Ser Phe Met 850 855 860 Glu His He Ala Met Pro He Tyr Lys Leu Leu Gin Asp Leu Phe Pro 865 870 875 880 Lys Ala Ala Glu Leu Tyr Glu Arg Val Ala Ser Asn Arg Glu His Trp 885 890 895 Thr Lys Val Ser His Lys Phe Thr He Arg Gly Leu Pro Ser Asn Asn 900 905 910 Ser Leu Asp Phe Leu Asp Glu Glu Tyr Glu Val Pro Asp Leu Asp Gly 915 920 925 Ala Arg Ala Pro He Asn Gly Cys Cys Ser Leu Asp Ala Glu 930 935 940 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3044 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 12..2834 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: GAATTCTGAT A ATG GGG CAG GCA TGC GGC CAC TCC ATC CTC TGC AGG AGC 50 Met Gly Gin Ala Cys Gly His Ser He Leu Cys Arg Ser 1 5 10 CAG CAG TAC CCG GCA GCG CGA CCG GCT GAG CCG CGG GGC CAG CAG GTC 98 Gin Gin Tyr Pro Ala Ala Arg Pro Ala Glu Pro Arg Gly Gin Gin Val 15 20 25 TTC CTC AAG CCG GAC GAG CCG CCG CCG CCG CCG CAG CCA TGC GCC GAC 146 Phe Leu Lys Pro Asp Glu Pro Pro Pro Pro Pro Gin Pro Cys Ala Asp 30 35 40 45 AGC CTG CAG GAC GCC TTG CTG AGT CTG GGC TCT GTC ATC GAC ATT TCA 194 Ser Leu Gin Asp Ala Leu Leu Ser Leu Gly Ser Val He Asp He Ser 50 55 60 GGC CTG CAA CGT GCT GTC AAG GAG GCC CTG TCA GCT GTG CTC CCC CGA 242 Gly Leu Gin Arg Ala Val Lys Glu Ala Leu Ser Ala Val Leu Pro Arg 65 70 75 GTG GAA ACT GTC TAC ACC TAC CTA CTG GAT GGT GAG TCC CAG CTG GTG 290 Val Glu Thr Val Tyr Thr Tyr Leu Leu Asp Gly Glu Ser Gin Leu Val 80 85 90 TGT GAG GAC CCC CCA CAT GAG CTG CCC CAG GAG GGG AAA GTC CGG GAG 338 Cys Glu Asp Pro Pro His Glu Leu Pro Gin Glu Gly Lys Val Arg Glu 95 100 105 GCT ATC ATC TCC CAG AAG CGG CTG GGC TGC AAT GGG CTG GGC TTC TCA 386 Ala He He Ser Gin Lys Arg Leu Gly Cys Asn Gly Leu Gly Phe Ser 110 115 120 125 GAC CTG CCA GGG AAG CCC TTG GCC AGG CTG GTG GCT CCA CTG GCT CCT 434 Asp Leu Pro Gly Lys Pro Leu Ala Arg Leu Val Ala Pro Leu Ala Pro 130 135 140 GAT ACC CAA GTG CTG GTC ATG CCG CTA GCG GAC AAG GAG GCT GGG GCC 482 Asp Thr Gin Val Leu Val Met Pro Leu Ala Asp Lys Glu Ala Gly Ala 145 150 155 GTG GCA GCT GTC ATC TTG GTG CAC TGT GGC CAG CTG AGT GAT AAT GAG 530 Val Ala Ala Val He Leu Val His Cys Gly Gin Leu Ser Asp Asn Glu 160 165 170 GAA TGG AGC CTG CAG GCG GTG GAG AAG CAT ACC CTG GTC GCC CTG CGG 578 Glu Trp Ser Leu Gin Ala Val Glu Lys His Thr Leu Val Ala Leu Arg 175 180 185 AGG GTG CAG GTC CTG CAG CAG CGC GGG CCC AGG GAG GCT CCC CGA GCC 626 Arg Val Gin Val Leu Gin Gin Arg Gly Pro Arg Glu Ala Pro Arg Ala 190 195 200 205 GTC CAG AAC CCC CCG GAG GGG ACG GCG GAA GAC CAG AAG GGC GGG GCG 674 Val Gin Asn Pro Pro Glu Gly Thr Ala Glu Asp Gin Lys Gly Gly Ala 210 215 220 GCG TAC ACC GAC CGC GAC CGC AAG ATC CTC CAA CTG TGC GGG GAA CTC 722 Ala Tyr Thr Asp Arg Asp Arg Lys He Leu Gin Leu Cys Gly Glu Leu 225 230 235 TAC GAC CTG GAT GCC TCT TCC CTG CAG CTC AAA GTG CTC CAA TAC CTG 770 Tyr Asp Leu Asp Ala Ser Ser Leu Gin Leu Lys Val Leu Gin Tyr Leu 240 245 250 CAG CAG GAG ACC CGG GCA TCC CGC TGC TGC CTC CTG CTG GTG TCG GAG 818 Gin Gin Glu Thr Arg Ala Ser Arg Cys Cys Leu Leu Leu Val Ser Glu 255 260 265 GAC AAT CTC CAG CTT TCT TGC AAG GTC ATC GGA GAC AAA GTG CTC GGG 866 Asp Asn Leu Gin Leu Ser Cys Lys Val He Gly Asp Lys Val Leu Gly 270 275 280 285 GAA GAG GTC AGC TTT CCC TTG ACA GGA TGC CTG GGC CAG GTG GTG GAA 914 Glu Glu Val Ser Phe Pro Leu Thr Gly Cys Leu Gly Gin Val Val Glu 290 295 300 GAC AAG AAG TCC ATC CAG CTG AAG GAC CTC ACC TCC GAG GAT GTA CAA 962 Asp Lys Lys Ser He Gin Leu Lys Asp Leu Thr Ser Glu Asp Val Gin 305 310 315 CAG CTG CAG AGC ATG TTG GGC TGT GAG CTG CAG GCC ATG CTC TGT GTC 1010 Gin Leu Gin Ser Met Leu Gly Cys Glu Leu Gin Ala Met Leu Cys Val 320 325 330 CCT GTC ATC AGC CGG GCC ACT GAC CAG GTG GTG GCC TTG GCC TGC GCC 1058 Pro Val He Ser Arg Ala Thr Asp Gin Val Val Ala Leu Ala Cys Ala 335 340 345 TTC AAC AAG CTA GAA GGA GAC TTG TTC ACC GAC GAG GAC GAG CAT GTG 1106 Phe Asn Lys Leu Glu Gly Asp Leu Phe Thr Asp Glu Asp Glu His Val 350 355 360 365 ATC CAG CAC TGC TTC CAC TAC ACC AGC ACC GTG CTC ACC AGC ACC CTG 1154 He Gin His Cys Phe His Tyr Thr Ser Thr Val Leu Thr Ser Thr Leu 370 375 380 GCC TTC CAG AAG GAA CAG AAA CTC AAG TGT GAG TGC CAG GCT CTT CTC 1202 Ala Phe Gin Lys Glu Gin Lys Leu Lys Cys Glu Cys Gin Ala Leu Leu 385 390 395 CAA GTG GCA AAG AAC CTC TTC ACC CAC CTG GAT GAC GTC TCT GTC CTG 1250 Gin Val Ala Lys Asn Leu Phe Thr His Leu Asp Asp Val Ser Val Leu 400 405 410 CTC CAG GAG ATC ATC ACG GAG GCC AGA AAC CTC AGC AAC GCA GAG ATC 1298 Leu Gin Glu He He Thr Glu Ala Arg Asn Leu Ser Asn Ala Glu He 415 420 425 TGC TCT GTG TTC CTG CTG GAT CAG AAT GAG CTG GTG GCC AAG GTG TTC 1346 Cys Ser Val Phe Leu Leu Asp Gin Asn Glu Leu Val Ala Lys Val Phe 430 435 440 445 GAC GGG GGC GTG GTG GAT GAT GAG AGC TAT GAG ATC CGC ATC CCG GCC 1394 Asp Gly Gly Val Val Asp Asp Glu Ser Tyr Glu He Arg He Pro Ala 450 455 460 GAT CAG GGC ATC GCG GGA CAC GTG GCG ACC ACG GGC CAG ATC CTG AAC 1442 Asp Gin Gly He Ala Gly His Val Ala Thr Thr Gly Gin He Leu Asn 465 470 475 ATC CCT GAC GCA TAT GCC CAT CCG CTT TTC TAC CGC GGC GTG GAC GAC 1490 He Pro Asp Ala Tyr Ala His Pro Leu Phe Tyr Arg Gly Val Asp Asp 480 485 490 AGC ACC GGC TTC CGC ACG CGC AAC ATC CTC TGC TTC CCC ATC AAG AAC 1538 Ser Thr Gly Phe Arg Thr Arg Asn He Leu Cys Phe Pro He Lys Asn 495 500 505 GAG AAC CAG GAG GTC ATC GGT GTG GCC GAG CTG GTG AAC AAG ATC AAT 1586 Glu Asn Gin Glu Val He Gly Val Ala Glu Leu Val Asn Lys He Asn 510 515 520 525 GGG CCA TGG TTC AGC AAG TTC GAC GAG GAC CTG GCG ACG GCC TTC TCC 1634 Gly Pro Trp Phe Ser Lys Phe Asp Glu Asp Leu Ala Thr Ala Phe Ser 530 535 540 ATC TAC TGC GGC ATC AGC ATC GCC CAT TCT CTC CTA TAC AAA AAA GTG 1682 He Tyr Cys Gly He Ser He Ala His Ser Leu Leu Tyr Lys Lys Val 545 550 555 AAT GAG GCT CAG TAT CGC AGC CAC CTG GCC AAT GAG ATG ATG ATG TAC 1730 Asn Glu Ala Gin Tyr Arg Ser His Leu Ala Asn Glu Met Met Met Tyr 560 565 570 CAC ATG AAG GTC TCC GAC GAT GAG TAT ACC AAA CTT CTC CAT GAT GGG 1778 His Met Lys Val Ser Asp Asp Glu Tyr Thr Lys Leu Leu His Asp Gly 575 580 585 ATC CAG CCT GTG GCT GCC ATT GAC TCC AAT TTT GCA AGT TTC ACC TAT 1826 He Gin Pro Val Ala Ala He Asp Ser Asn Phe Ala Ser Phe Thr Tyr 590 595 600 605 ACC CCT CGT TCC CTG CCC GAG GAT GAC ACG TCC ATG GCC ATC CTG AGC 1874 Thr Pro Arg Ser Leu Pro Glu Asp Asp Thr Ser Met Ala He Leu Ser 610 615 620 ATG CTG CAG GAC ATG AAT TTC ATC AAC AAC TAC AAA ATT GAC TGC CCG 1922 Met Leu Gin Asp Met Asn Phe He Asn Asn Tyr Lys He Asp Cys Pro 625 630 635 ACC CTG GCC CGG TTC TGT TTG ATG GTG AAG AAG GGC TAC CGG GAT CCC 1970 Thr Leu Ala Arg Phe Cys Leu Met Val Lys Lys Gly Tyr Arg Asp Pro 640 645 650 CCC TAC CAC AAC TGG ATG CAC GCC TTT TCT GTC TCC CAC TTC TGC TAC 2018 Pro Tyr His Asn Trp Met His Ala Phe Ser Val Ser His Phe Cys Tyr 655 660 665 CTG CTC TAC AAG AAC CTG GAG CTC ACC AAC TAC CTC GAG GAC ATC GAG 2066 Leu Leu Tyr Lys Asn Leu Glu Leu Thr Asn Tyr Leu Glu Asp He Glu 670 675 680 685 ATC TTT GCC TTG TTT ATT TCC TGC ATG TGT CAT GAC CTG GAC CAC AGA 2114 He Phe Ala Leu Phe He Ser Cys Met Cys His Asp Leu Asp His Arg 690 695 700 GGC ACA AAC AAC TCT TTC CAG GTG GCC TCG AAA TCT GTG CTG GCT GCG 2162 Gly Thr Asn Asn Ser Phe Gin Val Ala Ser Lys Ser Val Leu Ala Ala 705 710 715 CTC TAC AGC TCT GAG GGC TCC GTC ATG GAG AGG CAC CAC TTT GCT CAG 2210 Leu Tyr Ser Ser Glu Gly Ser Val Met Glu Arg His His Phe Ala Gin 720 725 730 GCC ATC GCC ATC CTC AAC ACC CAC GGC TGC AAC ATC TTT GAT CAT TTC 2258 Ala He Ala He Leu Asn Thr His Gly Cys Asn He Phe Asp His Phe 735 740 745 TCC CGG AAG GAC TAT CAG CGC ATG CTG GAT CTG ATG CGG GAC ATC ATC 2306 Ser Arg Lys Asp Tyr Gin Arg Met Leu Asp Leu Met Arg Asp He He 750 755 760 765 TTG GCC ACA GAC CTG GCC CAC CAT CTC CGC ATC TTC AAG GAC CTC CAG 2354 Leu Ala Thr Asp Leu Ala His His Leu Arg He Phe Lys Asp Leu Gin 770 775 780 AAG ATG GCT GAG GTG GGC TAC GAC CGA AAC AAC AAG CAG CAC CAC AGA 2402 Lys Met Ala Glu Val Gly Tyr Asp Arg Asn Asn Lys Gin His His Arg 785 790 795 CTT CTC CTC TGC CTC CTC ATG ACC TCC TGT GAC CTC TCT GAC CAG ACC 2450 Leu Leu Leu Cys Leu Leu Met Thr Ser Cys Asp Leu Ser Asp Gin Thr 800 805 810 AAG GGC TGG AAG ACT ACG AGA AAG ATC GCG GAG CTG ATC TAC AAA GAA 2498 Lys Gly Trp Lys Thr Thr Arg Lys He Ala Glu Leu He Tyr Lys Glu 815 820 825 TTC TTC TCC CAG GGA GAC CTG GAG AAG GCC ATG GGC AAC AGG CCG ATG 2546 Phe Phe Ser Gin Gly Asp Leu Glu Lys Ala Met Gly Asn Arg Pro Met 830 835 840 845 GAG ATG ATG GAC CGG GAG AAG GCC TAT ATC CCT GAG CTG CAA ATC AGC 2594 Glu Met Met Asp Arg Glu Lys Ala Tyr lie Pro Glu Leu Gin He Ser 850 855 860 TTC ATG GAG CAC ATT GCA ATG CCC ATC TAC AAG CTG TTG CAG GAC CTG 2642 Phe Met Glu His He Ala Met Pro He Tyr Lys Leu Leu Gin Asp Leu 865 870 875 TTC CCC AAA GCG GCA GAG CTG TAC GAG CGC GTG GCC TCC AAC CGT GAG 2690 Phe Pro Lys Ala Ala Glu Leu Tyr Glu Arg Val Ala Ser Asn Arg Glu 880 885 890 CAC TGG ACC AAG GTG TCC CAC AAG TTC ACC ATC CGC GGC CTC CCA AGT 2738 His Trp Thr Lys Val Ser His Lys Phe Thr He Arg Gly Leu Pro Ser 895 900 905 AAC AAC TCG CTG GAC TTC CTG GAT GAG GAG TAC GAG GTG CCT GAT CTG 2786 Asn Asn Ser Leu Asp Phe Leu Asp Glu Glu Tyr Glu Val Pro Asp Leu 910 915 920 925 GAT GGC ACT AGG GCC CCC ATC AAT GGC TGC TGC AGC CTT GAT GCT GAG 2834 Asp Gly Thr Arg Ala Pro He Asn Gly Cys Cys Ser Leu Asp Ala Glu 930 935 940 TGACTCGAGC GTCATATTAA TGGACGCAAA GCAAGGAAAT TGCGAGCGGG AAATAAGAAA 2894 CGATAGAAGT AGGAATCGAT ACCCGGTGCG TGCACATAAC AGTCTTTTAC CAATTAACAG 2954 GAGAGATTGA AGTGTCGAGA TACGAAATGA AATTTACTAC GACTACCGTA AAGAAATGCA 3014 TAAGCTCTGT TAGAGAAAAA TTGGTAGCCA 3044 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 941 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: Met Gly Gin Ala Cys Gly His Ser He Leu Cys Arg Ser Gin Gin Tyr 1 5 10 15 Pro Ala Ala Arg Pro Ala Glu Pro Arg Gly Gin Gin Val Phe Leu Lys 20 25 30 Pro Asp Glu Pro Pro Pro Pro Pro Gin Pro Cys Ala Asp Ser Leu Gin 35 40 45 Asp Ala Leu Leu Ser Leu Gly Ser Val He Asp He Ser Gly Leu Gin 50 55 60 Arg Ala Val Lys Glu Ala Leu Ser Ala Val Leu Pro Arg Val Glu Thr 65 70 75 80 Val Tyr Thr Tyr Leu Leu Asp Gly Glu Ser Gin Leu Val Cys Glu Asp 85 90 95 Pro Pro His Glu Leu Pro Gin Glu Gly Lys Val Arg Glu Ala He He 100 105 110 Ser Gin Lys Arg Leu Gly Cys Asn Gly Leu Gly Phe Ser Asp Leu Pro 115 120 125 Gly Lys Pro Leu Ala Arg Leu Val Ala Pro Leu Ala Pro Asp Thr Gin 130 135 140 Val Leu Val Met Pro Leu Ala Asp Lys Glu Ala Gly Ala Val Ala Ala 145 150 155 160 Val He Leu Val His Cys Gly Gin Leu Ser Asp Asn Glu Glu Trp Ser 165 170 175 Leu Gin Ala Val Glu Lys His Thr Leu Val Ala Leu Arg Arg Val Gin 180 185 190 Val Leu Gin Gin Arg Gly Pro Arg Glu Ala Pro Arg Ala Val Gin Asn 195 200 205 Pro Pro Glu Gly Thr Ala Glu Asp Gin Lys Gly Gly Ala Ala Tyr Thr 210 215 220 sp Arg Asp Arg Lys He Leu Gin Leu Cys Gly Glu Leu Tyr Asp Leu 225 230 235 240 sp Ala Ser Ser Leu Gin Leu Lys Val Leu Gin Tyr Leu Gin Gin Glu 245 250 255 Thr Arg Ala Ser Arg Cys Cys Leu Leu Leu Val Ser Glu Asp Asn Leu 260 265 270 Gin Leu Ser Cys Lys Val He Gly Asp Lys Val Leu Gly Glu Glu Val 275 280 285 Ser Phe Pro Leu Thr Gly Cys Leu Gly Gin Val Val Glu Asp Lys Lys 290 295 300 Ser He Gin Leu Lys Asp Leu Thr Ser Glu Asp Val Gin Gin Leu Gin 305 310 315 320 Ser Met Leu Gly Cys Glu Leu Gin Ala Met Leu Cys Val Pro Val He 325 330 335 Ser Arg Ala Thr Asp Gin Val Val Ala Leu Ala Cys Ala Phe Asn Lys 340 345 350 Leu Glu Gly Asp Leu Phe Thr Asp Glu Asp Glu His Val He Gin His 355 360 365 Cys Phe His Tyr Thr Ser Thr Val Leu Thr Ser Thr Leu Ala Phe Gin 370 375 380 Lys Glu Gin Lys Leu Lys Cys Glu Cys Gin Ala Leu Leu Gin Val Ala 385 390 395 400 Lys Asn Leu Phe Thr His Leu Asp Asp Val Ser Val Leu Leu Gin Glu 405 410 415 He He Thr Glu Ala Arg Asn Leu Ser Asn Ala Glu He Cys Ser Val 420 425 430 Phe Leu Leu Asp Gin Asn Glu Leu Val Ala Lys Val Phe Asp Gly Gly 435 440 445 Val Val Asp Asp Glu Ser Tyr Glu He Arg He Pro Ala Asp Gin Gly 450 455 460 He Ala Gly His Val Ala Thr Thr Gly Gin He Leu Asn He Pro Asp 465 470 475 480 Ala Tyr Ala His Pro Leu Phe Tyr Arg Gly Val Asp Asp Ser Thr Gly 485 490 495 Phe Arg Thr Arg Asn He Leu Cys Phe Pro He Lys Asn Glu Asn Gin 500 505 510 Glu Val He Gly Val Ala Glu Leu Val Asn Lys He Asn Gly Pro Trp 515 520 525 Phe ServLys Phe Asp Glu Asp Leu Ala Thr Ala Phe Ser He Tyr Cys 530 535 540 Gly He Ser He Ala His Ser Leu Leu Tyr Lys Lys Val Asn Glu Ala 545 550 555 560 Gin Tyr Arg Ser His Leu Ala Asn Glu Met Met Met Tyr His Met Lys 565 570 575 Val Ser Asp Asp Glu Tyr Thr Lys Leu Leu His Asp Gly He Gin Pro 580 585 590 Val Ala Ala He Asp Ser Asn Phe Ala Ser Phe Thr Tyr Thr Pro Arg 595 600 605 Ser Leu Pro Glu Asp Asp Thr Ser Met Ala He Leu Ser Met Leu Gin 610 615 620 Asp Met Asn Phe He Asn Asn Tyr Lys He Asp Cys Pro Thr Leu Ala 625 630 635 640 Arg Phe Cys Leu Met Val Lys Lys Gly Tyr Arg Asp Pro Pro Tyr His 645 650 655 Asn Trp Met His Ala Phe Ser Val Ser His Phe Cys Tyr Leu Leu Tyr 660 665 670 Lys Asn Leu Glu Leu Thr Asn Tyr Leu Glu Asp He Glu He Phe Ala 675 680 685 Leu Phe He Ser Cys Met Cys His Asp Leu Asp His Arg Gly Thr Asn 690 695 700 Asn Ser Phe Gin Val Ala Ser Lys Ser Val Leu Ala Ala Leu Tyr Ser 705 710 715 720 Ser Glu Gly Ser Val Met Glu Arg His His Phe Ala Gin Ala He Ala 725 730 735 He Leu Asn Thr His Gly Cys Asn He Phe Asp His Phe Ser Arg Lys 740 745 750 Asp Tyr Gin Arg Met Leu Asp Leu Met Arg Asp He He Leu Ala Thr 755 760 765 Asp Leu Ala His His Leu Arg He Phe Lys Asp Leu Gin Lys Met Ala 770 775 780 Glu Val Gly Tyr Asp Arg Asn Asn Lys Gin His His Arg Leu Leu Leu 785 790 795 800 Cys Leu Leu Met Thr Ser Cys Asp Leu Ser Asp Gin Thr Lys Gly Trp 805 810 815 Lys Thr Thr Arg Lys He Ala Glu Leu He Tyr Lys Glu Phe Phe Ser 820 825 830 Gin Gly Asp Leu Glu Lys Ala Met Gly Asn Arg Pro Met Glu Met Met 835 840 845 Asp Arg Glu Lys Ala Tyr He Pro Glu Leu Gin He Ser Phe Met Glu 850 855 860 His He Ala Met Pro He Tyr Lys Leu Leu Gin Asp Leu Phe Pro Lys 865 870 875 880 Ala Ala Glu Leu Tyr Glu Arg Val Ala Ser Asn Arg Glu His Trp Thr 885 890 895 Lys Val Ser His Lys Phe Thr He Arg Gly Leu Pro Ser Asn Asn Ser 900 905 910 Leu Asp Phe Leu Asp Glu Glu Tyr Glu Val Pro Asp Leu Asp Gly Thr 915 920 925 Arg Ala Pro He Asn Gly Cys Cys Ser Leu Asp Ala Glu 930 935 940 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: TCRTTNGTNG TNCCYTTCAT RTT 23 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: Asn Met Lys Gly Thr Thr Asn Asp 1 5 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1625 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 12..1616 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: GAATTCTGAT C ATG GGG TCT AGT GCC ACA GAG ATT GAA GAA TTG GAA AAC 50 Met Gly Ser Ser Ala Thr Glu He Glu Glu Leu Glu Asn 1 5 10 ACC ACT TTT AAG TAT CTT ACA GGA GAA CAG ACT GAA AAA ATG TGG CAG 98 Thr Thr Phe Lys Tyr Leu Thr Gly Glu Gin Thr Glu Lys Met Trp Gin 15 20 25 CGC CTG AAA GGA ATA CTA AGA TGC TTG GTG AAG CAG CTG GAA AGA GGT 146 Arg Leu Lys Gly He Leu Arg Cys Leu Val Lys Gin Leu Glu Arg Gly 30 35 40 45 GAT GTT AAC GTC GTC GAC TTA AAG AAG AAT ATT GAA TAT GCG GCA TCT 194 Asp Val Asn Val Val Asp Leu Lys Lys Asn He Glu Tyr Ala Ala Ser 50 55 60 GTG CTG GAA GCA GTT TAT ATC GAT GAA ACA AGA AGA CTT CTG GAT ACT 242 Val Leu Glu Ala Val Tyr He Asp Glu Thr Arg Arg Leu Leu Asp Thr 65 70 75 GAA GAT GAG CTC AGT GAC ATT CAG ACT GAC TCA GTC CCA TCT GAA GTC 290 Glu Asp Glu Leu Ser Asp He Gin Thr Asp Ser Val Pro Ser Glu Val 80 85 90 CGG GAC TGG TTG GCT TCT ACC TTT ACA CGG AAA ATG GGG ATG ACA AAA 338 Arg Asp Trp Leu Ala Ser Thr Phe Thr Arg Lys Met Gly Met Thr Lys 95 100 105 AAG AAA CCT GAG GAA AAA CCA AAA TTT CGG AGC ATT GTG CAT GCT GTT 386 Lys Lys Pro Glu Glu Lys Pro Lys Phe Arg Ser He Val His Ala Val 110 115 120 125 CAA GCT GGA ATT TTT GTG GAA AGA ATG TAC CGA AAA ACA TAT CAT ATG 434 Gin Ala Gly He Phe Val Glu Arg Met Tyr Arg Lys Thr Tyr His Met 130 135 140 GTT GGT TTG GCA TAT CCA GCA GCT GTC ATC GTA ACA TTA AAG GAT GTT 482 Val Gly Leu Ala Tyr Pro Ala Ala Val He Val Thr Leu Lys Asp Val 145 150 155 GAT AAA TGG TCT TTC GAT GTA TTT GCC CTA AAT GAA GCA AGT GGA GAG 530 Asp Lys Trp Ser Phe Asp Val Phe Ala Leu Asn Glu Ala Ser Gly Glu 160 165 170 CAT AGT CTG AAG TTT ATG ATT TAT GAA CTG TTT ACC AGA TAT GAT CTT 578 His Ser Leu Lys Phe Met He Tyr Glu Leu Phe Thr Arg Tyr Asp Leu 175 180 185 ATC AAC CGT TTC AAG ATT CCT GTT TCT TGC CTA ATC ACC TTT GCA GAA 626 He Asn Arg Phe Lys He Pro Val Ser Cys Leu He Thr Phe Ala Glu 190 195 200 205 GCT TTA GAA GTT GGT TAC AGC AAG TAC AAA AAT CCA TAT CAC AAT TTG 674 Ala Leu Glu Val Gly Tyr Ser Lys Tyr Lys Asn Pro Tyr His Asn Leu 210 215 220 ATT CAT GCA GCT GAT GTC ACT CAA ACT GTG CAT TAC ATA ATG CTT CAT 722 He His Ala Ala Asp Val Thr Gin Thr Val His Tyr He Met Leu His 225 230 235 ACA GGT ATC ATG CAC TGG CTC ACT GAA CTG GAA ATT TTA GCA ATG GTC 770 Thr Gly He Met His Trp Leu Thr Glu Leu Glu He Leu Ala Met Val 240 245 250 TTT GCT GCT GCC ATT CAT GAT TAT GAG CAT ACA GGG ACA ACA AAC AAC 818 Phe Ala Ala Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn Asn 255 260 265 TTT CAC ATT CAG ACA AGG TCA GAT GTT GCC ATT TTG TAT AAT GAT CGC 866 Phe His He Gin Thr Arg Ser Asp Val Ala He Leu Tyr Asn Asp Arg 270 275 280 285 TCT GTC CTT GAG AAT CAC CAC GTG AGT GCA GCT TAT CGA CTT ATG CAA 914 Ser Val Leu Glu Asn His His Val Ser Ala Ala Tyr Arg Leu Met Gin 290 295 300 GAA GAA GAA ATG AAT ATC TTG ATA AAT TTA TCC AAA GAT GAC TGG AGG 962 Glu Glu Glu Met Asn He Leu He Asn Leu Ser Lys Asp Asp Trp Arg 305 310 315 GAT CTT CGG AAC CTA GTG ATT GAA ATG GTT TTA TCT ACA GAC ATG TCA 1010 Asp Leu Arg Asn Leu Val He Glu Met Val Leu Ser Thr Asp Met Ser 320 325 330 GGT CAC TTC CAG CAA ATT AAA AAT ATA AGA AAC AGT TTG CAG CAG CCT 1058 Gly His Phe Gin Gin He Lys Asn He Arg Asn Ser Leu Gin Gin Pro 335 340 345 GAA GGG ATT GAC AGA GCC AAA ACC ATG TCC CTG ATT CTC CAC GCA GCA 1106 Glu Gly He Asp Arg Ala Lys Thr Met Ser Leu He Leu His Ala Ala 350 355 360 365 GAC ATC AGC CAC CCA GCC AAA TCC TGG AAG CTG CAT TAT CGG TGG ACC 1154 Asp He Ser His Pro Ala Lys Ser Trp Lys Leu His Tyr Arg Trp Thr 370 375 380 ATG GCC CTA ATG GAG GAG TTT TTC CTG CAG GGA GAT AAA GAA GCT GAA 1202 Met Ala Leu Met Glu Glu Phe Phe Leu Gin Gly Asp Lys Glu Ala Glu 385 390 395 TTA GGG CTT CCA TTT TCC CCA CTT TGT GAT CGG AAG TCA ACC ATG GTG 1250 Leu Gly Leu Pro Phe Ser Pro Leu Cys Asp Arg Lys Ser Thr Met Val 400 405 410 GCC CAG TCA CAA ATA GGT TTC ATC GAT TTC ATA GTA GAG CCA ACA TTT 1298 Ala Gin Ser Gin He Gly Phe He Asp Phe He Val Glu Pro Thr Phe 415 420 425 TCT CTT CTG ACA GAC TCA ACA GAG AAA ATT GTT ATT CCT CTT ATA GAG 1346 Ser Leu Leu Thr Asp Ser Thr Glu Lys He Val He Pro Leu He Glu 430 435 440 445 GAA GCC TCA AAA GCC GAA ACT TCT TCC TAT GTG GCA AGC AGC TCA ACC 1394 Glu Ala Ser Lys Ala Glu Thr Ser Ser Tyr Val Ala Ser Ser Ser Thr 450 455 460 ACC ATT GTG GGG TTA CAC ATT GCT GAT GCA CTA AGA CGA TCA AAT ACA 1442 Thr He Val Gly Leu His He Ala Asp Ala Leu Arg Arg Ser Asn Thr 465 470 475 AAA GGC TCC ATG AGT GAT GGG TCC TAT TCC CCA GAC TAC TCC CTT GCA 1490 Lys Gly Ser Met Ser Asp Gly Ser Tyr Ser Pro Asp Tyr Ser Leu Ala 480 485 490 GCA GTG GAC CTG AAG AGT TTC AAG AAC AAC CTG GTG GAC ATC ATT CAG 1538 Ala Val Asp Leu Lys Ser Phe Lys Asn Asn Leu Val Asp He He Gin 495 500 505 CAG AAC AAA GAG AGG TGG AAA GAG TTA GCT GCA CAA GAA GCA AGA ACC 1586 Gin Asn Lys Glu Arg Trp Lys Glu Leu Ala Ala Gin Glu Ala Arg Thr 510 515 520 525 AGT TCA CAG AAG TGT GAG TTT ATT CAT CAG TAACTCGAG 1625 Ser Ser Gin Lys Cys Glu Phe He His Gin 530 535 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 535 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: Met Gly Ser Ser Ala Thr Glu He Glu Glu Leu Glu Asn Thr Thr Phe 1 5 10 15 Lys Tyr Leu Thr Gly Glu Gin Thr Glu Lys Met Trp Gin Arg Leu Lys 20 25 30 Gly He Leu Arg Cys Leu Val Lys Gin Leu Glu Arg Gly Asp Val Asn 35 40 45 Val Val Asp Leu Lys Lys Asn He Glu Tyr Ala Ala Ser Val Leu Glu 50 55 60 Ala Val Tyr He Asp Glu Thr Arg Arg Leu Leu Asp Thr Glu Asp Glu 65 70 75 80 Leu Ser Asp He Gin Thr Asp Ser Val Pro Ser Glu Val Arg Asp Trp 85 90 95 Leu Ala Ser Thr Phe Thr Arg Lys Met Gly Met Thr Lys Lys Lys Pro 100 105 110 Glu Glu Lys Pro Lys Phe Arg Ser He Val His Ala Val Gin Ala Gly 115 120 125 He Phe Val Glu Arg Met Tyr Arg Lys Thr Tyr His Met Val Gly Leu 130 135 140 Ala Tyr Pro Ala Ala Val He Val Thr Leu Lys Asp Val Asp Lys Trp 145 150 155 160 Ser Phe Asp Val Phe Ala Leu Asn Glu Ala Ser Gly Glu His Ser Leu 165 170 175 Lys Phe Met He Tyr Glu Leu Phe Thr Arg Tyr Asp Leu He Asn Arg 180 185 190 Phe Lys He Pro Val Ser Cys Leu He Thr Phe Ala Glu Ala Leu Glu 195 200 205 Val Gly Tyr Ser Lys Tyr Lys Asn Pro Tyr His Asn Leu He His Ala 210 215 220 Ala Asp Val Thr Gin Thr Val His Tyr He Met Leu His Thr Gly He 225 230 235 240 Met His Trp Leu Thr Glu Leu Glu He Leu Ala Met Val Phe Ala Ala 245 250 255 Ala He His Asp Tyr Glu His Thr Gly Thr Thr Asn Asn Phe His He 260 265 270 Gin Thr Arg Ser Asp Val Ala He Leu Tyr Asn Asp Arg Ser Val Leu 275 280 285 Glu Asn..His His Val Ser Ala Ala Tyr Arg Leu Met Gin Glu Glu Glu 290 295 300 Met Asn He Leu He Asn Leu Ser Lys Asp Asp Trp Arg Asp Leu Arg 305 310 315 320 Asn Leu Val He Glu Met Val Leu Ser Thr Asp Met Ser Gly His Phe 325 330 335 Gin Gin He Lys Asn He Arg Asn Ser Leu Gin Gin Pro Glu Gly He 340 345 350 sp Arg Ala Lys Thr Met Ser Leu He Leu His Ala Ala Asp He Ser 355 360 365 His Pro Ala Lys Ser Trp Lys Leu His Tyr Arg Trp Thr Met Ala Leu 370 375 380 Met Glu Glu Phe Phe Leu Gin Gly Asp Lys Glu Ala Glu Leu Gly Leu 385 390 395 400 Pro Phe Ser Pro Leu Cys Asp Arg Lys Ser Thr Met Val Ala Gin Ser 405 410 415 Gin He Gly Phe He Asp Phe He Val Glu Pro Thr Phe Ser Leu Leu 420 425 430 Thr Asp Ser Thr Glu Lys He Val He Pro Leu He Glu Glu Ala Ser 435 440 445 Lys Ala Glu Thr Ser Ser Tyr Val Ala Ser Ser Ser Thr Thr He Val 450 455 460 Gly Leu His He Ala Asp Ala Leu Arg Arg Ser Asn Thr Lys Gly Ser 465 470 475 480 Met Ser Asp Gly Ser Tyr Ser Pro Asp Tyr Ser Leu Ala Ala Val Asp 485 490 495 Leu Lys Ser Phe Lys Asn Asn Leu Val Asp He He Gin Gin Asn Lys 500 505 510 Glu Arg Trp Lys Glu Leu Ala Ala Gin Glu Ala Arg Thr Ser Ser Gin 515 520 525 Lys Cys Glu Phe He His Gin 530 535 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2693 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 176..2077 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: GTCGCTTCAA TATTTCAAAA TGGATCCGGT TCTGTGGCGG GTGCGAGAGT GAGGCTGTGG 60 GGGACCTCCA GGCCGAACCT CCGCGAAGCC TCGGCCTTCT GCGTGCCCTG GCCCCGGGAG 120 GATAAGGATT TCCCTTCCCT CCTACTTGCG CGCGGAGCCG AGCTCTTGTT GAGCT ATG 178 Met 1 GAG TCG CCA ACC AAG GAG ATT GAA GAA TTT GAG AGC AAC TCT CTG AAA 226 Glu Ser Pro Thr Lys Glu He Glu Glu Phe Glu Ser Asn Ser Leu Lys 5 10 15 TAC CTG CAA CCG GAA CAG ATC GAG AAA ATC TGG CTT CGG CTC CGC GGG 274 Tyr Leu Gin Pro Glu Gin He Glu Lys He Trp Leu Arg Leu Arg Gly 20 25 30 CTG AGG AAA TAT AAG AAA ACG TCC CAG AGA TTA CGG TCT TTG GTC AAA 322 Leu Arg Lys Tyr Lys Lys Thr Ser Gin Arg Leu Arg Ser Leu Val Lys 35 40 45 CAA TTA GAG AGA GGG GAA GCT TCA GTG GTA GAT CTT AAG AAG AAT TTG 370 Gin Leu Glu Arg Gly Glu Ala Ser Val Val Asp Leu Lys Lys Asn Leu 50 55 60 65 GAA TAT GCA GCC ACA GTG CTT GAA TCT GTG TAT ATT GAT GAA ACA AGG 418 Glu Tyr Ala Ala Thr Val Leu Glu Ser Val Tyr He Asp Glu Thr Arg 70 75 80 AGA CTC CTG GAT ACA GAG GAT GAG CTC AGT GAC ATT CAG TCA GAT GCT 466 Arg Leu Leu Asp Thr Glu Asp Glu Leu Ser Asp He Gin Ser Asp Ala 85 90 95 GTG CCT TCT GAG GTC CGA GAC TGG CTG GCC TCC ACC TTC ACG CGG CAG 514 Val Pro Ser Glu Val Arg Asp Trp Leu Ala Ser Thr Phe Thr Arg Gin 100 105 110 ATG GGG ATG ATG CTC AGG AGG AGC GAC GAG AAG CCC CGG TTC AAG AGC 562 Met Gly Met Met Leu Arg Arg Ser Asp Glu Lys Pro Arg Phe Lys Ser 115 120 125 ATC GTT CAC GCA GTG CAG GCT GGG ATA TTT GTG GAG AGA ATG TAT AGA 610 He Val His Ala Val Gin Ala Gly He Phe Val Glu Arg Met Tyr Arg 130 135 140 145 CGG ACA TCA AAC ATG GTT GGA CTG AGC TAT CCA CCA GCT GTT ATT GAG 658 Arg Thr Ser Asn Met Val Gly Leu Ser Tyr Pro Pro Ala Val He Glu 150 155 160 GCA TTA AAG GAT GTG GAC AAG TGG TCC TTT GAC GTC TTT TCC CTC AAT 706 Ala Leu Lys Asp Val Asp Lys Trp Ser Phe Asp Val Phe Ser Leu Asn 165 170 175 GAG GCC AGT GGG GAT CAT GCA CTG AAA TTT ATT TTC TAT GAA CTA CTC 754 Glu Ala Ser Gly Asp His Ala Leu Lys Phe He Phe Tyr Glu Leu Leu 180 185 190 ACA CGT TAT GAT CTG ATC AGC CGT TTC AAG ATC CCC ATT TCT GCA CTT 802 Thr Arg Tyr Asp Leu He Ser Arg Phe Lys He Pro He Ser Ala Leu 195 200 205 GTC TCA TTT GTG GAG GCC CTG GAA GTG GGA TAC AGC AAG CAC AAA AAT 850 Val Ser Phe Val Glu Ala Leu Glu Val Gly Tyr Ser Lys His Lys Asn 210 215 220 225 CCT TAC CAT AAC TTA ATG CAC GCT GCC GAT GTT ACA CAG ACA GTG CAT 898 Pro Tyr His Asn Leu Met His Ala Ala Asp Val Thr Gin Thr Val His 230 235 240 TAC CTC CTC TAT AAG ACA GGA GTG GCG AAC TGG CTG ACG GAG CTG GAG 946 Tyr Leu Leu Tyr Lys Thr Gly Val Ala Asn Trp Leu Thr Glu Leu Glu 245 250 255 ATC TTT GCT ATA ATC TTC TCA GCT GCC ATC CAT GAC TAC GAG CAT ACC 994 He Phe Ala He He Phe Ser Ala Ala He His Asp Tyr Glu His Thr 260 265 270 GGA ACC ACC AAC AAT TTC CAC ATT CAG ACT CGG TCT GAT CCA GCT ATT 1042 Gly Thr Thr Asn Asn Phe His He Gin Thr Arg Ser Asp Pro Ala He 275 280 285 CTG TAT AAT GAC AGA TCT GTA CTG GAG AAT CAC CAT TTA AGT GCA GCT 1090 Leu Tyr Asn Asp Arg Ser Val Leu Glu Asn His His Leu Ser Ala Ala 290 295 300 305 TAT CGC CTT CTG CAA GAT GAC GAG GAA ATG AAT ATT TTG ATT AAC CTC 1138 Tyr Arg Leu Leu Gin Asp Asp Glu Glu Met Asn He Leu He Asn Leu 310 315 320 TCA AAG GAT GAC TGG AGG GAG TTT CGA ACC TTG GTA ATT GAA ATG GTG 1186 Ser Lys Asp Asp Trp Arg Glu Phe Arg Thr Leu Val He Glu Met Val 325 330 335 ATG GCC ACA GAT ATG TCT TGT CAC TTC CAA CAA ATC AAA GCA ATG AAG 1234 Met Ala Thr Asp Met Ser Cys His Phe Gin Gin He Lys Ala Met Lys 340 345 350 ACT GCT CTG CAG CAG CCA GAA GCC ATT GAA AAG CCA AAA GCC TTA TCC 1282 Thr Ala Leu Gin Gin Pro Glu Ala He Glu Lys Pro Lys Ala Leu Ser 355 360 365 CTT ATG CTG CAT ACA GCA GAT ATT AGC CAT CCA GCA AAA GCA TGG GAC 1330 Leu Met Leu His Thr Ala Asp He Ser His Pro Ala Lys Ala Trp Asp 370 375 380 385 CTC CAT CAT CGC TGG ACA ATG TCA CTC CTG GAG GAG TTC TTC AGA CAG 1378 Leu His His Arg Trp Thr Met Ser Leu Leu Glu Glu Phe Phe Arg Gin 390 395 400 GGT GAC AGA GAA GCA GAG CTG GGG CTG CCT TTT TCT CCT CTG TGT GAC 1426 Gly Asp Arg Glu Ala Glu Leu Gly Leu Pro Phe Ser Pro Leu Cys Asp 405 410 415 CGA AAG TCC ACT ATG GTT GCT CAG TCA CAA GTA GGT TTC ATT GAT TTC 1474 Arg Lys Ser Thr Met Val Ala Gin Ser Gin Val Gly Phe He Asp Phe 420 425 430 ATC GTG GAA CCC ACC TTC ACT GTG CTT ACG GAC ATG ACC GAG AAG ATT 1522 He Val Glu Pro Thr Phe Thr Val Leu Thr Asp Met Thr Glu Lys He 435 440 445 GTG AGT CCA TTA ATC GAT GAA ACC TCT CAA ACT GGT GGG ACA GGA CAG 1570 Val Ser Pro Leu He Asp Glu Thr Ser Gin Thr Gly Gly Thr Gly Gin 450 455 460 465 AGG CGT TCG AGT TTG AAT AGC ATC AGC TCG TCA GAT GCC AAG CGA TCA 1618 Arg Arg Ser Ser Leu Asn Ser He Ser Ser Ser Asp Ala Lys Arg Ser 470 475 480 GGT GTC AAG ACC TCT GGT TCA GAG GGA AGT GCC CCG ATC AAC AAT TCT 1666 Gly Val Lys Thr Ser Gly Ser Glu Gly Ser Ala Pro He Asn Asn Ser 485 490 495 GTC ATC TCC GTT GAC TAT AAG AGC TTT AAA GCT ACT TGG ACG GAA GTG 1714 Val He Ser Val Asp Tyr Lys Ser Phe Lys Ala Thr Trp Thr Glu Val 500 505 510 GTG CAC ATC AAT CGG GAG AGA TGG AGG GCC AAG GTA CCC AAA GAG GAG 1762 Val His He Asn Arg Glu Arg Trp Arg Ala Lys Val Pro Lys Glu Glu 515 520 525 AAG GCC AAG AAG GAA GCA GAG GAA AAG GCT CGC CTG GCC GCA GAG GAG 1810 Lys Ala Lys Lys Glu Ala Glu Glu Lys Ala Arg Leu Ala Ala Glu Glu 530 535 540 545 CAG CAA AAG GAA ATG GAA GCC AAA AGC CAG GCT GAA GAA GGC GCA TCT 1858 Gin Gin Lys Glu Met Glu Ala Lys Ser Gin Ala Glu Glu Gly Ala Ser 550 555 560 GGC AAA GCT GAG AAA AAG ACG TCT GGA GAA ACT AAG AAT CAA GTC AAT 1906 Gly Lys Ala Glu Lys Lys Thr Ser Gly Glu Thr Lys Asn Gin Val Asn 565 570 575 GGA ACA CGG GCA AAC AAA AGT GAC AAC CCT CGT GGG AAA AAT TCC AAA 1954 Gly Thr Arg Ala Asn Lys Ser Asp Asn Pro Arg Gly Lys Asn Ser Lys 580 585 590 GCC GAG AAG TCA TCA GGA GAA CAG CAA CAG AAT GGT GAC TTC AAA GAT 2002 Ala Glu Lys Ser Ser Gly Glu Gin Gin Gin Asn Gly Asp Phe Lys Asp 595 600 605 GGT AAA AAT AAG ACA GAC AAG AAG GAT CAC TCT AAC ATC GGA AAT GAT 2050 Gly Lys Asn Lys Thr Asp Lys Lys Asp His Ser Asn He Gly Asn Asp 610 615 620 625 TCA AAG AAA ACA GAT GAT TCA CAA GAG TAAAAAAGAC CTCATAGACA 2097 Ser Lys Lys Thr Asp Asp Ser Gin Glu 630 ATAAAAGAGG CTGCCAGTGT CTTGCATCAT TCTAGCTGAG CTTCTTCATT CTCCTTCTTC 2157 TCCTTCTTCC ACAAAGACCC ATATCTGGAG AAGGTGTACA ACTTTCAAAC ACAAGCCCCC 2217 CACCCCCTGA CCCTTGGCCT TCCCTCACAC CATCTCCTTC CAGGGGATGA ATCTTTGGGG 2277 GTTGGTTTGA GGTCTTAGAA CTCTGGGGGA TATTCCCCTG AGCAAAACAA ACAACGTGAG 2337 ATTTTTACTC AAACAGAAAC AAAACATGAA GGGGCATCCT CAAAATCCTT TGCTAATGAC 2397 CTGGCTTTCA AGGCATCTGT CTGGCCTGAT GAGAATGGAC ATCCTGGATA TGCTGGGAGA 2457 GGCCTGAAAA AAGCCACACA CACAGTAATT GCCATTTTAT GACTGTCAAT GCCGTTACTT 2517 TAAATGTTGT CATTTTTGCA CTGGCTACTG ATGATACAGC CATGCTGACA TTCATCACCG 2577 CAAAGATGAT GATTCCAGTC TCTGGTTCCT TTCCTGAGTC AGGAACATTT GTTTTCTCCA 2637 ATTTCCTTTC AGACTTAAAA TTGTTCTTAT GCTTTTTTTC CCACTTCTGT AATACA 2693 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 634 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Met Glu Ser Pro Thr Lys Glu He Glu Glu Phe Glu Ser Asn Ser Leu 1 5 10 15 Lys Tyr * Leu Gin Pro Glu Gin He Glu Lys He Trp Leu Arg Leu Arg 20 25 30 Gly Leu Arg Lys Tyr Lys Lys Thr Ser Gin Arg Leu Arg Ser Leu Val 35 40 45 Lys Gin Leu Glu Arg Gly Glu Ala Ser Val Val Asp Leu Lys Lys Asn 50 55 60 Leu Glu Tyr Ala Ala Thr Val Leu Glu Ser Val Tyr He Asp Glu Thr 65 70 75 80 Arg Arg Leu Leu Asp Thr Glu Asp Glu Leu Ser Asp He Gin Ser Asp 85 90 95 Ala Val Pro Ser Glu Val Arg Asp Trp Leu Ala Ser Thr Phe Thr Arg 100 105 110 Gin Met Gly Met Met Leu Arg Arg Ser Asp Glu Lys Pro Arg Phe Lys 115 120 125 Ser He Val His Ala Val Gin Ala Gly He Phe Val Glu Arg Met Tyr 130 135 140 Arg Arg Thr Ser Asn Met Val Gly Leu Ser Tyr Pro Pro Ala Val He 145 150 155 160 Glu Ala Leu Lys Asp Val Asp Lys Trp Ser Phe Asp Val Phe Ser Leu 165 170 175 Asn Glu Ala Ser Gly Asp His Ala Leu Lys Phe He Phe Tyr Glu Leu 180 185 190 Leu Thr Arg Tyr Asp Leu He Ser Arg Phe Lys He Pro He Ser Ala 195 200 205 Leu Val Ser Phe Val Glu Ala Leu Glu Val Gly Tyr Ser Lys His Lys 210 215 220 Asn Pro Tyr His Asn Leu Met His Ala Ala Asp Val Thr Gin Thr Val 225 230 235 240 His Tyr Leu Leu Tyr Lys Thr Gly Val Ala Asn Trp Leu Thr Glu Leu 245 250 255 Glu He Phe Ala He He Phe Ser Ala Ala He His Asp Tyr Glu His 260 265 270 Thr Gly Thr Thr Asn Asn Phe His He Gin Thr Arg Ser Asp Pro Ala 275 280 285 He Leu Tyr Asn Asp Arg Ser Val Leu Glu Asn His His Leu Ser Ala 290 295 300 Ala Tyr Arg Leu Leu Gin Asp Asp Glu Glu Met Asn He Leu He Asn 305 310 315 320 Leu Ser Lys Asp Asp Trp Arg Glu Phe Arg Thr Leu Val He Glu Met 325 330 335 Val Met Ala Thr Asp Met Ser Cys His Phe Gin Gin He Lys Ala Met 340 345 350 Lys Thr Ala Leu Gin Gin Pro Glu Ala He Glu Lys Pro Lys Ala Leu 355 360 365 Ser Leu. Met Leu His Thr Ala Asp He Ser His Pro Ala Lys Ala Trp 370 375 380 Asp Leu His His Arg Trp Thr Met Ser Leu Leu Glu Glu Phe Phe Arg 385 390 395 400 Gin Gly Asp Arg Glu Ala Glu Leu Gly Leu Pro Phe Ser Pro Leu Cys 405 410 415 Asp Arg Lys Ser Thr Met Val Ala Gin Ser Gin Val Gly Phe He Asp 420 425 430 Phe He Val Glu Pro Thr Phe Thr Val Leu Thr Asp Met Thr Glu Lys 435 440 445 He Val Ser Pro Leu He Asp Glu Thr Ser Gin Thr Gly Gly Thr Gly 450 455 460 Gin Arg Arg Ser Ser Leu Asn Ser He Ser Ser Ser Asp Ala Lys Arg 465 470 475 480 Ser Gly Val Lys Thr Ser Gly Ser Glu Gly Ser Ala Pro He Asn Asn 485 490 495 Ser Val He Ser Val Asp Tyr Lys Ser Phe Lys Ala Thr Trp Thr Glu 500 505 510 Val Val His He Asn Arg Glu Arg Trp Arg Ala Lys Val Pro Lys Glu 515 520 525 Glu Lys Ala Lys Lys Glu Ala Glu Glu Lys Ala Arg Leu Ala Ala Glu 530 535 540 Glu Gin Gin Lys Glu Met Glu Ala Lys Ser Gin Ala Glu Glu Gly Ala 545 550 555 560 Ser Gly Lys Ala Glu Lys Lys Thr Ser Gly Glu Thr Lys Asn Gin Val 565 570 575 Asn Gly Thr Arg Ala Asn Lys Ser Asp Asn Pro Arg Gly Lys Asn Ser 580 585 590 Lys Ala Glu Lys Ser Ser Gly Glu Gin Gin Gin Asn Gly Asp Phe Lys 595 600 605 Asp Gly Lys Asn Lys Thr Asp Lys Lys Asp His Ser Asn He Gly Asn 610 615 620 Asp Ser Lys Lys Thr Asp Asp Ser Gin Glu 625 630 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2077 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..1693 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: A CGG ACA TCA AAC ATG GTT GGA CTG AGC TAT CCA CCA GCT GTT ATT 46 Arg Thr Ser Asn Met Val Gly Leu Ser Tyr Pro Pro Ala Val He 1 5 10 15 GAG GCA TTA AAG GAT GTG GAC AAG TGG TCC TTT GAC GTC TTT TCC CTC 94 Glu Ala Leu Lys Asp Val Asp Lys Trp Ser Phe Asp Val Phe Ser Leu 20 25 30 AAT GAG GCC AGT GGG GAT CAT GCA CTG AAA TTT ATT TTC TAT GAA CTA 142 Asn Glu Ala Ser Gly Asp His Ala Leu Lys Phe He Phe Tyr Glu Leu 35 40 45 CTC ACA CGT TAT GAT CTG ATC AGC CGT TTC AAG ATC CCC ATT TCT GCA 190 Leu Thr Arg Tyr Asp Leu He Ser Arg Phe Lys He Pro He Ser Ala 50 55 60 CTT GTC TCA TTT GTG GAG GCC CTG GAA GTG GGA TAC AGC AAG CAC AAA 238 Leu Val Ser Phe Val Glu Ala Leu Glu Val Gly Tyr Ser Lys His Lys 65 70 75 AAT CCT TAC CAT AAC TTA ATG CAC GCT GCC GAT GTT ACA CAG ACA GTG 286 Asn Pro Tyr His Asn Leu Met His Ala Ala Asp Val Thr Gin Thr Val 80 85 90 95 CAT TAC CTC CTC TAT AAG ACA GGA GTG GCG AAC TGG CTG ACG GAG CTG 334 His Tyr Leu Leu Tyr Lys Thr Gly Val Ala Asn Trp Leu Thr Glu Leu 100 105 110 GAG ATC TTT GCT ATA ATC TTC TCA GCT GCC ATC CAT GAC TAC GAG CAT 382 Glu He Phe Ala He He Phe Ser Ala Ala He His Asp Tyr Glu His 115 120 125 ACC GGA ACC ACC AAC AAT TTC CAC ATT CAG ACT CGG TCT GAT CCA GCT 430 Thr Gly Thr Thr Asn Asn Phe His He Gin Thr Arg Ser Asp Pro Ala 130 135 140 ATT CTG TAT AAT GAC AGA TCT GTA CTG GAG AAT CAC CAT TTA AGT GCA 478 He Leu Tyr Asn Asp Arg Ser Val Leu Glu Asn His His Leu Ser Ala 145 150 155 GCT TAT CGC CTT CTG CAA GAT GAC GAG GAA ATG AAT ATT TTG ATT AAC 526 Ala Tyr Arg Leu Leu Gin Asp Asp Glu Glu Met Asn He Leu He Asn 160 165 170 175 CTC TCA AAG GAT GAC TGG AGG GAG TTT CGA ACC TTG GTA ATT GAA ATG 574 Leu Ser Lys Asp Asp Trp Arg Glu Phe Arg Thr Leu Val He Glu Met 180 185 190 GTG ATG GCC ACA GAT ATG TCT TGT CAC TTC CAA CAA ATC AAA GCA ATG 622 Val Met Ala Thr Asp Met Ser Cys His Phe Gin Gin He Lys Ala Met 195 200 205 AAG ACT GCT CTG CAG CAG CCA GAA GCC ATT GAA AAG CCA AAA GCC TTA 670 Lys Thr Ala Leu Gin Gin Pro Glu Ala He Glu Lys Pro Lys Ala Leu 210 215 220 TCC CTT ATG CTG CAT ACA GCA GAT ATT AGC CAT CCA GCA AAA GCA TGG 718 Ser Leu Met Leu His Thr Ala Asp He Ser His Pro Ala Lys Ala Trp 225 230 235 GAC CTC CAT CAT CGC TGG ACA ATG TCA CTC CTG GAG GAG TTC TTC AGA 766 Asp Leu His His Arg Trp Thr Met Ser Leu Leu Glu Glu Phe Phe Arg 240 245 250 255 CAG GGT GAC AGA GAA GCA GAG CTG GGG CTG CCT TTT TCT CCT CTG TGT 814 Gin Gly Asp Arg Glu Ala Glu Leu Gly Leu Pro Phe Ser Pro Leu Cys 260 265 270 GAC CGA AAG TCC ACT ATG GTT GCT CAG TCA CAA GTA GGT TTC ATT GAT 862 Asp Arg Lys Ser Thr Met Val Ala Gin Ser Gin Val Gly Phe He Asp 275 280 285 TTC ATC GTG GAA CCC ACC TTC ACT GTG CTT ACG GAC ATG ACC GAG AAG 910 Phe He Val Glu Pro Thr Phe Thr Val Leu Thr Asp Met Thr Glu Lys 290 295 300 ATT GTG AGT CCA TTA ATC GAT GAA ACC TCT CAA ACT GGT GGG ACA GGA 958 He Val Ser Pro Leu He Asp Glu Thr Ser Gin Thr Gly Gly Thr Gly 305 310 315 CAG AGG CGT TCG AGT TTG AAT AGC ATC AGC TCG TCA GAT GCC AAG CGA 1006 Gin Arg Arg Ser Ser Leu Asn Ser He Ser Ser Ser Asp Ala Lys Arg 320 325 330 335 TCA GGT GTC AAG ACC TCT GGT TCA GAG GGA AGT GCC CCG ATC AAC AAT 1054 Ser Gly Val Lys Thr Ser Gly Ser Glu Gly Ser Ala Pro He Asn Asn 340 345 350 TCT GTC ATC TCC GTT GAC TAT AAG AGC TTT AAA GCT ACT TGG ACG GAA 1102 Ser Val He Ser Val Asp Tyr Lys Ser Phe Lys Ala Thr Trp Thr Glu 355 360 365 GTG GTG CAC ATC AAT CGG GAG AGA TGG AGG GCC AAG GTA CCC AAA GAG 1150 Val Val His He Asn Arg Glu Arg Trp Arg Ala Lys Val Pro Lys Glu 370 375 380 GAG AAG GCC AAG AAG GAA GCA GAG GAA AAG GCT CGC CTG GCC GCA GAG 1198 Glu Lys Ala Lys Lys Glu Ala Glu Glu Lys Ala Arg Leu Ala Ala Glu 385 390 395 GAG CAG CAA AAG GAA ATG GAA GCC AAA AGC CAG GCT GAA GAA GGC GCA 1246 Glu Gin Gin Lys Glu Met Glu Ala Lys Ser Gin Ala Glu Glu Gly Ala 400 405 410 415 TCT GGC AAA GCT GAG AAA AAG ACG TCT GGA GAA ACT AAG AAT CAA GTC 1294 Ser Gly Lys Ala Glu Lys Lys Thr Ser Gly Glu Thr Lys Asn Gin Val 420 425 430 AAT GGA ACA CGG GCA AAC AAA AGT GAC AAC CCT CGT GGG AAA AAT TCC 1342 Asn Gly Thr Arg Ala Asn Lys Ser Asp Asn Pro Arg Gly Lys Asn Ser 435 440 445 AAA GCT GAG AAG TCA TCA GGA GAA CAG CAA CAG AAT GGT GAC TTC AAA 1390 Lys Ala Glu Lys Ser Ser Gly Glu Gin Gin Gin Asn Gly Asp Phe Lys 450 455 460 GAT GGT AAA AAT AAG ACA GAC AAG AAG GAT CAC TCT AAC ATC GGA AAT 1438 Asp Gly Lys Asn Lys Thr Asp Lys Lys Asp His Ser Asn He Gly Asn 465 470 475 GAT TCA AAG AAA ACA GAT GGC ACA AAA CAG CGT TCT CAC GGC TCA CCA 1486 Asp Ser Lys Lys Thr Asp Gly Thr Lys Gin Arg Ser His Gly Ser Pro 480 485 490 495 GCC CCA AGC ACC AGC TCC ACG TGT CGC CTT ACG TTG CCA GTC ATC AAG 1534 Ala Pro Ser Thr Ser Ser Thr Cys Arg Leu Thr Leu Pro Val He Lys 500 505 510 CCT CCT TTG CGT CAT TTT AAA CGC CCT GCT TAC GCA TCT AGC TCC TAT 1582 Pro Pro Leu Arg His Phe Lys Arg Pro Ala Tyr Ala Ser Ser Ser Tyr 515 520 525 GCA CCT TCA GTC TCA AAG AAA ACT GAT GAG CAT CCT GCA AGG TAC AAG 1630 Ala Pro Ser Val Ser Lys Lys Thr Asp Glu His Pro Ala Arg Tyr Lys 530 535 540 ATG CTA GAT CAG AGG ATC AAA ATG AAA AAG ATT CAG AAC ATC TCA CAT 1678 Met Leu Asp Gin Arg He Lys Met Lys Lys He Gin Asn He Ser His 545 550 555 AAC TGG AAC AGA AAA TAGGCCGAGG GGAAGAAGAG AGGGAGTGAA GGAGGGTCTA 1733 Asn Trp Asn Arg Lys 560 CCTATCTGCT TCTCAGCACC CACTGGCCAC AGCAGGACAC ACCTCCAAGA CCCTTGGAGG 1793 CTGTTGGAGC AGGTACTATC CTGGTTGACT CCACCAAGGT GAAATGAAAG TTGTATGTGA 1853 TTTTCCTCTT TGTTGTTCTT GTATAGACTT TTCAATTGCT GTATGTGGGA TCAGCCCAGA 1913 CGCCAGCAAC AAACTAGCAA GAGGGGTGTT TTTATGGTAT AAGTCTCTAA AAGTCTAAAT 1973 TGGACCAAAA TTAAAATGAC ACAAACTTAA AAAAAAATAA AATTCCTCTC ATTGCCACTT 2033 TTTTCAATCT CTAAAAGTTA CTTGCCCCCA AAAGAATATT GGTC 2077 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 564 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: Arg Thr Ser Asn Met Val Gly Leu Ser Tyr Pro Pro Ala Val He Glu 1 5 10 15 Ala Leu Lys Asp Val Asp Lys Trp Ser Phe Asp Val Phe Ser Leu Asn 20 25 30 Glu Ala Ser Gly Asp His Ala Leu Lys Phe He Phe Tyr Glu Leu Leu 35 40 45 Thr Arg Tyr Asp Leu He Ser Arg Phe Lys He Pro He Ser Ala Leu 50 55 60 Val Ser Phe Val Glu Ala Leu Glu Val Gly Tyr Ser Lys His Lys Asn 65 70 75 80 Pro Tyr His Asn Leu Met His Ala Ala Asp Val Thr Gin Thr Val His 85 90 95 Tyr Leu Leu Tyr Lys Thr Gly Val Ala Asn Trp Leu Thr Glu Leu Glu 100 105 110 He Phe Ala He He Phe Ser Ala Ala He His Asp Tyr Glu His Thr 115 120 125 Gly Thr Thr Asn Asn Phe His He Gin Thr Arg Ser Asp Pro Ala He 130 135 140 Leu Tyr Asn Asp Arg Ser Val Leu Glu Asn His His Leu Ser Ala Ala 145 150 155 160 Tyr Arg Leu Leu Gin Asp Asp Glu Glu Met Asn He Leu He Asn Leu 165 170 175 Ser Lys Asp Asp Trp Arg Glu Phe Arg Thr Leu Val He Glu Met Val 180 185 190 Met Ala Thr Asp Met Ser Cys His Phe Gin Gin He Lys Ala Met Lys 195 200 205 Thr Ala Leu Gin Gin Pro Glu Ala He Glu Lys Pro Lys Ala Leu Ser 210 215 220 Leu Met Leu His Thr Ala Asp He Ser His Pro Ala Lys Ala Trp Asp 225 230 235 240 Leu His His Arg Trp Thr Met Ser Leu Leu Glu Glu Phe Phe Arg Gin 245 250 255 Gly Asp Arg Glu Ala Glu Leu Gly Leu Pro Phe Ser Pro Leu Cys Asp 260 265 270 Arg Lys Ser Thr Met Val Ala Gin Ser Gin Val Gly Phe He Asp Phe 275 280 285 He Val Glu Pro Thr Phe Thr Val Leu Thr Asp Met Thr Glu Lys He 290 295 300 Val Ser Pro Leu He Asp Glu Thr Ser Gin Thr Gly Gly Thr Gly Gin 305 310 315 320 Arg Arg Ser Ser Leu Asn Ser He Ser Ser Ser Asp Ala Lys Arg Ser 325 330 335 Gly Val Lys Thr Ser Gly Ser Glu Gly Ser Ala Pro He Asn Asn Ser 340 345 350 Val He Ser Val Asp Tyr Lys Ser Phe Lys Ala Thr Trp Thr Glu Val 355 360 365 Val His He Asn Arg Glu Arg Trp Arg Ala Lys Val Pro Lys Glu Glu 370 375 380 Lys Ala Lys Lys Glu Ala Glu Glu Lys Ala Arg Leu Ala Ala Glu Glu 385 390 395 400 Gin Gin Lys Glu Met Glu Ala Lys Ser Gin Ala Glu Glu Gly Ala Ser 405 410 415 Gly Lys Ala Glu Lys Lys Thr Ser Gly Glu Thr Lys Asn Gin Val Asn 420 425 430 Gly Thr Arg Ala Asn Lys Ser Asp Asn Pro Arg Gly Lys Asn Ser Lys 435 440 445 Ala Glu Lys Ser Ser Gly Glu Gin Gin Gin Asn Gly Asp Phe Lys Asp 450 455 460 Gly Lys Asn Lys Thr Asp Lys Lys Asp His Ser Asn He Gly Asn Asp 465 470 475 480 Ser Lys Lys Thr Asp Gly Thr Lys Gin Arg Ser His Gly Ser Pro Ala 485 490 495 Pro Ser Thr Ser Ser Thr Cys Arg Leu Thr Leu Pro Val He Lys Pro 500 505 510 Pro Leu Arg His Phe Lys Arg Pro Ala Tyr Ala Ser Ser Ser Tyr Ala 515 520 525 Pro Ser; Val Ser Lys Lys Thr Asp Glu His Pro Ala Arg Tyr Lys Met 530 535 540 Leu Asp Gin Arg He Lys Met Lys Lys He Gin Asn He Ser His Asn 545 550 555 560 Trp Asn Arg Lys (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: TACGAAGCTT TGATGGGGTC TACTGCTAC 29 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: TACGAAGCTT TGATGGTTGG CTTGGCATAT C 31 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: ATTACCCCTC ATAAAG 16 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: TACGAAGCTT TGATGCGCCG ACAGCCTGC 29 (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: GGTCTCCTGT TGCAGATATT G 21

Claims: WHAT IS CLAIMED IS; 1. A purified and isolated polynucleotide sequence consisting essentially of polynucleotide sequence encoding a mammalian Ca 2+ /calmodulin stimulated cyclic nucleotide phosphodiesterase polypeptide. 2. A purified and isolated polynucleotide sequence consisting essentially of polynucleotide sequence encoding a mammalian cyclic GMP stimulated cyclic nucleotide phosphodiesterase polypeptide. 3. A polynucleotide sequence according to claim 1 or 2 which encodes a human phosphodiesterase polypeptide. 4. A polynucleotide sequence according to claim 3 selected from the group consisting of the human DNA inserts present in vectors pGSPDE6.1 (A.T.C.C. 68583), pGSPDE7.1 (A.T.C.C. 68585), pGSPDE9.2 (A.T.C.C. 68584), λ CaM H6a (A.T.C.C. 75000) pcamH3EF (A.T.C.C. 68964), pHcam61-6N-7 (A.T.C.C. 68963), pcamHella (A.T.C.C. 68965) , and pHcgsβn (A.T.C.C. 68962). 5. A polynucleotide sequence according to claim 1 or 2 which encodes a bovine phosphodiesterase polypeptide. 6. A polynucleotide sequence according to claim 5 which encodes a bovine brain 61 kDa Ca 2+ /calmodulin stimulated phosphodiesterase polypeptide. 7. A polynucleotide sequence according to claim 5 encoding a bovine brain 63 kDa Ca 2+ /calmodulin stimulated phosphodiesterase polypeptide. 8. A polynucleotide sequence according to claim 5 which encodes a bovine heart 59 kDa Ca 2+ /calmodulin stimulated phosphodiesterase polypeptide. 9. A DNA sequence according to claim 8 which is SEQ ID NO: 16. 10. A DNA sequence according to claim 5 selected from the group consisting of the bovine DNA inserts present in vectors pl2.3A (A.T.C.C. 68577), pCaM- 40 (A.T.C.C. 68576), pBBCGS PDE-5 (A.T.C.C. 68578), pBBCGS PDE-7 (A.T.C.C. 68580), and p3CGS-5 (A.T.C.C. 68579) . 11. A cDNA sequence according to claims 1 or 2. 12. A genomic DNA sequence according to claims 1 or 2. 13. A DNA vector having inserted therein a DNA sequence according to claim 1 or 2. 14. A procaryotic or eucaryotic host cell stably transformed with a polynucleotide sequence according to claim 1 or 2. 15. A yeast host cell according to claim 14. 16. A polypeptide product of the expression in a transformed procaryotic or eucaryotic host cell of a polynucleotide sequence according to claim 1 or 2. 17. A polypeptide product according to claim 16 as expressed in a yeast host cell. 18. A purified and isolated polynucleotide sequence consisting essentially of a polynucleotide sequence encoding a polypeptide having the enzymatic activity of a mammalian Ca 2+ /calmodulin stimulated cyclic nucleotide phosphodiesterase and selected from the group consisting of: (a) the mammalian DNA inserts in vectors pCAM- 40 (A.T.C.C. 68576), pl2.3 (A.T.C.C. 68577), and pHcamδl- 6N-7 (A.T.C.C. 68963); (b) polynucleotide sequences which hybridize under stringent hybridization conditions to a DNA sequence selected from the mammalian DNA inserts in vectors pCAM-40 (A.T.C.C. 68576), pl2.3A (A.T.C.C. 68577), λ CAM H6a (A.T.C.C. 75000), pHcam61-6N-7 (A.T.C.C. 68963), pcamH3EF (A.T.C.C. 68964), and pcamHella (A.T.C.C. 68965); (c) polynucleotide sequences which hybridize under stringent hybridization conditions to the sequence set forth in SEQ ID NO: 16; (d) polynucleotide sequences encoding the same polypeptide as the polynucleotide sequences of (a) , (b) and (c) above by means of degenerate codons. 19. A polypeptide product of the expression in a transformed or transfected procaryotic or eucaryotic host cell of a polynucleotide sequence according to claim 18. 20. A polypeptide product according to claim 19 as expressed in a yeast host cell. 21. A purified and isolated polynucleotide sequence consisting essentially of a polynucleotide sequence encoding a polypeptide having the enzymatic activity of a mammalian cyclic GMP stimulated nucleotide phosphodiesterase and selected from the group consisting of: (a) the mammalian DNA inserts in vectors P3CGS-5 (A.T.C.C. 68579) and pHcgsβn (A.T.C.C. 68962); (b) polynucleotide sequences which hybridize under stringent hybridization conditions to the mammalian DNA inserts in vectors p3CGS-5 (A.T.C.C. 68579) , pHcgsβn (A.T.C.C. 68962), pGSPDEδ.l (A.T.C.C. 68583), pGSPDE7.1 (A.T.C.C.68585) , pGSPDE9.2 (A.T.C.C. 68584), pBBCGSPDE-5 (A.T.C.C. 68578) and pBBCGSPDE-7 (A.T.C.C. 68580); and (c) DNA sequences encoding the same polypeptide as the DNA sequences of (a) and (b) above by means of degenerate codons. 22. A polypeptide product of the expression in a transformed or transfected procaryotic or eucaryotic host cell of a polynucleotide sequence according to claim 21. 23. A polypeptide product according to claim 22 as expressed in a yeast host cell. 24. An antibody substance specifically immunoreactive with a polypeptide product according to claim 16, 19 or 22. 25. A method for producing a polypeptide having the enzymatic activity of a mammalian Ca 2+ /calmodulin stimulated cyclic nucleotide phosphodiesterase, said method comprising: (a) stably transforming or transfecting a procaryotic or eucaryotic host cell with a polynucleotide sequence according to claim 1 or 18; and (b) growing the host cell formed in step (a) in a nutrient medium under conditions allowing expression of said DNA sequence in said host cell. 26. A method according to claim 25 further including the step of isolating the polypeptide product of expression of said polynucleotide sequence in said host cell. 27. A method according to claim 25 wherein said host cell is a yeast host cell. 28. A method for producing a polypeptide having the enzymatic activity of a cyclic GMP stimulated cyclic nucleotide phosphodiesterase, said method comprising: (a) stably transforming or transfecting a procaryotic or eucaryotic host cell with a polynucleotide sequence according to claim 2 or 21; and (b) growing the host cell formed in step (a) in a nutrient medium under conditions allowing expression of said DNA sequence in said host cell. 29. A method according to claim 28 further including the step of isolating the polypeptide product of expression of said polynucleotide sequence in said host cell. 30. A method according to claim 28 wherein said host cell is a yeast host cell. 31. An assay method for identifying a chemical agent which modifies the enzymatic activity of a mammalian Ca 2+ /calmodulin sensitive cyclic nucleotide phosphodiesterase, said method comprising: (a) stably transforming, with a polynucleotide sequence according to claim 1 or 18, a procaryotic or eucaryotic host cell having a phenotypic character susceptible to alteration upon expression of said polynucleotide sequence; (b) growing the host cell formed in step (a) in a nutrient medium under conditions allowing expression of said polynucleotide sequence in said host cell accompanied by the corresponding alteration in the host cell phenotype; (c) contacting the host cells grown according to step (b) with a chemical agent to be assayed; and, (d) determining any modification in the alteration of the phenotype of said host cells contacted with said chemical agent in step (c) . 32. An assay method according to claim 31 wherein said host cell is a yeast host cell. 33. An assay method for identifying a chemical agent which modifies the enzymatic activity of a mammalian cyclic GMP stimulated cyclic nucleotide phosphodiesterase, said method comprising: (a) stably transforming, with a polynucleotide sequence according to claim 2 or 21, a procaryotic or eucaryotic host cell having a phenotypic character susceptible to alteration upon expression of said polynucleotide sequence in said host; (b) growing the host cell formed in step (a) in a nutrient medium under conditions allowing expression of said polynucleotide sequence in said host cell accompanied by the corresponding alteration in the host cell phenotype; (c) contacting the host cells grown according to step (b) with a chemical agent to be assayed; and. (d) determining any modification in the alteration of the phenotype of said host cells contacted with said chemical agent in step (d) . 34. An assay method according to claim 33 wherein the host cell is a yeast host cell. 35. An assay method for identifying a chemical agent which modifies the enzymatic activity of a mammalian Ca 2+ /calmodulin sensitive cyclic nucleotide phosphodiesterase, said method comprising: (a) stably transforming, with a polynucleotide sequence according to claim 1 or 18, a procaryotic or eucaryotic host cell having a phenotypic character susceptible to alteration upon expression of said polynucleotide sequence; (b) growing the host cell formed in step (a) in a nutrient medium under conditions allowing expression of said polynucleotide sequence in said host cell accompanied by the corresponding alteration in the host cell phenotype; (c) identifying said host cells having an altered phenotype; (d) disrupting said host cell; (e) isolating cytosol from said disrupted host cell; (f) contacting said cytosol with said chemical agent; and (g) determining whether said enzymatic activity has been altered. 36. An assay method according to claim 35 wherein said host cell is a yeast host cell. 37. An assay method for identifying a chemical agent which modifies the enzymatic activity of a mammalian cyclic GMP stimulated cyclic nucleotide phosphodiesterase, said method comprising: (a) stably transforming, with a polynucleotide sequence according to claim 2 or 21, a procaryotic or eucaryotic host cell having a phenotypic character susceptible to alteration upon expression of said polynucleotide sequence in said host; (b) growing the host cell formed in step (a) in a nutrient medium under conditions allowing expression of said polynucleotide sequence in said host cell phenotype; (c) identifying said host cells having an altered phenotype; (d) disrupting said host cell; (e) isolating cytosol from said disrupted host cell; (f) contacting said cytosol with said chemical agent; and (g) determining whether said enzymatic activity has been altered. 38. An assay method according to claim 37 wherein the host cell is a yeast host cell.

Inventors: BEAVO JOSEPH A, BENTLEY J KELLEY, CHARBONNEAU HARRY, SONNENBURG WILLIAM K, BEAVO, JOSEPH, A., BENTLEY, J., KELLEY, CHARBONNEAU, HARRY, SONNENBURG, WILLIAM, K.
Applicants: UNIV WASHINGTON, THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGT
Application year: 1992
Main classification: C12N15
IPC codes: C07K14, C07K16, C12N1, C12N9, C12N15, C12Q1, C12R1, G01N33